ATE174067T1 - Screening-verfahren für genbanken (recombinant libraries) - Google Patents

Screening-verfahren für genbanken (recombinant libraries)

Info

Publication number: ATE174067T1
Authority: AT; Austria
Prior art keywords: protein; encoding; screening process; interest; nucleotide sequences
Prior art date: 1990-05-01

Application number

AT91908963T

Other languages

English (en)

Inventor

William J Dower

Steven E Cwirla

Original Assignee

Affymax Tech Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-01

Filing date

1991-05-01

Publication date

1998-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24060691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE174067(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-05-01 Application filed by Affymax Tech Nv filed Critical Affymax Tech Nv

1998-12-15 Application granted granted Critical

1998-12-15 Publication of ATE174067T1 publication Critical patent/ATE174067T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Crystallography & Structural Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT91908963T 1990-05-01 1991-05-01 Screening-verfahren für genbanken (recombinant libraries) ATE174067T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/517,659 US5427908A (en)	1990-05-01	1990-05-01	Recombinant library screening methods

Publications (1)

Publication Number	Publication Date
ATE174067T1 true ATE174067T1 (de)	1998-12-15

Family

ID=24060691

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT91908963T ATE174067T1 (de)	1990-05-01	1991-05-01	Screening-verfahren für genbanken (recombinant libraries)
AT98200770T ATE286985T1 (de)	1990-05-01	1991-05-01	Siebtestverfahren für genbanken (recombinant libraries)

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT98200770T ATE286985T1 (de)	1990-05-01	1991-05-01	Siebtestverfahren für genbanken (recombinant libraries)

Country Status (10)

Country	Link
US (2)	US5427908A (de)
EP (3)	EP1555328A3 (de)
JP (1)	JP3344584B2 (de)
AT (2)	ATE174067T1 (de)
AU (1)	AU7793991A (de)
DE (3)	DE69133437T2 (de)
DK (2)	DK0527839T3 (de)
ES (2)	ES2124224T3 (de)
GR (1)	GR3029421T3 (de)
WO (1)	WO1991017271A1 (de)

Families Citing this family (2228)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5547839A (en)	1989-06-07	1996-08-20	Affymax Technologies N.V.	Sequencing of surface immobilized polymers utilizing microflourescence detection
US7413537B2 (en)	1989-09-01	2008-08-19	Dyax Corp.	Directed evolution of disulfide-bonded micro-proteins
US5747334A (en) *	1990-02-15	1998-05-05	The University Of North Carolina At Chapel Hill	Random peptide library
US5498538A (en) *	1990-02-15	1996-03-12	The University Of North Carolina At Chapel Hill	Totally synthetic affinity reagents
US5427908A (en) *	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
DK0600866T3 (da) *	1990-06-01	1998-03-09	Chiron Corp	Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
US6172197B1 (en) *	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
GB9206318D0 (en) *	1992-03-24	1992-05-06	Cambridge Antibody Tech	Binding substances
US6916605B1 (en) *	1990-07-10	2005-07-12	Medical Research Council	Methods for producing members of specific binding pairs
US7063943B1 (en)	1990-07-10	2006-06-20	Cambridge Antibody Technology	Methods for producing members of specific binding pairs
GB9015198D0 (en) *	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US6258530B1 (en)	1990-09-28	2001-07-10	Ixsys, Inc.	Surface expression libraries of randomized peptides
US6893845B1 (en)	1990-09-28	2005-05-17	Applied Molecular Evolution, Inc.	Surface expression libraries of heteromeric receptors
US5698426A (en) *	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
US5871974A (en) *	1990-09-28	1999-02-16	Ixsys Inc.	Surface expression libraries of heteromeric receptors
US5770434A (en) *	1990-09-28	1998-06-23	Ixsys Incorporated	Soluble peptides having constrained, secondary conformation in solution and method of making same
ES2113940T3 (es) *	1990-12-03	1998-05-16	Genentech Inc	Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992010588A1 (en) *	1990-12-06	1992-06-25	Affymax Technologies N.V.	Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
DE69131017T2 (de) *	1990-12-20	1999-07-15	Ixsys, Inc., San Diego, Calif.	Optimierung von bindenden proteinen
DE69233769D1 (de)	1991-03-01	2009-09-24	Dyax Corp	Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
EP0575410B1 (de) *	1991-03-07	1999-05-19	BRADBURY, Andrew Raymon Morton	Auswahl spezifischer proteine durch ein biologisches verfahren
AU662148B2 (en) *	1991-04-10	1995-08-24	Scripps Research Institute, The	Heterodimeric receptor libraries using phagemids
US5955341A (en) *	1991-04-10	1999-09-21	The Scripps Research Institute	Heterodimeric receptor libraries using phagemids
US5962255A (en) *	1992-03-24	1999-10-05	Cambridge Antibody Technology Limited	Methods for producing recombinant vectors
US5858657A (en) *	1992-05-15	1999-01-12	Medical Research Council	Methods for producing members of specific binding pairs
US5871907A (en)	1991-05-15	1999-02-16	Medical Research Council	Methods for producing members of specific binding pairs
US6225447B1 (en)	1991-05-15	2001-05-01	Cambridge Antibody Technology Ltd.	Methods for producing members of specific binding pairs
US6492160B1 (en)	1991-05-15	2002-12-10	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
DE4122599C2 (de) *	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
DK0604552T3 (da) *	1991-09-18	1997-08-04	Affymax Tech Nv	Fremgangsmåde til syntese af forskellige samlinger af oligomerer
PT1696031E (pt) *	1991-12-02	2010-06-25	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) *	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
WO1994000470A1 (en) *	1992-06-30	1994-01-06	The Wistar Institute Of Anatomy And Biology	DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES
WO1994005781A1 (en) *	1992-09-04	1994-03-17	The Scripps Research Institute	Phagemids coexpressing a surface receptor and a surface heterologous protein
DE4243770A1 (de) *	1992-12-23	1994-06-30	Behringwerke Ag	Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung
AU6235294A (en)	1993-02-02	1994-08-29	Scripps Research Institute, The	Methods for producing polypeptide binding sites
CA2173990A1 (en) *	1993-10-12	1995-04-20	Narasinga Rao	A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5922545A (en) *	1993-10-29	1999-07-13	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
US7034110B2 (en)	1994-01-05	2006-04-25	Arqule, Inc.	Method of identifying chemical compounds having selected properties for a particular application
PT744958E (pt)	1994-01-31	2003-11-28	Univ Boston	Bancos de anticorpos policlonais
US20060078561A1 (en) *	1994-01-31	2006-04-13	The Trustees Of Boston University	Polyclonal antibody libraries
US6335160B1 (en) *	1995-02-17	2002-01-01	Maxygen, Inc.	Methods and compositions for polypeptide engineering
US5525735A (en) *	1994-06-22	1996-06-11	Affymax Technologies Nv	Methods for synthesizing diverse collections of pyrrolidine compounds
US5525734A (en) *	1994-06-22	1996-06-11	Affymax Technologies N.V.	Methods for synthesizing diverse collections of pyrrolidine compounds
US6576236B1 (en)	1994-07-01	2003-06-10	Dana Farber Cancer Institute	Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US6010861A (en) *	1994-08-03	2000-01-04	Dgi Biotechnologies, Llc	Target specific screens and their use for discovering small organic molecular pharmacophores
US7820798B2 (en) *	1994-11-07	2010-10-26	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7597886B2 (en) *	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US5712171A (en)	1995-01-20	1998-01-27	Arqule, Inc.	Method of generating a plurality of chemical compounds in a spatially arranged array
US5766914A (en) *	1995-01-26	1998-06-16	Michigan State University	Method of producing and purifying enzymes
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
US5834184A (en) *	1995-05-17	1998-11-10	Harada; Kazuo	In vivo selection of RNA-binding peptides
ATE219517T1 (de) *	1995-08-18	2002-07-15	Morphosys Ag	Protein-/(poly)peptidbibliotheken
US6696248B1 (en)	1995-08-18	2004-02-24	Morphosys Ag	Protein/(poly)peptide libraries
US7368111B2 (en)	1995-10-06	2008-05-06	Cambridge Antibody Technology Limited	Human antibodies specific for TGFβ2
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US6953663B1 (en) *	1995-11-29	2005-10-11	Affymetrix, Inc.	Polymorphism detection
US6300063B1 (en)	1995-11-29	2001-10-09	Affymetrix, Inc.	Polymorphism detection
US6537776B1 (en)	1999-06-14	2003-03-25	Diversa Corporation	Synthetic ligation reassembly in directed evolution
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
AU2527397A (en) *	1996-03-13	1997-10-01	Protein Design Labs, Inc.	Fas ligand fusion proteins and their uses
US5866341A (en) *	1996-04-03	1999-02-02	Chugai Pharmaceutical Co., Ltd.	Compositions and methods for screening drug libraries
US6696251B1 (en)	1996-05-31	2004-02-24	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US6300065B1 (en)	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US6699658B1 (en)	1996-05-31	2004-03-02	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
CN1254376A (zh)	1996-10-01	2000-05-24	杰龙公司	端粒酶逆转录酶
US6139817A (en) *	1996-10-15	2000-10-31	Smithkline Beecham Corporation	Method for determining gene essentiality in a pathogen
IL119587A (en) *	1996-11-07	2000-12-06	Univ Ramot	Method of preparing and for obtaining bimolecular interactions
US5922537A (en) *	1996-11-08	1999-07-13	N.o slashed.AB Immunoassay, Inc.	Nanoparticles biosensor
US5942422A (en) *	1996-11-14	1999-08-24	The Trustees Of Columbia University In The City Of New York	Method for generating a directed, recombinant fusion nucleic acid
US6057098A (en)	1997-04-04	2000-05-02	Biosite Diagnostics, Inc.	Polyvalent display libraries
EP0985033A4 (de) *	1997-04-04	2005-07-13	Biosite Inc	Polyvalente und polyklonale bibliotheken
US6555310B1 (en)	1997-04-04	2003-04-29	Biosite Diagnostics, Inc.	Polyclonal libraries
WO1998046796A1 (en) *	1997-04-11	1998-10-22	The Regents Of The University Of California	A method of screening nucleotide sequences to identify disruptors or effectors of biological processes or pathways
AU7137398A (en)	1997-04-16	1998-11-11	Millennium Pharmaceuticals, Inc.	Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
CA2297070A1 (en)	1997-08-01	1999-02-11	Morphosys Ag	Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
AU9395398A (en) *	1997-09-19	1999-04-12	Chiron Corporation	Subtractive protein screening for gene identification
US6607878B2 (en)	1997-10-06	2003-08-19	Stratagene	Collections of uniquely tagged molecules
GB9722131D0 (en) *	1997-10-20	1997-12-17	Medical Res Council	Method
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US6893877B2 (en)	1998-01-12	2005-05-17	Massachusetts Institute Of Technology	Methods for screening substances in a microwell array
US6759243B2 (en)	1998-01-20	2004-07-06	Board Of Trustees Of The University Of Illinois	High affinity TCR proteins and methods
US6335185B1 (en)	1998-02-03	2002-01-01	University Technologies International Inc.	Bacteriophage vectors generated by bacteriophage/plasmid recombination
US6841347B1 (en)	1998-02-05	2005-01-11	The General Hospital Corporation	In vivo construction of DNA libraries
WO1999040208A1 (en) *	1998-02-05	1999-08-12	The General Hospital Corporation	In vivo construction of dna libraries
EP1066369B1 (de) *	1998-03-18	2006-07-19	Quark Biotech, Inc.	Selektion/subtraktionsansatz zur genidentifizierung
EP1093457B8 (de)	1998-03-19	2011-02-02	Human Genome Sciences, Inc.	Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US7056517B2 (en)	1998-04-13	2006-06-06	The Forsyth Institute	Glucosyltransferase immunogens
US7163682B2 (en)	1998-04-13	2007-01-16	The Forsyth Institute	Glucan binding protein and glucosyltransferase immunogens
AU771224B2 (en)	1998-07-13	2004-03-18	Board Of Regents, The University Of Texas System	Cancer treatment methods using antibodies to aminophospholipids
US6323325B1 (en)	1998-07-23	2001-11-27	The United States Of America As Represented By The Department Of Health And Human Services	Agents that bind to and inhibit human cytochrome P450 2A6
US6335428B1 (en) *	1998-07-23	2002-01-01	The United States Of America As Represented By The Department Of Health And Human Services	Agents that bind to and inhibit human cytochrome P450 1A2
CA2334170A1 (en)	1998-07-27	2000-02-10	Genentech, Inc.	Improved transformation efficiency in phage display through modification of a coat protein
US6190908B1 (en) *	1998-08-12	2001-02-20	The Scripps Research Institute	Modulation of polypeptide display on modified filamentous phage
EP1115734A4 (de) *	1998-09-24	2004-07-21	Univ Duke	Methoden zur messung von protein-protein wechselwirkungen in lebenden zellen
US6420110B1 (en)	1998-10-19	2002-07-16	Gpc Biotech, Inc.	Methods and reagents for isolating biologically active peptides
GB9826247D0 (en) *	1998-11-30	1999-01-20	Nycomed Pharma As	Method
AU3382800A (en)	1999-02-26	2000-09-14	Millennium Pharmaceuticals, Inc.	Secreted proteins and uses thereof
EP2357192A1 (de)	1999-02-26	2011-08-17	Human Genome Sciences, Inc.	Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
US6642353B1 (en)	1999-03-17	2003-11-04	Chugai Seiyaku Kabushiki Kaisha	Peptide ligands for the erythropoietin receptor
DE19915057A1 (de)	1999-04-01	2000-10-19	Forschungszentrum Borstel	Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
US6492497B1 (en)	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
US20020102613A1 (en)	1999-05-18	2002-08-01	Hoogenboom Hendricus Renerus Jacobus Mattheus	Novel Fab fragment libraries and methods for their use
EP1054018B1 (de) *	1999-05-18	2009-01-28	Dyax Corp.	Fab Fragmentbibliotheken und Verfahren für deren Verwendung
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US7291714B1 (en)	1999-06-30	2007-11-06	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
US20040001826A1 (en) *	1999-06-30	2004-01-01	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
EP1990409A3 (de)	1999-07-20	2011-05-18	MorphoSys AG	Bakteriophage
US7179638B2 (en)	1999-07-30	2007-02-20	Large Scale Biology Corporation	Microarrays and their manufacture by slicing
US6713309B1 (en)	1999-07-30	2004-03-30	Large Scale Proteomics Corporation	Microarrays and their manufacture
PT1210428E (pt)	1999-08-23	2015-07-21	Genetics Inst Llc	Pd-1, um recetor para b7-4 e suas utilizações
US20070111259A1 (en) *	1999-10-02	2007-05-17	Medarex, Inc.	Human antibodies
US6794132B2 (en)	1999-10-02	2004-09-21	Biosite, Inc.	Human antibodies
US7135287B1 (en)	1999-10-02	2006-11-14	Biosite, Inc.	Human antibodies
CA2387018C (en)	1999-10-12	2008-02-12	Chemocentryx, Inc.	Chemokine receptor
US6642046B1 (en) *	1999-12-09	2003-11-04	Motorola, Inc.	Method and apparatus for performing biological reactions on a substrate surface
US6589778B1 (en)	1999-12-15	2003-07-08	Amersham Biosciences Ab	Method and apparatus for performing biological reactions on a substrate surface
US6569674B1 (en)	1999-12-15	2003-05-27	Amersham Biosciences Ab	Method and apparatus for performing biological reactions on a substrate surface
US20060073509A1 (en) *	1999-11-18	2006-04-06	Michael Kilpatrick	Method for detecting and quantitating multiple subcellular components
EP1234031B2 (de)	1999-11-30	2021-11-24	Mayo Foundation For Medical Education And Research	B7-h1, ein neuartiges immunregulierendes molekül
US6680209B1 (en)	1999-12-06	2004-01-20	Biosite, Incorporated	Human antibodies as diagnostic reagents
EP1240319A1 (de) *	1999-12-15	2002-09-18	Genentech, Inc.	"shotgun scanning", eine methode zur kartierung von funktionellen protein epitopen
US6632608B2 (en)	1999-12-30	2003-10-14	President And Fellows Of Harvard College	Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
PL356836A1 (en)	2000-02-10	2004-07-12	Abbott Laboratories	Antibodies that bind human interleukin-18 and methods of making and using
WO2001061054A2 (en) *	2000-02-18	2001-08-23	Board Of Trustees Of The Leland Stanford Junior University	Apparatus and methods for parallel processing of micro-volume liquid reactions
US20020151040A1 (en)	2000-02-18	2002-10-17	Matthew O' Keefe	Apparatus and methods for parallel processing of microvolume liquid reactions
AU2001247616B2 (en)	2000-04-11	2007-06-14	Genentech, Inc.	Multivalent antibodies and uses therefor
EP1274720A4 (de)	2000-04-12	2004-08-18	Human Genome Sciences Inc	Albumin enthaltende fusionsproteine
US7495070B2 (en) *	2000-04-24	2009-02-24	Yale University	Protein binding miniature proteins
US7297762B2 (en) *	2000-04-24	2007-11-20	Yale University	Modified avian pancreatic polypeptide miniature binding proteins
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
DK2026073T3 (en)	2000-04-29	2016-07-25	Univ Iowa Res Found	Diagnosis and treatment of macular degeneration-related disorders
EP1714661A3 (de)	2000-05-19	2012-03-14	The Center for Blood Research, INC.	Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
US20030031675A1 (en)	2000-06-06	2003-02-13	Mikesell Glen E.	B7-related nucleic acids and polypeptides useful for immunomodulation
CA2410458A1 (en)	2000-06-08	2001-12-13	The Center For Blood Research, Inc.	Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury
WO2001096528A2 (en)	2000-06-15	2001-12-20	Human Genome Sciences, Inc.	Human tumor necrosis factor delta and epsilon
AU2001268427B2 (en)	2000-06-16	2007-03-29	Glaxosmithkline Intellectual Property Limited	Antibodies that immunospecifically bind to blys
US20020055110A1 (en) *	2000-06-23	2002-05-09	Ian Tomlinson	Matrix screening method
US20020115068A1 (en) *	2000-06-23	2002-08-22	Ian Tomlinson	Matrix screening method
EP1320599A2 (de)	2000-06-28	2003-06-25	Genetics Institute, LLC	Pd-l2 moleküle: pd-l1 liganden und ihre verwendungen
MXPA02012867A (es) *	2000-06-29	2003-09-05	Abbott Lab	Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
ATE497507T1 (de)	2000-07-14	2011-02-15	Cropdesign Nv	Inhibitoren für cyclin-dependent-kinase von pflanzen
ATE415978T1 (de)	2000-07-27	2008-12-15	Genentech Inc	Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en)	2000-08-07	2005-06-07	Centocor, Inc.	Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en)	2000-08-07	2007-10-30	Centocor, Inc.	Anti-dual integrin antibodies, compositions, methods and uses
CA2417432C (en)	2000-09-01	2010-11-02	The Center For Blood Research, Inc.	Modified polypeptides stabilized in a desired conformation and methods for producing same
GB0022978D0 (en)	2000-09-19	2000-11-01	Oxford Glycosciences Uk Ltd	Detection of peptides
JP2004515233A (ja)	2000-11-01	2004-05-27	イルーシスセラポーティクス，インコーポレーテッド	タンパク質トランススプライシングによる二重特異性分子の作製方法
US6821731B2 (en)	2000-11-28	2004-11-23	Wyeth	Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
WO2002044419A2 (en)	2000-11-28	2002-06-06	Wyeth	Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU1994402A (en)	2000-11-28	2002-06-11	Mediummune Inc	Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7427665B2 (en) *	2000-12-08	2008-09-23	Alexion Pharmaceuticals, Inc.	Chronic lymphocytic leukemia cell line
US20040198661A1 (en) *	2000-12-08	2004-10-07	Bowdish Katherine S.	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002046400A2 (en) *	2000-12-08	2002-06-13	The Board Of Trustees Of The University Of Illinois	Mutated class ii major histocompatibility proteins
US20060057651A1 (en) *	2000-12-08	2006-03-16	Bowdish Katherine S	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) *	2000-12-08	2016-02-02	Alexion Pharmaceuticals, Inc.	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) *	2000-12-08	2008-08-05	Alexion Pharmaceuticals, Inc.	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP4336498B2 (ja)	2000-12-12	2009-09-30	メディミューン，エルエルシー	延長した半減期を有する分子ならびにその組成物および用途
US6933109B2 (en) *	2000-12-22	2005-08-23	Large Scale Proteomics Corporation	Rapid particle detection
ES2390425T3 (es)	2000-12-22	2012-11-12	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
US7132510B2 (en) *	2000-12-29	2006-11-07	Bio-Technology General (Israel) Ltd.	Specific human antibodies for selective cancer therapy
US20040001839A1 (en) *	2000-12-29	2004-01-01	Avigdor Levanon	Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) *	2000-12-29	2004-01-01	Avigdor Levanon	Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) *	2000-12-29	2004-01-01	Janette Lazarovits	Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
PA8535501A1 (es)	2001-01-05	2003-07-28	Pfizer	Anticuerpos contra el receptor del factor de crecimiento similar a insulina
WO2002064612A2 (en)	2001-02-09	2002-08-22	Human Genome Sciences, Inc.	Human g-protein chemokine receptor (ccr5) hdgnr10
US7323327B2 (en)	2001-02-23	2008-01-29	Dsm Ip Assets B.V.	Genes encoding novel proteolytic enzymes
US20020160527A1 (en)	2001-02-26	2002-10-31	3M Innovative Properties Company	Combinatorial library comprising pouches as packages for library members and method therefor
US20030165873A1 (en)	2001-03-02	2003-09-04	Come Jon H.	Three hybrid assay system
WO2002098370A2 (en) *	2001-03-02	2002-12-12	Medimmune, Inc.	Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
CA2440649A1 (en)	2001-03-07	2002-09-19	Children's Medical Center Corporation	Method to screen peptide display libraries using minicell display
US8981061B2 (en)	2001-03-20	2015-03-17	Novo Nordisk A/S	Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) *	2001-03-20	2012-07-31	Cosmo Research & Development S.P.A.	Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) *	2001-03-20	2013-11-12	Marco Colonna	A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) *	2001-03-20	2009-03-26	Bioxell S.P.A.	Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
WO2002076196A1 (en)	2001-03-22	2002-10-03	Abbott Gmbh & Co. Kg	Transgenic animals expressing antibodies specific for genes of interest and uses thereof
US7514263B2 (en)	2001-04-02	2009-04-07	3M Innovative Properties Company	Continuous process for the production of combinatorial libraries of materials
WO2002079499A1 (en)	2001-04-02	2002-10-10	Wyeth	Pd-1, a receptor for b7-4, and uses therefor
US20020146753A1 (en) *	2001-04-06	2002-10-10	Henrik Ditzel	Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
DE60236646D1 (de)	2001-04-13	2010-07-22	Human Genome Sciences Inc	Anti-VEGF-2 Antikörper
CN1636062A (zh)	2001-04-16	2005-07-06	惠氏控股公司	编码多肽抗原的新肺炎链球菌可读框及其应用
US20050053973A1 (en) *	2001-04-26	2005-03-10	Avidia Research Institute	Novel proteins with targeted binding
US20050048512A1 (en) *	2001-04-26	2005-03-03	Avidia Research Institute	Combinatorial libraries of monomer domains
US20030157561A1 (en) *	2001-11-19	2003-08-21	Kolkman Joost A.	Combinatorial libraries of monomer domains
JP4369662B2 (ja) *	2001-04-26	2009-11-25	アビディアインコーポレイテッド	単量体ドメインのコンビナトリアルライブラリー
US20050089932A1 (en) *	2001-04-26	2005-04-28	Avidia Research Institute	Novel proteins with targeted binding
US20040175756A1 (en) *	2001-04-26	2004-09-09	Avidia Research Institute	Methods for using combinatorial libraries of monomer domains
CA2448142A1 (en)	2001-05-22	2002-11-28	Merck & Co., Inc.	Beta-secretase substrates and uses thereof
CN100594935C (zh)	2001-05-25	2010-03-24	人体基因组科学有限公司	免疫特异性结合trail受体的抗体
US7087600B2 (en) *	2001-05-31	2006-08-08	Medarex, Inc.	Peptidyl prodrugs and linkers and stabilizers useful therefor
WO2002098280A2 (en) *	2001-06-04	2002-12-12	Ikonisys Inc.	Method for detecting infectious agents using computer controlled automated image analysis
WO2005010044A2 (en)	2003-07-08	2005-02-03	Genentech, Inc.	Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2817619A1 (en)	2001-06-08	2002-12-08	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
US7803915B2 (en) *	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
KR100576674B1 (ko)	2001-06-20	2006-05-10	제넨테크, 인크.	종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
EP2333070A3 (de)	2001-06-22	2011-09-07	Pioneer Hi-Bred International, Inc.	Defensinpolynucleotide und Verfahren zu ihrer Verwendung
EP1493028A4 (de) *	2001-07-06	2006-06-14	Genentech Inc	Im phagen-display präsentierte liganden der pdz-domäne
US6867189B2 (en) *	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
US6833441B2 (en)	2001-08-01	2004-12-21	Abmaxis, Inc.	Compositions and methods for generating chimeric heteromultimers
US20040142325A1 (en)	2001-09-14	2004-07-22	Liat Mintz	Methods and systems for annotating biomolecular sequences
CA2492823A1 (en) *	2001-09-14	2003-03-27	Cytos Biotechnology Ag	In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
ES2431929T3 (es)	2001-09-18	2013-11-28	Genentech, Inc.	Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
AU2002327704A1 (en) *	2001-09-21	2003-04-01	Raven Biotechnologies, Inc.	Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US20030082188A1 (en)	2001-10-11	2003-05-01	Tso J. Yun	Treatment of prostate cancer by inhibitors of NCAM2
US20040005709A1 (en) *	2001-10-24	2004-01-08	Hoogenboom Henricus Renerus Jacobus Mattheus	Hybridization control of sequence variation
US7175983B2 (en) *	2001-11-02	2007-02-13	Abmaxis, Inc.	Adapter-directed display systems
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US20030185870A1 (en)	2001-11-20	2003-10-02	Grinstaff Mark W.	Interfacial biomaterials
EP1461428B1 (de)	2001-12-03	2012-03-21	Alexion Pharmaceuticals, Inc.	Verfahren zur Herstellung von Hybridantikörper
AU2002361385B2 (en)	2001-12-18	2009-11-19	Centre National De La Recherche Scientifique Cnrs	Novel death associated proteins of the THAP family and related Par4 pathways involved in apoptosis control
US7858297B2 (en)	2001-12-18	2010-12-28	Centre National De La Recherche Scientifique Cnrs	Chemokine-binding protein and methods of use
WO2003054155A2 (en)	2001-12-19	2003-07-03	Bristol-Myers Squibb Company	Pichia pastoris formate dehydrogenase and uses therefor
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
EP2067472A1 (de)	2002-01-02	2009-06-10	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
JP2005523688A (ja) *	2002-01-18	2005-08-11	ブリストル−マイヤーズ　スクイブ　カンパニー	タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
WO2003104428A2 (en) *	2002-01-21	2003-12-18	Vaccinex, Inc.	Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7094579B2 (en)	2002-02-13	2006-08-22	Xoma Technology Ltd.	Eukaryotic signal sequences for prokaryotic expression
WO2003073910A2 (en) *	2002-03-01	2003-09-12	Bayer Corporation	Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
ES2329565T3 (es) *	2002-03-01	2009-11-27	Siemens Healthcare Diagnostics Inc.	Pruebas para monitorear pacientes con cancer, basadas en los niveles de analito de dominio extracelular (ecd) del factor receptor del crecimiento epidermico (egfr),solo o en combinacion con otros analitos,en muestras de fluidos corporales.
EP1572149A2 (de)	2002-03-07	2005-09-14	The Forsyth Institute	Immunogenität von glucan-bindungsprotein
WO2009095742A1 (en)	2008-01-31	2009-08-06	Cellectis	New i-crei derived single-chain meganuclease and uses thereof
WO2003085093A2 (en) *	2002-04-01	2003-10-16	Human Genome Sciences, Inc.	Antibodies that specifically bind to gmad
GB0207533D0 (en)	2002-04-02	2002-05-08	Oxford Glycosciences Uk Ltd	Protein
US7745192B2 (en)	2002-04-03	2010-06-29	Venomics Pty Limited	Prothrombin activating protein
US7358419B2 (en)	2002-04-08	2008-04-15	Pioneer Hi-Bred International, Inc.	Enhanced silk exsertion under stress
EP1492870A4 (de) *	2002-04-12	2005-08-03	Raven Biotechnologies Inc	An integrin-alpha-v-beta-6 bindende antikörper sowie verfahren zur verwendung davon
JP2005535572A (ja)	2002-04-12	2005-11-24	メディミューン，インコーポレーテッド	組換え抗インターロイキン−９抗体
CA2481507A1 (en)	2002-04-16	2003-10-30	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
DK1355152T3 (da)	2002-04-17	2010-06-14	Deutsches Krebsforsch	Fremgangsmåde til at identificere en forbindelse til modulering af wnt-signalkaskaden
US20030206898A1 (en)	2002-04-26	2003-11-06	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
US20040048319A1 (en) *	2002-05-03	2004-03-11	Mather Jennie P.	ALCAM and ALCAM modulators
JP2005529152A (ja)	2002-05-17	2005-09-29	プロテインデザインラブスインコーポレイティド	抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
PL373887A1 (en)	2002-05-21	2005-09-19	Dsm Ip Assets B.V.	Novel phospholipases and uses thereof
CA2488441C (en) *	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
EP2305710A3 (de)	2002-06-03	2013-05-29	Genentech, Inc.	Synthetische Antikörperphagenbibliotheken
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
ATE488530T1 (de) *	2002-06-19	2010-12-15	Raven Biotechnologies Inc	Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
AU2003279240A1 (en) *	2002-06-21	2004-01-06	Genetix Pharmaceuticals, Inc.	Methods for purifying viral particles for gene therapy
WO2004002500A1 (en)	2002-06-28	2004-01-08	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
US20040208877A1 (en) *	2002-07-01	2004-10-21	Avigdor Levanon	Antibodies and uses thereof
US20040202665A1 (en) *	2002-07-01	2004-10-14	Janette Lazarovits	Compositions and methods for therapeutic treatment
US7572442B2 (en)	2002-07-15	2009-08-11	Board Of Regents, The University Of Texas System	Selected antibody compositions for binding to aminophospholipids
EP2314629B2 (de)	2002-07-18	2022-11-16	Merus N.V.	Rekombinante Herstellung von Mischungen aus Aantikörpern
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
PL218992B1 (pl)	2002-07-19	2015-02-27	Abbott Biotech Ltd	Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
US7250551B2 (en)	2002-07-24	2007-07-31	President And Fellows Of Harvard College	Transgenic mice expressing inducible human p25
AU2003253193B2 (en)	2002-07-30	2009-07-02	Morphosys Ag	Novel tricistronic vectors and uses therefor
CA2495121A1 (en)	2002-08-10	2004-02-19	Yale University	Nogo receptor antagonists
WO2004016750A2 (en)	2002-08-14	2004-02-26	Macrogenics, Inc.	FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
AR042417A1 (es)	2002-08-19	2005-06-22	Dsm Ip Assets Bv	Lipasas y usos de las mismas
US7455989B2 (en)	2002-08-20	2008-11-25	Yeda Research And Development Co. Ltd.	AKAP84 and its use for visualization of biological structures
WO2004018999A2 (en)	2002-08-20	2004-03-04	Millenium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US8277753B2 (en)	2002-08-23	2012-10-02	Life Technologies Corporation	Microfluidic transfer pin
AU2003268486A1 (en)	2002-09-04	2004-03-29	Biopolymer Engineering, Inc.	Cancer therapy using whole glucan particles and antibodies
CA2497628A1 (en) *	2002-09-05	2004-03-18	Medimmune, Inc.	Methods of preventing or treating cell malignancies by administering cd2 antagonists
WO2010011999A2 (en)	2008-07-25	2010-01-28	The Regents Of The University Of California	Methods and compositions for eliciting an amyloid-selective immune response
CA2500901A1 (en) *	2002-10-04	2004-04-22	Rinat Neuroscience Corp.	Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
UA80447C2 (en)	2002-10-08	2007-09-25		Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EP1556083B1 (de) *	2002-10-08	2011-02-02	Rinat Neuroscience Corp.	Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
US7255860B2 (en)	2002-10-08	2007-08-14	Rinat Neuroscience Corp.	Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
SI1551876T1 (sl)	2002-10-16	2011-07-29	Purdue Pharma Lp	Protitelesa, ki se vežejo na celično povezan CA 125/0722P, in postopki za njihovo uporabo
TW200509968A (en)	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
US8506959B2 (en)	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2004044161A2 (en) *	2002-11-06	2004-05-27	Fraunhofer Usa	Expression of foreign sequences in plants using trans-activation system
US7692063B2 (en) *	2002-11-12	2010-04-06	Ibio, Inc.	Production of foreign nucleic acids and polypeptides in sprout systems
US7683238B2 (en) *	2002-11-12	2010-03-23	iBio, Inc. and Fraunhofer USA, Inc.	Production of pharmaceutically active proteins in sprouted seedlings
US7491509B2 (en)	2003-02-03	2009-02-17	Fraunhofer Usa, Inc.	System for expression of genes in plants
US7405061B2 (en) *	2002-11-13	2008-07-29	Raven Biotechnologies, Inc.	Antigen PIPA and antibodies that bind thereto
US20040180422A1 (en) *	2002-11-26	2004-09-16	Dyax Corp.	Methods and compositions for controlling valency of phage display
WO2004074818A2 (en)	2002-12-20	2004-09-02	Biotrove, Inc.	Assay apparatus and method using microfluidic arrays
US20060094108A1 (en) *	2002-12-20	2006-05-04	Karl Yoder	Thermal cycler for microfluidic array assays
JP2006513187A (ja) *	2002-12-23	2006-04-20	ライナットニューロサイエンスコーポレイション	タキソール誘発性感覚性ニューロパシーを処置するための方法
US9498530B2 (en)	2002-12-24	2016-11-22	Rinat Neuroscience Corp.	Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
EP2270048B1 (de)	2002-12-24	2015-11-11	Rinat Neuroscience Corp.	Anti-NGF Antikörper und Verfahren zu ihrer Verwendung
US7569364B2 (en)	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
JP2007524348A (ja)	2003-01-07	2007-08-30	ダイアックス、コープ	クニッツドメインライブラリー
US20050079574A1 (en) *	2003-01-16	2005-04-14	Genentech, Inc.	Synthetic antibody phage libraries
WO2004065560A2 (en) *	2003-01-18	2004-08-05	Rinat Neuroscience Corp.	Methods of screening for modulators of nerve growth factor
MXPA05007615A (es) *	2003-01-21	2005-09-30	Bristol Myers Squibb Co	Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo.
AU2004208031B2 (en)	2003-01-28	2009-10-08	Cellectis	Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20050111598A (ko)	2003-02-19	2005-11-25	리나트 뉴로사이언스 코퍼레이션	신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
DK1594542T3 (da)	2003-02-20	2010-10-11	Seattle Genetics Inc	Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
US20040180387A1 (en)	2003-03-13	2004-09-16	Fujirebio Diagnostics, Inc.	Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
PL2248899T3 (pl) *	2003-03-19	2015-10-30	Biogen Ma Inc	Białko wiążące receptor nogo
US20070014786A1 (en) *	2003-03-20	2007-01-18	Rinat Neuroscience Corp.	Methods for treating taxol-induced gut disorder
US7294701B2 (en) *	2003-04-02	2007-11-13	Technion Research & Development Foundation Ltd.	Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US20040202995A1 (en) *	2003-04-09	2004-10-14	Domantis	Nucleic acids, proteins, and screening methods
KR20110094361A (ko)	2003-04-11	2011-08-23	메디뮨 엘엘씨	재조합 ｉｌ９ 항체 및 그의 용도
US20040208876A1 (en)	2003-04-18	2004-10-21	Kim Kyung Jin	Monoclonal antibodies to hepatocyte growth factor
US7321065B2 (en)	2003-04-18	2008-01-22	The Regents Of The University Of California	Thyronamine derivatives and analogs and methods of use thereof
US20050025763A1 (en)	2003-05-08	2005-02-03	Protein Design Laboratories, Inc.	Therapeutic use of anti-CS1 antibodies
US7709610B2 (en)	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
US20050014932A1 (en)	2003-05-15	2005-01-20	Iogenetics, Llc	Targeted biocides
PL1633189T3 (pl)	2003-05-19	2017-12-29	Prothena Biosciences Limited	Skrócone fragmenty alfa-synukleiny w chorobie z ciałami lewy'ego
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
ES2427641T3 (es)	2003-05-22	2013-10-31	Ibio, Inc.	Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
WO2004106375A1 (en)	2003-05-30	2004-12-09	Merus Biopharmaceuticals B.V. I.O.	Fab library for the preparation of anti vegf and anti rabies virus fabs
US9708410B2 (en)	2003-05-30	2017-07-18	Janssen Biotech, Inc.	Anti-tissue factor antibodies and compositions
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
PT2272868E (pt)	2003-06-05	2015-07-07	Genentech Inc	Terapêutica de combinação para distúrbios de células b
CN1279056C (zh) *	2003-06-06	2006-10-11	马菁	肿瘤相关抗原sm5－1的特异性抗体及其应用
US20050232926A1 (en) *	2003-06-06	2005-10-20	Oncomax Acquisition Corp.	Antibodies specific for cancer associated antigen SM5-1 and uses thereof
EP2093570A1 (de)	2003-06-06	2009-08-26	Genentech, Inc.	Modulierung der Interaktion zwischen HGF-beta-Kette und c-Met
CA2542232A1 (en)	2003-06-09	2005-01-20	Alnylam Pharmaceuticals, Inc.	Method for treating neurodegenerative disease by inhibiting alpha-synuclein
US20050152906A1 (en) *	2003-06-30	2005-07-14	Avigdor Levanon	Specific human antibodies
US20050266009A1 (en) *	2003-06-30	2005-12-01	Savient Pharmaceuticals, Inc.	Antibodies and uses thereof
US20050069955A1 (en) *	2003-06-30	2005-03-31	Daniel Plaksin	Antibodies and uses thereof
US8153410B2 (en)	2003-07-07	2012-04-10	Fox Chase Cancer Center	Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20060162014A1 (en)	2003-07-07	2006-07-20	Jaffe Eileen K	Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
WO2005010040A1 (en) *	2003-07-15	2005-02-03	Barros Research Institute	Eimeria tenella antigen for immunotherapy of coccidiosis
WO2005010163A2 (en) *	2003-07-15	2005-02-03	Barros Research Institute	Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
US7619059B2 (en)	2003-07-29	2009-11-17	Life Technologies Corporation	Bimolecular optical probes
CA2445420A1 (en) *	2003-07-29	2005-01-29	Invitrogen Corporation	Kinase and phosphatase assays
US7727752B2 (en)	2003-07-29	2010-06-01	Life Technologies Corporation	Kinase and phosphatase assays
US7758859B2 (en) *	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
EP1668111A4 (de)	2003-08-08	2008-07-02	Genenews Inc	Osteoarthritis-biomarker und verwendungen davon
US20060228350A1 (en) *	2003-08-18	2006-10-12	Medimmune, Inc.	Framework-shuffling of antibodies
JP2007502837A (ja) *	2003-08-18	2007-02-15	テシスバイオサイエンス，インコーポレイテッド	小型エピトープ抗体を使用するサンプルの複雑さを低減するための方法
US20050048617A1 (en)	2003-08-18	2005-03-03	Medimmune, Inc.	Humanization of antibodies
US7046714B2 (en) *	2003-09-10	2006-05-16	Intel Corporation	Method and apparatus for Raman ring resonator based laser/wavelength converter
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
NZ545968A (en) *	2003-09-18	2010-01-29	Raven Biotechnologies Inc	KID3 and KID3 antibodies that bind thereto
CN102517381A (zh)	2003-10-07	2012-06-27	千年药品公司	用于鉴定、评价、预防和治疗卵巢癌的核酸分子和蛋白质
IL158287A0 (en)	2003-10-07	2004-05-12	Yeda Res & Dev	Antibodies to nik, their preparation and use
EP2093298A3 (de)	2003-10-10	2009-09-23	Deutsches Krebsforschungszentrum	Zusammensetzungen zur Diagnose und Therapie für mit aberranter Expression von Futrins (R-Spondins) assoziierten Krankheiten
GB0325836D0 (en) *	2003-11-05	2003-12-10	Celltech R&D Ltd	Biological products
US20050100965A1 (en)	2003-11-12	2005-05-12	Tariq Ghayur	IL-18 binding proteins
PL2295073T3 (pl)	2003-11-17	2014-09-30	Genentech Inc	Przeciwciało przeciwko CD22 do leczenia nowotworu pochodzącego z układu krwiotwórczego
SI1983000T1 (sl)	2003-11-21	2015-12-31	Ucb Biopharma Sprl	Postopek za zdravljenje multiple skleroze z zaviranjem aktivnosti il-17
CA2548180C (en) *	2003-12-04	2014-02-04	Vaccinex, Inc.	Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
KR101374514B1 (ko)	2003-12-10	2014-03-13	메다렉스, 인코포레이티드	Ｉｐ―１０ 항체 및 그의 용도
ES2399050T3 (es)	2003-12-10	2013-03-25	Medarex, Inc.	Anticuerpos contra interferón alfa y sus usos
WO2005058965A1 (en)	2003-12-11	2005-06-30	Genentech, Inc.	Methods and compositions for inhibiting c-met dimerization and activation
GB0329825D0 (en) *	2003-12-23	2004-01-28	Celltech R&D Ltd	Biological products
US20050266425A1 (en) *	2003-12-31	2005-12-01	Vaccinex, Inc.	Methods for producing and identifying multispecific antibodies
AU2005205533B2 (en)	2004-01-07	2012-03-22	Novartis Vaccines And Diagnostics, Inc.	M-CSF-specific monoclonal antibody and uses thereof
MX370489B (es)	2004-01-09	2019-12-16	Pfizer	Anticuerpos contra madcam.
AU2005205412B2 (en)	2004-01-20	2011-08-11	Merus N.V.	Mixtures of binding proteins
US20060014211A1 (en)	2004-01-21	2006-01-19	Fujirebio Diagnostics, Inc.	Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity
US20060147946A1 (en) *	2004-01-27	2006-07-06	Pinchas Akiva	Novel calcium channel variants and methods of use thereof
JP5010923B2 (ja)	2004-02-09	2012-08-29	ヒューマンジノームサイエンシーズ，インコーポレイテッド	アルブミン融合蛋白質
CA2555820C (en)	2004-02-19	2016-01-19	Genentech, Inc.	Cdr-repaired antibodies
EP1769068B1 (de) *	2004-02-20	2014-12-31	iBio, Inc.	Systeme und verfahren zur klonalen expression in pflanzen
CA2560066A1 (en)	2004-03-01	2005-09-15	The Cbr Institute For Biomedical Research, Inc.	Natural igm antibodies and inhibitors thereof
CA2559171A1 (en)	2004-03-12	2005-09-29	Biotrove, Inc.	Nanoliter array loading
KR20080075045A (ko)	2004-03-24	2008-08-13	트리패스 이미징, 인코포레이티드	자궁경부 질환의 검사 방법 및 조성물
EP1786463A4 (de) *	2004-03-26	2009-05-20	Human Genome Sciences Inc	Antikörper gegen nogo-rezeptor
AU2005243247B2 (en)	2004-04-07	2012-03-01	Regents Of The University Of Minnesota	Methods for treating bone cancer pain by administering a nerve growth factor antagonist
TWI439284B (zh)	2004-04-09	2014-06-01	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
US7785903B2 (en) *	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
AU2005238446B2 (en)	2004-04-15	2009-07-30	Banyan Biomarkers Inc.	Neural proteins as biomarkers for nervous system injury and other neural disorders
ES2442386T3 (es)	2004-04-23	2014-02-11	Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr	Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
EP1789453A2 (de) *	2004-05-18	2007-05-30	Genentech, Inc.	Haupthüllproteinvarianten des m13-virus zur c-terminalen und bi-terminalen anzeige eines heterologen proteins
US7517903B2 (en) *	2004-05-19	2009-04-14	Medarex, Inc.	Cytotoxic compounds and conjugates
US7691962B2 (en) *	2004-05-19	2010-04-06	Medarex, Inc.	Chemical linkers and conjugates thereof
CN102453763A (zh)	2004-06-03	2012-05-16	阿什洛米克斯控股有限公司	诊断应激的药物和方法
AU2005252699B2 (en)	2004-06-07	2010-12-23	Macrogenics West, Inc.	Transferrin receptor antibodies
US20060008844A1 (en)	2004-06-17	2006-01-12	Avidia Research Institute	c-Met kinase binding proteins
KR20150041193A (ko)	2004-06-21	2015-04-15	메다렉스, 엘.엘.시.	인터페론 알파 수용체 1 항체 및 그의 용도
GB0414054D0 (en)	2004-06-23	2004-07-28	Owen Mumford Ltd	Improvements relating to automatic injection devices
KR101239542B1 (ko)	2004-06-24	2013-03-07	바이오겐 아이덱 엠에이 인코포레이티드	탈수초화를 수반하는 병의 치료
US7973134B2 (en)	2004-07-07	2011-07-05	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
EP1789593B1 (de)	2004-07-09	2017-03-15	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	Lösliche formen von hendra-virus-g-glycoprotein
US6986264B1 (en) *	2004-07-15	2006-01-17	Carrier Corporation	Economized dehumidification system
RU2342159C2 (ru)	2004-07-16	2008-12-27	Пфайзер Продактс Инк.	Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
US7342093B2 (en)	2004-07-23	2008-03-11	University Of Massachusetts	Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
GEP20115195B (en)	2004-07-30	2011-04-11	Rinat Neuroscience Corp	Antibodies directed against amyloid-beta peptide and use thereof
WO2006017673A2 (en)	2004-08-03	2006-02-16	Biogen Idec Ma Inc.	Taj in neuronal function
US12070731B2 (en)	2004-08-04	2024-08-27	Life Technologies Corporation	Methods and systems for aligning dispensing arrays with microfluidic sample arrays
US7572600B2 (en)	2004-08-04	2009-08-11	Chemocentryx, Inc.	Enzymatic activities in chemokine-mediated inflammation
US20060105453A1 (en)	2004-09-09	2006-05-18	Brenan Colin J	Coating process for microfluidic sample arrays
WO2006017694A1 (en) *	2004-08-05	2006-02-16	Biosite Incorporated	Compositions and methods for phage display of polypeptides
MX2007001679A (es)	2004-08-09	2007-05-23	Elan Pharm Inc	Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
US20060057105A1 (en) *	2004-08-20	2006-03-16	Stern Michael E	Methods of treating ocular inflammation and allergy
WO2006026759A2 (en)	2004-09-03	2006-03-09	Genentech, Inc.	Humanized anti-beta7 antagonists and uses therefor
FI20041204A0 (fi)	2004-09-16	2004-09-16	Riikka Lund	Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
AU2005286770A1 (en)	2004-09-21	2006-03-30	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7935790B2 (en)	2004-10-04	2011-05-03	Cell Singaling Technology, Inc.	Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
DK3428191T3 (da)	2004-10-06	2025-01-02	Mayo Found Medical Education & Res	B7-h1 og pd-1 til behandling af renalcellekarcinom
WO2006047417A2 (en)	2004-10-21	2006-05-04	University Of Florida Research Foundation, Inc.	Detection of cannabinoid receptor biomarkers and uses thereof
AU2005306997B2 (en)	2004-10-25	2012-07-05	Merck Sharp & Dohme Corp.	Anti-ADDL antibodies and uses thereof
WO2006047639A2 (en)	2004-10-27	2006-05-04	Medimmune, Inc.	Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060094062A1 (en) *	2004-11-01	2006-05-04	Medimmune, Inc.	Ultra high throughput capture lift screening methods
GB0426146D0 (en)	2004-11-29	2004-12-29	Bioxell Spa	Therapeutic peptides and method
PE20061329A1 (es)	2004-12-15	2006-12-08	Neuralab Ltd	Anticuerpos ab humanizados para mejorar la cognicion
US7807789B2 (en)	2004-12-21	2010-10-05	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US7850960B2 (en)	2004-12-30	2010-12-14	University Of Washington	Methods for regulation of stem cells
WO2006076584A2 (en)	2005-01-12	2006-07-20	Raven Biotechnologies, Inc.	Kid31 and antibodies that bind thereto
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
WO2006083852A2 (en) *	2005-01-31	2006-08-10	Raven Biotechnologies, Inc.	Luca2 and antibodies that bind thereto
CA2596273C (en)	2005-02-02	2017-11-14	Raven Biotechnologies, Inc.	Adam-9 modulators
WO2006084078A2 (en) *	2005-02-02	2006-08-10	Raven Biotechnologies, Inc.	Jam-3 and antibodies that bind thereto
WO2006084092A2 (en) *	2005-02-03	2006-08-10	Raven Biotechnologies, Inc.	Antibodies to oncostatin m receptor
KR101363252B1 (ko) *	2005-02-04	2014-02-13	레이븐 바이오테크놀로지스, 인코퍼레이티드	Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
CN103497993A (zh)	2005-02-07	2014-01-08	基因信息公司	轻度骨关节炎生物标志物及其用途
US8088579B2 (en)	2005-02-14	2012-01-03	University Of Iowa Research Foundation	Complement factor H for diagnosis of age-related macular degeneration
HUE025945T2 (en)	2005-02-15	2016-07-28	Univ Duke	Anti-CD19 antibodies and their applications in oncology
MX2007009878A (es) *	2005-02-18	2007-10-03	Medarex Inc	Anticuerpos monoclonales para antigeno de membrana especifica para prostata (amep).
DE102005008765B4 (de) *	2005-02-25	2016-06-16	Siemens Healthcare Gmbh	Kontrastmittel auf der Basis von Bakteriophagen, diese enthaltende Zusammensetzung, deren Verwendung und Verfahren zu deren Herstellung
EP1858545A2 (de) *	2005-03-04	2007-11-28	Curedm Inc.	Verfahren und pharmazeutische zusammensetzungen zur behandlung von diabetes mellitus typ 1 und anderer erkrankungen
US20090142338A1 (en) *	2005-03-04	2009-06-04	Curedm, Inc.	Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
WO2006095345A2 (en) *	2005-03-08	2006-09-14	Ramot At Tel-Aviv University Ltd.	Targeted drug-carrying bacteriophages
EP1869076A2 (de)	2005-03-10	2007-12-26	Genentech, Inc.	Verfahren und zusammensetzungen zur modulation der gefässintegrität
EP1869192B1 (de)	2005-03-18	2016-01-20	MedImmune, LLC	Rahmenmischung von antikörpern
CA2601400A1 (en)	2005-03-19	2006-09-28	Medical Research Council	Improvements in or relating to treatment and prevention of viral infections
EP3312196B1 (de)	2005-03-23	2019-07-17	Genmab A/S	Antikörper gegen cd38 zur behandlung von multiplem myelom
GB0506912D0 (en)	2005-04-05	2005-05-11	Celltech R&D Ltd	Biological products
US7714016B2 (en) *	2005-04-08	2010-05-11	Medarex, Inc.	Cytotoxic compounds and conjugates with cleavable substrates
ES2707152T3 (es)	2005-04-15	2019-04-02	Macrogenics Inc	Diacuerpos covalentes y usos de los mismos
US20060269556A1 (en) *	2005-04-18	2006-11-30	Karl Nocka	Mast cell activation using siglec 6 antibodies
EP1871418B1 (de)	2005-04-19	2014-03-19	Seattle Genetics, Inc.	Humanisierte, anti-cd70-bindende wirkstoffe und ihre verwendung
EP1877075A4 (de)	2005-04-25	2008-07-30	Pfizer	Antikörper gegen myostatin
NZ562234A (en)	2005-04-26	2009-09-25	Pfizer	P-cadherin antibodies
AR054260A1 (es) *	2005-04-26	2007-06-13	Rinat Neuroscience Corp	Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
US7595380B2 (en)	2005-04-27	2009-09-29	Tripath Imaging, Inc.	Monoclonal antibodies and methods for their use in the detection of cervical disease
PA8672101A1 (es)	2005-04-29	2006-12-07	Centocor Inc	Anticuerpos anti-il-6, composiciones, métodos y usos
PE20061323A1 (es)	2005-04-29	2007-02-09	Rinat Neuroscience Corp	Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
AU2006244445B2 (en)	2005-05-05	2013-04-18	Duke University	Anti-CD19 antibody therapy for autoimmune disease
PL2161336T5 (pl)	2005-05-09	2017-10-31	Ono Pharmaceutical Co	Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
KR101465456B1 (ko)	2005-05-16	2014-11-27	애브비 바이오테크놀로지 리미티드	미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
PL1899364T5 (pl)	2005-05-17	2024-12-09	University Of Connecticut	Kompozycje i sposoby immunomodulacji w organizmie
PE20061444A1 (es)	2005-05-19	2007-01-15	Centocor Inc	Anticuerpo anti-mcp-1, composiciones, metodos y usos
EA013821B1 (ru)	2005-05-25	2010-08-30	Кьюрдм, Инк.	Проостровковые пептиды человека, их производные и аналоги и способы их применения
NZ564092A (en)	2005-05-27	2010-05-28	Biogen Idec Inc	TWEAK binding antibodies
BRPI0611600B8 (pt)	2005-06-17	2021-05-25	Wyeth Corp	método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
KR20080025174A (ko)	2005-06-23	2008-03-19	메디뮨 인코포레이티드	응집 및 단편화 프로파일이 최적화된 항체 제제
CN103146708A (zh) *	2005-06-30	2013-06-12	Abbvie公司	Il-12/p40结合蛋白
EP2452694B1 (de)	2005-06-30	2018-11-14	Janssen Biotech, Inc.	Anti-IL-23-Antikörper, Zusammensetzungen, Verfahren und Verwendung
CA2612241C (en)	2005-07-01	2018-11-06	Medarex, Inc.	Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1910565A4 (de)	2005-07-07	2009-10-28	Athlomics Pty Ltd	Polynukleotidmarkergene und deren expression zur diagnose von endotoxämie
CA2902070A1 (en)	2005-07-08	2007-01-18	Biogen Idec Ma Inc.	Sp35 antibodies and uses thereof
EP1904652A2 (de) *	2005-07-08	2008-04-02	Brystol-Myers Squibb Company	Mit dosisabhängigem ödem assoziierte einzelnukleotid-polymorphismen und verfahren zur verwendung davon
WO2007014169A2 (en)	2005-07-22	2007-02-01	Y's Therapeutics Co, Ltd.	Anti-cd26 antibodies and methods of use thereof
WO2007016285A2 (en)	2005-07-28	2007-02-08	Novartis Ag	M-csf specific monoclonal antibody and uses thereof
US20080307549A1 (en)	2005-08-03	2008-12-11	Adelaide Research & Innovation Pty Ltd.	Polysaccharide Synthases
CN101378781B (zh) *	2005-08-03	2013-08-07	美国弗劳恩霍夫股份有限公司	制造免疫球蛋白的组合物和方法
JP2009504685A (ja) *	2005-08-15	2009-02-05	アラーナ・テラピューティクス・リミテッド	新世界霊長類フレームワーク領域を用いる設計された抗体
JP5364870B2 (ja)	2005-08-19	2013-12-11	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリン及びその使用
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
EP2500353A3 (de)	2005-08-19	2012-10-10	Abbott Laboratories	Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US20070041905A1 (en)	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
US20070202512A1 (en) *	2005-08-19	2007-08-30	Bristol-Myers Squibb Company	Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
WO2007027906A2 (en)	2005-08-31	2007-03-08	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in leukemia signaling pathways
KR101536506B1 (ko)	2005-09-07	2015-07-14	암젠 프레몬트 인코포레이티드	액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
US8945573B2 (en)	2005-09-08	2015-02-03	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Targeted identification of immunogenic peptides
US8193328B2 (en)	2005-09-08	2012-06-05	Philadelphia Health & Education Corporation	Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
AU2006290567A1 (en) *	2005-09-14	2007-03-22	Ucb Pharma S.A	Comb polymers
US9062126B2 (en)	2005-09-16	2015-06-23	Raptor Pharmaceuticals Inc.	Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
NZ566395A (en)	2005-09-26	2012-03-30	Medarex Inc	Human monoclonal antibodies to CD70
AU2006294554B2 (en)	2005-09-26	2013-03-21	E. R. Squibb & Sons, L.L.C.	Antibody-drug conjugates and methods of use
CN101277974A (zh)	2005-09-30	2008-10-01	阿伯特有限及两合公司	排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
GB0521139D0 (en)	2005-10-18	2005-11-23	Univ Sheffield	Therapeutic agent
JP5237817B2 (ja)	2005-10-21	2013-07-17	ジーンニュースインコーポレーティッド	バイオマーカー産物レベルを疾患に相関させるための方法および装置
US7910708B2 (en)	2005-10-21	2011-03-22	Novartis Ag	Anti-IL13 human antibodies
WO2007050793A2 (en)	2005-10-25	2007-05-03	The Johns Hopkins University	Methods and compositions for the treatment of marfan syndrome and associated disorders
CN101365679B (zh)	2005-10-26	2012-11-14	梅达莱克斯公司	制备cc-1065类似物的方法和化合物
EP1948680A4 (de)	2005-10-28	2010-01-13	Univ California	Verfahren und verbindungen zum nachweis und zum isolieren von lymphomzellen
PT1948235E (pt)	2005-11-01	2013-11-26	Abbvie Biotechnology Ltd	Métodos de determinação da eficácia de adalimumab em sujeitos com espondilite anquilosante, utilizando ctx-ii e mmp3 como biomarcadores
US20070099246A1 (en) *	2005-11-03	2007-05-03	Sandy John D	Antibodies, assays and kits to quantitate cartilage destruction
WO2007056161A1 (en)	2005-11-04	2007-05-18	Biogen Idec Ma Inc.	Methods for promoting neurite outgrowth and survival of dopaminergic neurons
EP1957531B1 (de)	2005-11-07	2016-04-13	Genentech, Inc.	Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
ZA200804082B (en)	2005-11-07	2010-02-24	Scripps Research Inst	Compositions and methods for controlling tissue factor signaling specificity
UA96139C2 (uk)	2005-11-08	2011-10-10	Дженентек, Інк.	Антитіло до нейропіліну-1 (nrp1)
CA2627190A1 (en)	2005-11-10	2007-05-24	Medarex, Inc.	Duocarmycin derivatives as novel cytotoxic compounds and conjugates
ES2433251T5 (es)	2005-11-14	2020-03-13	Teva Pharmaceuticals Int Gmbh	Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
WO2007059166A2 (en)	2005-11-14	2007-05-24	Weber Georg F	Peptide sequence that promotes tumor invasion
EP1951890A4 (de)	2005-11-16	2009-06-24	Ambrx Inc	Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren
EP2805971A1 (de)	2005-11-28	2014-11-26	ZymoGenetics, Inc.	IL-21-Antagonisten
PT1976877E (pt)	2005-11-30	2014-04-29	Abbvie Inc	Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
AU2006350038B2 (en)	2005-11-30	2011-09-15	Massachusetts Institute Of Technology	Pathogen detection biosensor
BRPI0619249A2 (pt)	2005-11-30	2011-09-20	Abbott Lab	anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
JP4976412B2 (ja)	2005-12-01	2012-07-18	ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー	エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
EP1965827B1 (de)	2005-12-02	2015-02-25	Biogen Idec MA Inc.	Behandlung von entmyelinisierenden erkrankungen
KR101434682B1 (ko) *	2005-12-02	2014-08-27	제넨테크, 인크.	결합 폴리펩티드 및 이들의 용도
EP1960434B1 (de)	2005-12-08	2012-07-11	Medarex, Inc.	Humane monoklonale antikörper gegen fucosyl-gm1 und verfahren zur anwendung von anti-fucosyl-gm1
CN101356194B (zh)	2005-12-09	2013-06-12	Ucb医药有限公司	对人il-6具有特异性的抗体分子
DOP2006000277A (es)	2005-12-12	2007-08-31	Bayer Pharmaceuticals Corp	Anticuerpos anti mn y métodos para su utilización
US8014957B2 (en)	2005-12-15	2011-09-06	Fred Hutchinson Cancer Research Center	Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US10183986B2 (en)	2005-12-15	2019-01-22	Industrial Technology Research Institute	Trimeric collagen scaffold antibodies
US20070264687A1 (en)	2005-12-15	2007-11-15	Min-Yuan Chou	Recombinant triplex scaffold-based polypeptides
US7632498B2 (en)	2005-12-19	2009-12-15	Tripath Imaging, Inc.	MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
RS55963B1 (sr)	2005-12-29	2017-09-29	Janssen Biotech Inc	Humana anti-il-23 antitela, kompozicije, metode i upotrebe
US8075884B2 (en)	2006-01-12	2011-12-13	Alexion Pharmaceuticals, Inc.	Antibodies to OX-2/CD200 and uses thereof
US20070166774A1 (en) *	2006-01-17	2007-07-19	Groman Ernest V	Functional immunoassay
US20120208824A1 (en)	2006-01-20	2012-08-16	Cell Signaling Technology, Inc.	ROS Kinase in Lung Cancer
CA2640423C (en)	2006-01-27	2016-03-15	Biogen Idec Ma Inc.	Nogo receptor antagonists
EP1987360B1 (de)	2006-01-27	2012-03-07	Tripath Imaging, Inc.	Verfahren zur identifizierung von patienten mit erhöhter wahrscheinlichkeit des auftretens eines ovarialkarzinoms und zusammensetzungen dafür
EP1987361A4 (de) *	2006-01-30	2009-03-04	Invitrogen Corp	Zusammensetzungen und verfahren zur erkennung und quantifizierung toxischer substanzen in krankheitsstadien
US20070175313A1 (en) *	2006-01-31	2007-08-02	Kevin Vandervliet	MP3 player holder assembly
CN103232540A (zh) *	2006-02-01	2013-08-07	赛法隆澳大利亚控股有限公司	结构域抗体构建体
AU2007215082B2 (en) *	2006-02-13	2012-07-12	Ibio, Inc.	HPV antigens, vaccine compositions, and related methods
WO2008048344A2 (en) *	2006-02-13	2008-04-24	Fraunhofer Usa, Inc.	Bacillus anthracis antigens, vaccine compositions, and related methods
EP1984405A4 (de) *	2006-02-13	2010-06-30	Fraunhofer Usa Inc	Influenza-antigene, impfstoffzusammensetzungen und zugehörige verfahren
WO2007120975A2 (en)	2006-02-13	2007-10-25	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Variants in complement regulatory genes predict age-related macular degeneration
TWI417301B (zh)	2006-02-21	2013-12-01	Wyeth Corp	對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en)	2006-02-21	2007-12-16	Wyeth Corp	Methods of using antibodies against human IL-22
DK2514823T3 (en)	2006-03-03	2018-07-23	Promis Neurosciences Inc	Methods and compositions for treating and detecting failed SOD1-mediated diseases
WO2007103469A2 (en)	2006-03-06	2007-09-13	Aeres Biomedical Ltd.	Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1996942A1 (de) *	2006-03-10	2008-12-03	Tethys Bioscience, Inc.	Multiplex-protein-fraktionierung
EP2010569A4 (de)	2006-03-20	2009-09-09	Xoma Technology Ltd	Für gastrin spezifische humane antikörper, materialien und methoden
CL2007000851A1 (es)	2006-03-30	2008-03-14	Novartis Ag	Anticuerpo anti receptor del factor de crecimiento del hepatocito (c-met); adn que codifican cadenas livianas y pesadas del anticuerpo; composicion farmaceutica y kit que comprenden dicho anticuerpo; metodo para tratar trastorno relacionado con c-met
JP5514539B2 (ja)	2006-03-31	2014-06-04	メダレックス・リミテッド・ライアビリティ・カンパニー	ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
AR059922A1 (es)	2006-04-01	2008-05-07	Galaxy Biotech Llc	Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2738179A1 (de)	2006-04-05	2014-06-04	AbbVie Biotechnology Ltd	Antikörperreinigung
AU2007243946B2 (en)	2006-04-05	2012-11-29	Curis, Inc.	Method for using BOC/CDO to modulate hedgehog signaling
US8071323B2 (en)	2006-04-07	2011-12-06	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Human monoclonal antibodies that bind human insulin like growth factors and their use
CA2564435A1 (en)	2006-04-10	2007-10-10	Abbott Biotechnology Ltd.	Methods for monitoring and treating intestinal disorders
EP2708242A3 (de)	2006-04-10	2014-03-26	Abbott Biotechnology Ltd	Anwendungen und Zusammensetzungen zur Behandlung von Morbus Bechterew
EP2666472A3 (de)	2006-04-10	2014-04-02	Abbott Biotechnology Ltd	Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
JP2009534390A (ja) *	2006-04-21	2009-09-24	アムジェンインコーポレイテッド	生物医薬品製剤のための緩衝剤
TWI395754B (zh)	2006-04-24	2013-05-11	Amgen Inc	人類化之ｃ-ｋｉｔ抗體
US10522240B2 (en)	2006-05-03	2019-12-31	Population Bio, Inc.	Evaluating genetic disorders
US7702468B2 (en)	2006-05-03	2010-04-20	Population Diagnostics, Inc.	Evaluating genetic disorders
CA2651567A1 (en) *	2006-05-09	2007-11-22	Genentech, Inc.	Binding polypeptides with optimized scaffolds
GB0611116D0 (en)	2006-06-06	2006-07-19	Oxford Genome Sciences Uk Ltd	Proteins
CN101516912B (zh)	2006-06-07	2013-10-30	生物联合公司	识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
MX2008015771A (es)	2006-06-14	2009-01-27	Macrogenics Inc	Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
EP2158898A1 (de)	2006-06-23	2010-03-03	Aegis Therapeutics LLC	Stabilisierung von Alkylglykosidzusammensetzungen und zugehöriges Verfahren
AU2007281876B2 (en)	2006-06-26	2013-09-05	Macrogenics, Inc.	FcgammaRIIB-specific antibodies and methods of use thereof
TWI498137B (zh)	2006-06-30	2015-09-01	Abbvie Biotechnology Ltd	自動注射裝置
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
NZ596269A (en)	2006-07-05	2012-12-21	Catalyst Biosciences Inc	Protease screening methods and proteases identified thereby
EA020324B1 (ru)	2006-07-18	2014-10-30	Санофи-Авентис	АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
JP5638804B2 (ja)	2006-08-04	2014-12-10	アストラゼネカアクチボラグ	ＥｒｂＢ２に対する抗体
JP5406027B2 (ja)	2006-08-04	2014-02-05	ノバルティスアーゲー	ＥｐｈＢ３特異的抗体およびその使用
JP5244103B2 (ja)	2006-08-09	2013-07-24	ホームステッドクリニカルコーポレイション	器官特異的蛋白質およびその使用方法
US7939636B2 (en)	2006-08-11	2011-05-10	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in c-Src signaling pathways
EP2046834B9 (de)	2006-08-11	2013-04-10	Ono Pharmaceutical Co., Ltd.	Monoklonale antikörper gegen stromal derived factor-1 (sdf-1-)
WO2008017126A1 (en)	2006-08-11	2008-02-14	Csl Limited	Treatment of pulmonary disease conditions
EP3018144A1 (de)	2006-08-18	2016-05-11	XOMA Technology Ltd.	Prlr-spezifischer antikörper und verwendungen davon
EA021255B1 (ru)	2006-08-28	2015-05-29	Киова Хакко Кирин Ко., Лимитед	Антагонистические моноклональные антитела человека, специфичные в отношении light человека
KR20090088852A (ko)	2006-09-05	2009-08-20	메다렉스, 인코포레이티드	골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
PL3339445T3 (pl) *	2006-09-08	2020-12-14	Abbvie Bahamas Ltd.	Białka wiążące interleukinę 13
JPWO2008032833A1 (ja)	2006-09-14	2010-01-28	株式会社医学生物学研究所	Ａｄｃｃ活性を増強させた抗体及びその製造方法
US20090252745A1 (en) *	2006-09-15	2009-10-08	Duke University	Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis
AU2007302448C1 (en)	2006-09-26	2019-02-14	Genmab A/S	Combination treatment of CD38-expressing tumors
ES2625798T3 (es)	2006-10-02	2017-07-20	E. R. Squibb & Sons, L.L.C.	Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
EP2081553B1 (de) *	2006-10-06	2020-08-12	Amgen Inc.	Stabile antikörper-formulierungen
MX2009003542A (es)	2006-10-12	2009-04-15	Wyeth Corp	Metodos y composiciones con opalescencia reducida.
NZ576032A (en) *	2006-10-12	2012-03-30	Genentech Inc	Antibodies to lymphotoxin-alpha
EP2064335A4 (de)	2006-10-16	2011-03-30	Medimmune Llc	Moleküle mit reduzierter halbwertzeit, zusammensetzungen und ihre verwendung
GB0620729D0 (en)	2006-10-18	2006-11-29	Ucb Sa	Biological products
EP1914242A1 (de)	2006-10-19	2008-04-23	Sanofi-Aventis	Neue Antikörper gegen CD38 zur Behandlung von Krebs
DK2068922T3 (da)	2006-10-19	2012-10-08	Csl Ltd	Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
JP5623743B2 (ja) *	2006-10-20	2014-11-12	アムジエン・インコーポレーテツド	安定なポリペプチド製剤
US7846434B2 (en)	2006-10-24	2010-12-07	Trubion Pharmaceuticals, Inc.	Materials and methods for improved immunoglycoproteins
US8192951B2 (en)	2006-11-03	2012-06-05	Wyeth Llc	Glycolysis-inhibiting substances in cell culture
AU2007325872B2 (en)	2006-11-08	2012-12-13	Macrogenics West, Inc.	TES7 and antibodies that bind thereto
AU2007334264A1 (en)	2006-11-15	2008-06-26	Medarex, Inc.	Human monoclonal antibodies to BTLA and methods of use
JP2010510235A (ja)	2006-11-15	2010-04-02	ファンクショナル・ジェネティクス・インコーポレーテッド	抗ｔｓｇ１０１抗体およびウイルス感染の処置のためのその使用
US7488807B2 (en)	2006-11-22	2009-02-10	3M Innovative Properties Company	Antibody with protein A selectivity
WO2008064306A2 (en) *	2006-11-22	2008-05-29	Curedm, Inc.	Methods and compositions relating to islet cell neogenesis
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
DK2099823T4 (da)	2006-12-01	2022-05-09	Seagen Inc	Målbindingsmiddelvarianter og anvendelser deraf
EP2097097B1 (de)	2006-12-01	2018-05-30	E. R. Squibb & Sons, L.L.C.	Antikörper, insbesondere menschliche antikörper, die an cd22 binden und deren verwendung
HUE041957T2 (hu)	2006-12-01	2019-06-28	Novartis Ag	Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére
CA2673123C (en)	2006-12-05	2019-04-30	Decode Genetics Ehf.	Genetic markers for risk management of cardiac arrhythmia
EP2687232A1 (de)	2006-12-06	2014-01-22	MedImmune, LLC	Verfahren zur Behandlung von systemischem Lupus erythematodes
KR20140119831A (ko)	2006-12-07	2014-10-10	노파르티스 아게	Ｅｐｈｂ３에 대한 길항제 항체
US20080139790A1 (en) *	2006-12-08	2008-06-12	Jennings Philip A	Chimeric antibodies
CL2007003622A1 (es)	2006-12-13	2009-08-07	Medarex Inc	Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
AU2007333098A1 (en)	2006-12-14	2008-06-19	Medarex, Inc.	Human antibodies that bind CD70 and uses thereof
EP3124045A3 (de)	2006-12-20	2017-05-03	Xoma (Us) Llc	Behandlung von il-1-beta-bedingten erkrankungen
MX2009006594A (es) *	2006-12-21	2009-08-12	Amgen Inc	Formulaciones de ph regulado y estables que contienen polipeptidos.
AR064464A1 (es) *	2006-12-22	2009-04-01	Genentech Inc	Anticuerpos anti - receptor del factor de crecimiento insulinico
US8440185B2 (en)	2006-12-26	2013-05-14	The Johns Hopkins University	Compositions and methods for the treatment of immunologic disorders
US7931896B2 (en)	2006-12-27	2011-04-26	The Johns Hopkins University	Compositions and methods for treating inflammation and auto-immune diseases
CA2947292C (en)	2006-12-27	2019-07-23	Emory University	Compositions and methods for the treatment of infections and tumors
US7989173B2 (en)	2006-12-27	2011-08-02	The Johns Hopkins University	Detection and diagnosis of inflammatory disorders
TWI412367B (zh)	2006-12-28	2013-10-21	梅達雷克斯有限責任公司	化學鏈接劑與可裂解基質以及其之綴合物
EP2114443A4 (de) *	2006-12-29	2011-08-10	Abbott Lab	Doppelt spezifische il-1a/il-1b-antikörper
CN101636168B (zh)	2007-01-09	2013-05-29	比奥根艾迪克Ma公司	Sp35抗体及其用途
US8128926B2 (en)	2007-01-09	2012-03-06	Biogen Idec Ma Inc.	Sp35 antibodies and uses thereof
AU2008204335B2 (en)	2007-01-11	2013-06-13	Michael Bacher	Diagnosis and treatment of Alzheimer's and other neurodementing diseases
BRPI0807236A2 (pt)	2007-02-07	2019-09-24	Decode Genetics Ehf	métodos para determinar uma suscetibilidade para câncer de próstata em um indivíduo humano, para identificar um marcador para uso em avaliação de suscetibilidade para câncer de próstata e para genotipificar uma amostra de ácido nucleico obtida de um indivíduo humano sob risco de, ou diagnosticado com, câncer de prostáta, para avaliar um indivíduo humano para probabiliade da resposta a um agente terapêutico para prevenir e/ou melhorar sintomas associados com câncer de próstata, para predizer prognóstico de um indivíduo diagnosticado com câncer e para monitorar progresso de um tratamento de um indivíduo sofrendo tratamento para câncer de próstata, kit para avaliar suscetibilidade para câncer de próstata em um indivíduo humano, uso de uma sonda de oligonucleotídeo, meio legível por computador, e , aparelho para determinar um indicador genético para câncer de próstata em um indivíduo humano.
BRPI0806403A2 (pt)	2007-02-09	2011-09-06	Genentech Inc	anticorpo anti-robo4, usode um anticorpo e método de obtenção de imagem
US20110076752A1 (en) *	2007-02-09	2011-03-31	Medimmune, Llc	Antibody library display by yeast cell plasma membrane
WO2008101184A2 (en) *	2007-02-16	2008-08-21	The Board Of Trustees Of Southern Illinois University	Arl-1 specific antibodies
US8685666B2 (en) *	2007-02-16	2014-04-01	The Board Of Trustees Of Southern Illinois University	ARL-1 specific antibodies and uses thereof
SG178789A1 (en)	2007-02-16	2012-03-29	Merrimack Pharmaceuticals Inc	Antibodies against erbb3 and uses thereof
KR20090122439A (ko) *	2007-02-21	2009-11-30	메다렉스, 인코포레이티드	단일 아미노산을 갖는 화학적 링커 및 이의 접합체
KR101571523B1 (ko)	2007-02-21	2015-11-24	디코드 제네틱스 이에이치에프	심혈관 질환과 연관된 유전적 감수성 변이
US7875431B2 (en)	2007-02-22	2011-01-25	Genentech, Inc.	Methods for detecting inflammatory bowel disease
PL2118300T3 (pl)	2007-02-23	2015-11-30	Prothena Biosciences Ltd	Zapobieganie i leczenie synukleinopatii i amyloidozy
LT3067066T (lt)	2007-02-23	2019-06-25	Prothena Biosciences Limited	Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas
EP2447719B1 (de)	2007-02-26	2016-08-24	Oxford BioTherapeutics Ltd	Proteine
WO2008104803A2 (en)	2007-02-26	2008-09-04	Oxford Genome Sciences (Uk) Limited	Proteins
EP2124952A2 (de)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Verfahren zur behandlung von amyloidosen
EP1972639A3 (de)	2007-03-07	2008-12-03	Cell Signaling Technology, Inc.	Reagenzien zur Erkennung von Proteinphosphorylierung in Karzinom-Signalwegen
SG196697A1 (en)	2007-03-22	2014-02-13	Biogen Idec Inc	Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
US8785135B2 (en)	2007-03-22	2014-07-22	Heptares Therapeutics Limited	Mutant G-protein coupled receptors and methods for selecting them
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US20090068684A1 (en)	2007-03-26	2009-03-12	Cell Signaling Technology, Inc.	Serine and threoninephosphorylation sites
BRPI0809435A2 (pt) *	2007-03-27	2014-09-09	Sea Lane Biotechnologies, Llc	Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
US20100209434A1 (en)	2007-03-30	2010-08-19	Medimmune, Llc	Antibody formulation
PA8775101A1 (es)	2007-04-02	2008-11-19	Pfizer	Anticuerpos anti-ige
AP2009005028A0 (en)	2007-04-10	2009-12-31	Univ Tulane	Soluble and membrane-anchored forms of lassa virussubunit proteins
US7807168B2 (en) *	2007-04-10	2010-10-05	Vaccinex, Inc.	Selection of human TNFα specific antibodies
EP2481797A1 (de)	2007-04-13	2012-08-01	Catalyst Biosciences, Inc.	Modifizierte Faktor-VII-Polypeptide und Verwendungen dafür
US7977462B2 (en)	2007-04-19	2011-07-12	Cell Signaling Technology, Inc.	Tyrosine phosphorylation sites
EP1983003A3 (de)	2007-04-19	2009-03-11	Peter Hornbeck	Tyrosinphosphorylationsstellen und spezifische Antikörper
EP2145902A3 (de)	2007-04-19	2010-09-29	Peter Hornbeck	Tyrosinphosphorylations-Stellen und spezifische Antikörper
TW200902708A (en)	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
US8778348B2 (en) *	2007-04-28	2014-07-15	Ibio Inc.	Trypanosoma antigens, vaccine compositions, and related methods
US20090053831A1 (en)	2007-05-01	2009-02-26	Cell Signaling Technology, Inc.	Tyrosine phosphorylation sites
CA2686039A1 (en) *	2007-05-03	2008-11-13	Tethys Bioscience, Inc.	Binding reagents that contain small epitope binding molecules
EP2164868B1 (de)	2007-05-04	2015-03-25	Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA	Gentechnisch gewonnene variable domänen von kaninchen-antikörpern und deren verwendung
EP2703011A3 (de)	2007-05-07	2014-03-26	MedImmune, LLC	Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
WO2008143666A2 (en)	2007-05-17	2008-11-27	Genentech, Inc.	Crystal structures of neuropilin fragments and neuropilin-antibody complexes
DK3072525T3 (en)	2007-05-14	2018-04-30	Astrazeneca Ab	PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
JP2010527603A (ja)	2007-05-25	2010-08-19	ディコーデジェネテクスイーエイチエフ	乳癌のリスクアセスメント、診断、予後診断および治療における使用のためのマーカーとしてのＣＨＲ５ｐ１２および１０ｑ２６上の遺伝的変異
US20090232801A1 (en) *	2007-05-30	2009-09-17	Abbot Laboratories	Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
PE20090329A1 (es) *	2007-05-30	2009-03-27	Abbott Lab	Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US7709215B2 (en)	2007-06-01	2010-05-04	Cytonics Corporation	Method for diagnosing and treating acute joint injury
US8999337B2 (en)	2007-06-11	2015-04-07	Abbvie Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
CA2691075C (en)	2007-06-15	2017-04-11	Daniela Gast	Treatment of tumors using specific anti-l1 antibody
CA2691434C (en)	2007-06-21	2020-07-21	Macrogenics, Inc.	Covalent diabodies and uses thereof
US8404252B2 (en)	2007-07-11	2013-03-26	Fraunhofer Usa, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
AU2008293885A1 (en)	2007-07-13	2009-03-05	The John Hopkins University	B7-DC variants
ES2528922T3 (es)	2007-07-16	2015-02-13	Genentech, Inc.	Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
ATE543835T1 (de)	2007-07-16	2012-02-15	Genentech Inc	Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
EP2182943B1 (de)	2007-07-23	2016-10-26	Janssen Biotech, Inc.	Verfahren und zusammensetzungen zur behandlung von fibrosebedingten erkrankungen mit il-17-antagonisten
US8986684B2 (en) *	2007-07-25	2015-03-24	Alexion Pharmaceuticals, Inc.	Methods and compositions for treating autoimmune disease
SI2182983T1 (sl)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
ES2700141T3 (es)	2007-08-02	2019-02-14	Gilead Biologics Inc	Anticuerpos inhibidores LOXL2 y usos de los mismos
US20100273722A1 (en) *	2007-08-06	2010-10-28	Yale University	Modified miniature proteins
WO2009097006A2 (en)	2007-08-10	2009-08-06	Medarex, Inc.	Hco32 and hco27 and related examples
ES2628395T3 (es)	2007-08-15	2017-08-02	Bayer Pharma Aktiengesellschaft	Anticuerpo regulado por proteasa
CA2696764A1 (en) *	2007-08-20	2009-02-26	Fraunhofer Usa, Inc.	Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
KR20100089816A (ko) *	2007-08-21	2010-08-12	모르포시스 아게	이황화 결합을 형성하기 위한 개선된 방법
EP2185188B1 (de)	2007-08-22	2014-08-06	Medarex, L.L.C.	Ortsspezifische bindung von wirkstoffen oder anderen mitteln an gentechnisch hergestellte antikörper mit c-terminalen erweiterungen
ES2534434T3 (es) *	2007-08-30	2015-04-22	Curedm Group Holdings, Llc	Composiciones y métodos de uso de péptidos proislotes y análogos de los mismos
EP2190469B1 (de)	2007-09-04	2015-02-25	Compugen Ltd.	Polypeptide und polynukleotide und ihre verwendung als zielmolekül zur herstellung von arzneimitteln und biologika
GB0717337D0 (en)	2007-09-06	2007-10-17	Ucb Pharma Sa	Method of treatment
US8629246B2 (en)	2007-09-26	2014-01-14	Ucb Pharma S.A.	Dual specificity antibody fusions
AU2008304111B2 (en)	2007-09-27	2014-04-24	Amgen Inc.	Pharmaceutical formulations
JP5674469B2 (ja) *	2007-10-11	2015-02-25	バイオジェン・アイデック・エムエイ・インコーポレイテッド	ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
WO2009052293A1 (en)	2007-10-16	2009-04-23	Zymogenetics, Inc.	Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
EP3741851A1 (de)	2007-10-18	2020-11-25	Cell Signaling Technology, Inc.	Translokation und mutante ros-kinase in humanem nichtkleinzelligem lungenkarzinom
EA201000603A1 (ru)	2007-10-23	2010-12-30	Новартис Аг	ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
US20100324154A1 (en)	2007-11-01	2010-12-23	Hageman Gregory S	Assessing susceptibility to vascular disorders
CN101951954A (zh)	2007-11-02	2011-01-19	诺瓦提斯公司	调节低密度脂蛋白受体相关蛋白6(lrp6)的分子和方法
BRPI0819195A2 (pt)	2007-11-05	2017-05-23	Medimmune Llc	métodos para tratar escleroderma em um paciente em necessidade de tal tratamento e para aliviar um ou mais dos sintomas associados com escleroderma em um paciente em necessidade de tal tratamento.
KR101811965B1 (ko)	2007-11-07	2017-12-22	셀덱스 쎄라퓨틱스, 인크.	인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체
CN101918540B (zh) *	2007-11-08	2016-05-11	比奥根Ma公司	Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用
MX2010005104A (es)	2007-11-09	2010-08-04	Peregrine Pharmaceuticals Inc	Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
US8088715B2 (en) *	2007-11-13	2012-01-03	Ikonisys, Inc.	Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope
EP3381445B1 (de)	2007-11-15	2023-10-25	Amgen Inc.	Wässrige antikörperformulierung mit stabilisierung durch antioxidantien zur parenteralen verabreichung
WO2009067546A2 (en)	2007-11-19	2009-05-28	Celera Corpration	Lung cancer markers and uses thereof
WO2009067580A2 (en)	2007-11-20	2009-05-28	Pioneer Hi-Bred International, Inc.	Maize ethylene signaling genes and modulation of same for improved stress tolerance in plants
US20090203043A1 (en)	2007-11-21	2009-08-13	Peter Hornbeck	Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
WO2009070642A1 (en) *	2007-11-28	2009-06-04	Medimmune, Llc	Protein formulation
US8697360B2 (en)	2007-11-30	2014-04-15	Decode Genetics Ehf.	Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
TWI580694B (zh)	2007-11-30	2017-05-01	建南德克公司	抗-ｖｅｇｆ抗體
GB0724051D0 (en)	2007-12-08	2008-01-16	Medical Res Council	Mutant proteins and methods for producing them
DK2222706T4 (en)	2007-12-14	2016-11-21	Novo Nordisk As	Antibodies that bind to NKG2D and its use
US8779088B2 (en)	2007-12-17	2014-07-15	Marfl Ab	Vaccine for the treatment of Mycobacterium related disorders
CN105732813A (zh)	2007-12-18	2016-07-06	生物联合公司	识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
GB0724860D0 (en)	2007-12-20	2008-01-30	Heptares Therapeutics Ltd	Screening
DK2391650T3 (en)	2007-12-20	2015-01-12	Xoma Us Llc	Methods of treating gout
CA2709354C (en)	2007-12-21	2014-06-17	Amgen Inc.	Anti-amyloid antibodies and uses thereof
JP5690593B2 (ja) *	2007-12-26	2015-03-25	ヴァクシネックス，インコーポレイテッド	抗ｃ３５抗体併用療法および方法
PT2237803E (pt)	2007-12-28	2015-10-16	Prothena Biosciences Ltd	Tratamento e profilaxia da amiloidose
GB0800277D0 (en)	2008-01-08	2008-02-13	Imagination Tech Ltd	Video motion compensation
WO2009088105A1 (en)	2008-01-11	2009-07-16	Gene Techno Science Co., Ltd.	HUMANIZED ANTI-α9 INTEGRIN ANTIBODIES AND THE USES THEREOF
ES2613963T3 (es)	2008-01-18	2017-05-29	Medimmune, Llc	Anticuerpos manipulados con cisteína para conjugación específica de sitio
AU2009206306B2 (en)	2008-01-25	2013-06-06	Amgen Inc.	Ferroportin antibodies and methods of use
PT2247620T (pt)	2008-01-31	2016-08-23	Genentech Inc	Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
AU2009212442C1 (en)	2008-02-05	2014-07-17	Bristol-Myers Squibb Company	Alpha 5 - beta 1 antibodies and their uses
CN101952454B (zh)	2008-02-08	2014-06-04	米迪缪尼有限公司	具有减弱的Fc配体亲和性的抗IFNAR1抗体
GB0802474D0 (en)	2008-02-11	2008-03-19	Heptares Therapeutics Ltd	Mutant proteins and methods for selecting them
US20090215119A1 (en) *	2008-02-13	2009-08-27	Dyax Corp.	Methods for producing specific binding pairs
EP2247755B1 (de)	2008-02-14	2015-01-28	Decode Genetics EHF	Suszeptibilitätsvarianten für lungenkrebs
AU2009219358A1 (en)	2008-02-28	2009-09-03	3M Innovative Properties Company	Antibodies to Clostridium difficile spores and uses thereof
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
US20090233809A1 (en) *	2008-03-04	2009-09-17	Affymetrix, Inc.	Resequencing methods for identification of sequence variants
US20110020368A1 (en)	2008-03-25	2011-01-27	Nancy Hynes	Treating cancer by down-regulating frizzled-4 and/or frizzled-1
AU2009233327B2 (en)	2008-04-01	2014-11-13	Decode Genetics Ehf	Susceptibility variants for peripheral arterial disease and abdominal aortic aneurysm
HUE029925T2 (en)	2008-04-02	2017-04-28	Macrogenics Inc	HER2 / neu-specific antibodies and methods using them
JP5785490B2 (ja)	2008-04-02	2015-09-30	マクロジェニクス，インコーポレーテッド	Ｂｃｒ複合体特異的抗体およびその使用方法
WO2009126306A2 (en)	2008-04-10	2009-10-15	Cell Signaling Technology, Inc.	Compositions and methods for detecting egfr mutations in cancer
BRPI0911652A2 (pt)	2008-04-11	2015-08-04	Merrimack Pharmaceuticals Inc	Ligantes de albumina sérica humana e seus conjugados
KR101674097B1 (ko)	2008-04-11	2016-11-08	시애틀 지네틱스, 인크.	췌장, 난소 및 다른 암의 검출 및 치료
GB0807413D0 (en)	2008-04-23	2008-05-28	Ucb Pharma Sa	Biological products
CA2721716C (en)	2008-04-24	2019-09-24	Gene Techno Science Co., Ltd.	Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
TWI593423B (zh)	2008-04-25	2017-08-01	戴埃克斯有限公司	Ｆｃ受體結合蛋白
US20090269786A1 (en) *	2008-04-25	2009-10-29	The Board Of Trustees Of The University Of Illinois	RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
JP5646457B2 (ja)	2008-04-29	2014-12-24	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリン及びその使用
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
JP2011519279A (ja)	2008-05-01	2011-07-07	アムジエン・インコーポレーテツド	抗ヘプシジン抗体及び使用の方法
CN102076865B (zh)	2008-05-02	2016-03-16	西雅图基因公司	用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
RU2518351C2 (ru)	2008-05-09	2014-06-10	Эббви Дойчланд Гмбх Унд Ко.Кг,	Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
MX2010012368A (es) *	2008-05-16	2010-12-06	Genentech Inc	Uso de biomarcadores para evaluar un tratamiento contra trastornos inflamatorios gastrointestinales con antagonistas de beta7-integrina.
BRPI0912035A2 (pt)	2008-05-29	2017-05-23	Galaxy Biotech Llc	anticorpo monoclonal, composição farmacêutica, uso de uma composição farmacêutica, mab de camundongo na forma quimérica ou humanizada, e, anticorpo humanizado
EP2304439A4 (de)	2008-05-29	2012-07-04	Nuclea Biotechnologies Llc	Anti-phospho-akt-antikörper
EP3002299A1 (de)	2008-06-03	2016-04-06	AbbVie Inc.	Dual-variable- domain-immunglobuline und ihre verwendungen
PE20100054A1 (es) *	2008-06-03	2010-03-03	Abbott Lab	Inmunoglobulina con dominio variable dual
CA2726845C (en)	2008-06-04	2017-09-26	Macrogenics, Inc.	Antibodies with altered binding to fcrn and methods of using same
CA2728473A1 (en)	2008-06-20	2009-12-23	National University Corporation Okayama University	Antibody against oxidized ldl/.beta.2gpi complex and use of the same
CA2729934A1 (en)	2008-07-07	2010-01-14	Decode Genetics Ehf	Genetic variants for breast cancer risk assessment
MX2010014574A (es) *	2008-07-08	2011-04-27	Abbott Lab	Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
RU2559525C2 (ru)	2008-07-08	2015-08-10	Эббви Инк	Белки, связывающие простагландин е2, и их применение
JP2011527572A (ja)	2008-07-09	2011-11-04	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Ｌｉｎｇｏ抗体または断片を含む組成物
JP5986745B2 (ja)	2008-07-15	2016-09-06	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
US8148088B2 (en)	2008-07-18	2012-04-03	Abgent	Regulation of autophagy pathway phosphorylation and uses thereof
WO2010010469A2 (en) *	2008-07-25	2010-01-28	Abbott Gmbh & Co. Kg	Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
US9182406B2 (en) *	2008-08-04	2015-11-10	Biodesy, Inc.	Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
PY09026846A (es)	2008-08-05	2015-09-01	Novartis Ag	Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
AR072999A1 (es)	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR20160116056A (ko)	2008-08-14	2016-10-06	테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디	항-ｉｌ-12/ｉｌ-23 항체
JP5723774B2 (ja)	2008-09-05	2015-05-27	プレジデントアンドフェローズオブハーバードカレッジ	タンパク質および核酸の連続的指向性進化
TWI516501B (zh)	2008-09-12	2016-01-11	禮納特神經系統科學公司	Ｐｃｓｋ９拮抗劑類
CN102224254A (zh)	2008-09-23	2011-10-19	哈佛大学校长及研究员协会	Sirt4及其用途
US20100075329A1 (en)	2008-09-23	2010-03-25	O'toole Margot	Methods for predicting production of activating signals by cross-linked binding proteins
PL2342226T3 (pl)	2008-09-26	2017-01-31	Dana-Farber Cancer Institute, Inc.	Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
CA2736904A1 (en)	2008-09-26	2010-04-01	Wyeth Llc	Compatible display vector systems
US8734803B2 (en)	2008-09-28	2014-05-27	Ibio Inc.	Humanized neuraminidase antibody and methods of use thereof
SMT202000101T1 (it)	2008-10-10	2020-03-13	Childrens Medical Center	Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
WO2010045315A1 (en)	2008-10-14	2010-04-22	Dyax Corp.	Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
CN107011415A (zh)	2008-10-20	2017-08-04	光州科学技术院	双齿肽结合物
TW201024318A (en)	2008-10-20	2010-07-01	Abbott Lab	Isolation and purification of antibodies using protein A affinity chromatography
CA2741523C (en)	2008-10-24	2022-06-21	Jonathan S. Towner	Human ebola virus species and compositions and methods thereof
CA2739352C (en)	2008-10-29	2021-07-13	Wyeth Llc	Methods for purification of single domain antigen binding molecules
KR101593285B1 (ko)	2008-10-29	2016-02-11	아블린쓰 엔.브이.	단일 도메인 항원 결합 분자의 제형
EP3199553B1 (de)	2008-10-29	2019-04-24	Circular Commitment Company	Methoden und mittel zur diagnose und behandlung von hepatozellulärem karzinom
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
BRPI0919881B1 (pt)	2008-10-31	2021-09-08	Centocor Ortho Biotech Inc	Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
PL3290052T3 (pl)	2008-11-07	2020-06-29	Galaxy Biotech, Llc	Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
US9447176B2 (en)	2008-11-10	2016-09-20	Alexion Pharmaceuticals, Inc.	Methods and compositions for treating complement-associated disorders
JP5933975B2 (ja)	2008-11-12	2016-06-15	メディミューン，エルエルシー	抗体製剤
WO2010062995A2 (en)	2008-11-26	2010-06-03	Five Prime Therapeutics, Inc.	Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
EP2370593B1 (de)	2008-11-28	2016-03-30	Emory University	Verfahren zur bestimmung der wirksamkeit von pd-1 antagonisten
US20100233079A1 (en) *	2008-12-04	2010-09-16	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
EP2865689A1 (de)	2008-12-08	2015-04-29	Compugen Ltd.	FAM26F Polypeptide und Polynukleotide und Verwendungen davon als Arzneimittel-Target zur Herstellung von Arzneimitteln und Biologika
EP4209510B1 (de)	2008-12-09	2024-01-31	F. Hoffmann-La Roche AG	Anti-pd-l1-antikörper und deren verwendung zur verbesserung der t-zellfunktion
CN102245771B (zh)	2008-12-16	2013-04-10	诺瓦提斯公司	酵母展示系统
ES2733067T3 (es)	2008-12-19	2019-11-27	Macrogenics Inc	Diacuerpos covalentes y usos de los mismos
EP2382238A1 (de)	2008-12-31	2011-11-02	Biogen Idec MA Inc.	Anti-lymphotoxin-antik?rper
WO2010080985A1 (en)	2009-01-08	2010-07-15	Dana-Farber Cancer Institute, Inc.	Compositions and methods for induced brown fat differentiation
GB0900425D0 (en)	2009-01-12	2009-02-11	Ucb Pharma Sa	Biological products
EP2387584A1 (de)	2009-01-14	2011-11-23	IQ Therapeutics BV	Kombinierte antikörper zur behandlung und vorbeugung von durch bacillus anthracis, entsprechenden bakterien und deren toxinen hervorgerufenen erkrankungen
WO2010085510A1 (en)	2009-01-20	2010-07-29	Zadeh Homayoun H	Antibody mediated osseous regeneration
CA2750581A1 (en)	2009-01-21	2010-07-29	Oxford Biotherapeutics Ltd.	Pta089 protein
US20100260752A1 (en)	2009-01-23	2010-10-14	Biosynexus Incorporated	Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
CN102369217A (zh) *	2009-01-29	2012-03-07	雅培制药有限公司	Il-1结合蛋白
US20110165063A1 (en) *	2009-01-29	2011-07-07	Abbott Laboratories	Il-1 binding proteins
WO2010086828A2 (en)	2009-02-02	2010-08-05	Rinat Neuroscience Corporation	Agonist anti-trkb monoclonal antibodies
WO2010087927A2 (en)	2009-02-02	2010-08-05	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en)	2009-02-12	2010-08-19	Human Genome Sciences, Inc.	Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
JP5979877B2 (ja)	2009-02-12	2016-08-31	セル・シグナリング・テクノロジー・インコーポレイテツド	ヒト癌における変異ｒｏｓ発現
WO2010093627A2 (en)	2009-02-12	2010-08-19	Centocor Ortho Biotech Inc.	Fibronectin type iii domain based scaffold compositions, methods and uses
BRPI1008692B8 (pt)	2009-02-17	2021-05-25	Ucb Biopharma Sprl	anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
US8030026B2 (en)	2009-02-24	2011-10-04	Abbott Laboratories	Antibodies to troponin I and methods of use thereof
WO2010101818A1 (en)	2009-03-02	2010-09-10	Pioneer Hi-Bred International, Inc.	Nac transcriptional activators involved in abiotic stress tolerance
PT2403878T (pt)	2009-03-05	2017-09-01	Squibb & Sons Llc	Anticorpos completamente humanos específicos a cadm1
EP2403880A1 (de)	2009-03-05	2012-01-11	Tripath Imaging, Inc.	Monoklonale antikörper gegen matrixmetalloproteinase-7 (mmp-7) und verfahren zu ihrer verwendung beim nachweis von eierstockkrebs
TW201613969A (en) *	2009-03-05	2016-04-16	Abbvie Inc	IL-17 binding proteins
AU2010221188A1 (en)	2009-03-06	2011-10-20	Tripath Imaging, Inc.	Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
WO2010100247A1 (en)	2009-03-06	2010-09-10	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research	Novel therapy for anxiety
KR101667227B1 (ko)	2009-03-10	2016-10-18	가부시키가이샤 진 테크노 사이언스	인간화된 ｋ33ｎ 단일 클론 항체의 제조, 발현 및 해석
GB0904214D0 (en)	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
US8420092B2 (en)	2009-03-19	2013-04-16	Ben-Gurion University Of The Negev Research And Development Authority	Method of treating diabetes by administering an anti-NKp46 antibody
EP3385279B1 (de)	2009-03-20	2020-02-26	Amgen Inc.	Träger-immunglobuline und verwendungen davon
CA2757382A1 (en)	2009-04-01	2010-10-21	Kristi Elkins	Anti-fcrh5 antibodies and immunoconjugates
NZ595918A (en)	2009-04-03	2013-07-26	Decode Genetics Ehf	Genetic markers for risk management of atrial fibrillation and stroke
CN102458464B (zh)	2009-04-08	2016-08-03	利普厄姆公司	用于治疗炎性疾病的新方法
EP2241323A1 (de)	2009-04-14	2010-10-20	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tenascin-W und Hirnkrebs
US20120052064A1 (en)	2009-04-17	2012-03-01	Yuuki Ito	Anti-hgf antibody combinational cancer therapies
EP3009454A3 (de)	2009-04-20	2016-10-19	Oxford Bio Therapeutics Limited	Antikörper spezifisch gegen cadherin-17
US9062116B2 (en)	2009-04-23	2015-06-23	Infinity Pharmaceuticals, Inc.	Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
CA2993053A1 (en)	2009-04-27	2010-11-04	Novartis Ag	Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
US8715657B2 (en)	2009-04-27	2014-05-06	Novartis Ag	Therapeutic antibodies binding IL12Rβ1
US8741581B2 (en)	2009-04-27	2014-06-03	Technion Research And Development Foundation Ltd.	Markers for cancer detection
MX2011011541A (es)	2009-04-29	2012-02-28	Abbott Biotech Ltd	Dispositivo de inyeccion automatico.
JP5925116B2 (ja)	2009-04-29	2016-05-25	ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド	Ｅｒｇモノクローナル抗体
KR20120088550A (ko)	2009-05-04	2012-08-08	애보트 리서치 비.브이.	증진된 생체내 안정성을 갖는 신경 성장 인자(ｎｇｆ)에 대한 항체
JP2012526839A (ja)	2009-05-13	2012-11-01	シーレーンバイオテクノロジーズ，エルエルシー	インフルエンザウイルスに対する中和分子
AU2010249470B2 (en) *	2009-05-20	2015-06-25	Novimmune S.A.	Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
WO2010136598A1 (en)	2009-05-29	2010-12-02	Morphosys Ag	A collection and methods for its use
EP2261242A1 (de)	2009-06-10	2010-12-15	Universite Catholique De Louvain	Aspartat-N-Acetyltransferaseenzym, Diagnoseverfahren und therapeutisches Verfahren
US9090690B2 (en)	2009-06-18	2015-07-28	Pfizer Inc.	Anti Notch-1 antibodies
GB0910725D0 (en)	2009-06-22	2009-08-05	Heptares Therapeutics Ltd	Mutant proteins and methods for producing them
CA2766405A1 (en)	2009-06-22	2011-01-13	Medimmune, Llc	Engineered fc regions for site-specific conjugation
US20120101262A1 (en)	2009-06-25	2012-04-26	Bristol-Myers Squibb Company	Protein purification by caprylic acid (octanoic acid) precipitation
CA2764729C (en) *	2009-06-26	2019-04-02	Sea Lane Biotechnologies, Llc	Expression of surrogate light chains
EP2272979A1 (de)	2009-06-30	2011-01-12	Centre National de la Recherche Scientifique (CNRS)	Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
CN102481380A (zh)	2009-07-09	2012-05-30	霍夫曼-拉罗奇有限公司	体内肿瘤血管系统成像
AU2010269841A1 (en)	2009-07-10	2012-02-23	Decode Genetics Ehf	Genetic markers associated with risk of diabetes mellitus
TW201109438A (en) *	2009-07-29	2011-03-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
CN102596220A (zh)	2009-07-31	2012-07-18	韦恩州立大学	单磷酸化的脂质a衍生物
US9259476B2 (en)	2009-07-31	2016-02-16	Wayne State University	Monophosphorylated lipid A derivatives
WO2011017492A2 (en)	2009-08-05	2011-02-10	Pioneer Hi-Bred International, Inc.	Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
DK2464664T3 (da)	2009-08-13	2016-01-18	Crucell Holland Bv	Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
AU2010282340B2 (en)	2009-08-13	2016-12-22	The Johns Hopkins University	Methods of modulating immune function
WO2011021146A1 (en)	2009-08-20	2011-02-24	Pfizer Inc.	Osteopontin antibodies
EP2292266A1 (de)	2009-08-27	2011-03-09	Novartis Forschungsstiftung, Zweigniederlassung	Behandlung von Krebs durch Modulation von Copine III
US8623358B2 (en)	2009-08-29	2014-01-07	Abbvie Inc.	Therapeutic DLL4 binding proteins
CA2772204A1 (en)	2009-08-31	2011-03-03	Amplimmune, Inc.	Methods and compositions for the inhibition of transplant rejection
US20110059111A1 (en)	2009-09-01	2011-03-10	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
AR078254A1 (es)	2009-09-01	2011-10-26	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011029823A1 (en)	2009-09-09	2011-03-17	Novartis Ag	Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
ES2667258T3 (es)	2009-09-10	2018-05-10	Ucb Biopharma Sprl	Anticuerpos multivalentes
JP5785550B2 (ja)	2009-09-15	2015-09-30	シーエスエル、リミテッド	神経疾患の処置方法
US20110189183A1 (en)	2009-09-18	2011-08-04	Robert Anthony Williamson	Antibodies against candida, collections thereof and methods of use
US20120244170A1 (en)	2009-09-22	2012-09-27	Rafal Ciosk	Treating cancer by modulating mex-3
WO2011037983A1 (en)	2009-09-23	2011-03-31	Medarex, Inc.	Cation exchange chromatography
US8926976B2 (en)	2009-09-25	2015-01-06	Xoma Technology Ltd.	Modulators
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
WO2011038301A2 (en)	2009-09-25	2011-03-31	Xoma Technology Ltd.	Screening methods
CA2774636C (en)	2009-09-25	2019-05-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to hiv-1 and their use
EP2483307A1 (de)	2009-09-29	2012-08-08	Fraunhofer USA, Inc.	Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren
KR20120082906A (ko)	2009-09-30	2012-07-24	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
UY32914A (es)	2009-10-02	2011-04-29	Sanofi Aventis	Anticuerpos que se usan específicamente al receptor epha2
WO2011043823A2 (en)	2009-10-09	2011-04-14	Georgetown University	Polypeptides that home to atherosclerotic plaque
EP2470569A1 (de)	2009-10-13	2012-07-04	Oxford Biotherapeutics Ltd.	Antikörper gegen epha10
MX2012004415A (es)	2009-10-15	2012-05-08	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
WO2011045352A2 (en)	2009-10-15	2011-04-21	Novartis Forschungsstiftung	Spleen tyrosine kinase and brain cancers
ES2813398T3 (es)	2009-10-20	2021-03-23	Abbvie Inc	Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
BR112012009409A2 (pt)	2009-10-22	2017-02-21	Genentech Inc	método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
US9234037B2 (en)	2009-10-27	2016-01-12	Ucb Biopharma Sprl	Method to generate antibodies to ion channels
US20110098862A1 (en)	2009-10-27	2011-04-28	ExxonMobil Research Engineering Company Law Department	Multi-stage processes and control thereof
CA2778673A1 (en) *	2009-10-27	2011-05-05	Karen Margrete Miller	Function modifying nav 1.7 antibodies
GB0922435D0 (en)	2009-12-22	2010-02-03	Ucb Pharma Sa	Method
GB0922434D0 (en)	2009-12-22	2010-02-03	Ucb Pharma Sa	antibodies and fragments thereof
UY32979A (es) *	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120213801A1 (en)	2009-10-30	2012-08-23	Ekaterina Gresko	Phosphorylated Twist1 and cancer
WO2011053707A1 (en) *	2009-10-31	2011-05-05	Abbott Laboratories	Antibodies to receptor for advanced glycation end products (rage) and uses thereof
US20120282177A1 (en)	2009-11-02	2012-11-08	Christian Rohlff	ROR1 as Therapeutic and Diagnostic Target
US20120277144A1 (en)	2009-11-04	2012-11-01	Henricus Johannes Duckers	Novel compounds for modulating neovascularisation and methods of treatment using these compounds
US9244063B2 (en)	2009-11-11	2016-01-26	Gentian As	Immunoassay for assessing related analytes of different origin
US8968740B2 (en)	2009-11-13	2015-03-03	Dana-Farber Cancer Institute, Inc.	Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
GB0920127D0 (en)	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
DK2501822T3 (da)	2009-11-17	2017-11-27	Squibb & Sons Llc	Fremgangsmåder til forbedret proteinproduktion
GB0920324D0 (en)	2009-11-19	2010-01-06	Ucb Pharma Sa	Antibodies
AU2010321832B2 (en)	2009-11-20	2014-08-14	Amgen Inc.	Anti-Orai1 antigen binding proteins and uses thereof
PE20121584A1 (es)	2009-11-30	2012-11-29	Genentech Inc	Composiciones y metodos para el diagnostico y el tratamiento de tumores
US9428586B2 (en)	2009-12-01	2016-08-30	Compugen Ltd	Heparanase splice variant
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
JP2013512672A (ja)	2009-12-02	2013-04-18	アムジエン・インコーポレーテツド	ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
KR20120118002A (ko)	2009-12-08	2012-10-25	애보트 게엠베하 운트 콤파니 카게	망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍａ 단백질에 대한 모노클로날 항체
IN2012DN04908A (de)	2009-12-09	2015-09-25	Inst Nat Sante Rech Med
WO2011075185A1 (en)	2009-12-18	2011-06-23	Oligasis	Targeted drug phosphorylcholine polymer conjugates
US20110165161A1 (en) *	2009-12-23	2011-07-07	Shih-Yao Lin	Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
ES2688093T3 (es)	2010-01-06	2018-10-30	Dyax Corp.	Proteínas de unión a calicreína plasmática
JP6012473B2 (ja)	2010-01-11	2016-10-25	アレクシオンファーマシューティカルズ，インコーポレイテッド	抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
WO2011088163A1 (en)	2010-01-14	2011-07-21	President And Fellows Of Harvard College	Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
TWI513466B (zh)	2010-01-20	2015-12-21	Boehringer Ingelheim Int	抗凝血劑解毒劑
WO2011091134A2 (en)	2010-01-22	2011-07-28	Dana-Farber Cancer Institute, Inc.	Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
WO2011097301A2 (en)	2010-02-02	2011-08-11	Abbott Biotechnology Ltd.	METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
TWI518325B (zh)	2010-02-04	2016-01-21	自治醫科大學	對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
WO2011097511A1 (en)	2010-02-05	2011-08-11	The United States Of America, As Represented By The Secretary Department Of Health & Human Services	REGULATORY B CELLS (tBREGS) AND THEIR USE
US9173961B2 (en)	2010-02-10	2015-11-03	Immunogen, Inc.	CD20 antibodies and uses thereof
KR20130000384A (ko)	2010-02-18	2013-01-02	더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티	뉴레귤린 길항제 및 암의 치료에서의 그의 용도
US9375473B2 (en)	2010-02-19	2016-06-28	Cornell Research Foundation, Inc.	Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
NZ601293A (en)	2010-02-23	2014-10-31	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
AR080291A1 (es)	2010-02-24	2012-03-28	Rinat Neuroscience Corp	Anticuerpos antagonistas anti receptor de il-7 y procedimientos
US20130058915A1 (en)	2010-03-02	2013-03-07	Children's Medica Center Corporation	Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
EP2542582A4 (de)	2010-03-02	2013-12-04	Abbvie Inc	Therapeutische dll4-bindende proteine
PH12012501751A1 (en)	2010-03-04	2012-11-12	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12018501083A1 (en)	2010-03-04	2019-02-18	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011107586A1 (en)	2010-03-05	2011-09-09	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research,	Smoc1, tenascin-c and brain cancers
BR112012022917A2 (pt)	2010-03-11	2017-01-10	Pfizer	anticorpos com ligação a antígeno dependente de ph
EP2547365A1 (de)	2010-03-17	2013-01-23	Abbott Research B.V.	Anti-ngf-antikörperzusammensetzungen
WO2013040142A2 (en)	2011-09-16	2013-03-21	Iogenetics, Llc	Bioinformatic processes for determination of peptide binding
WO2011119484A1 (en)	2010-03-23	2011-09-29	Iogenetics, Llc	Bioinformatic processes for determination of peptide binding
EP2550297B1 (de)	2010-03-25	2019-01-23	UCB Biopharma SPRL	Mit disulfid stabilisierte dvd-lg-moleküle
GB201005064D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
US20150231215A1 (en)	2012-06-22	2015-08-20	Randolph J. Noelle	VISTA Antagonist and Methods of Use
US10745467B2 (en)	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
MX342017B (es)	2010-03-26	2016-09-09	Dartmouth College	Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
WO2011130332A1 (en)	2010-04-12	2011-10-20	Academia Sinica	Glycan arrays for high throughput screening of viruses
NZ602892A (en)	2010-04-13	2014-08-29	Celldex Therapeutics Inc	Antibodies that bind human cd27 and uses thereof
EP2558494B1 (de)	2010-04-15	2018-05-23	AbbVie Inc.	Amyloid-beta-bindende proteine
US20130034543A1 (en)	2010-04-19	2013-02-07	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear	Modulating xrn1
KR20130103301A (ko) *	2010-04-20	2013-09-23	광주과학기술원	전사인자에 특이적으로 결합하는 ｔｆ-ｂｐｂ
KR20130103302A (ko) *	2010-04-20	2013-09-23	광주과학기술원	Ｃｙｔｏｋｉｎｅ에 특이적으로 결합하는 ｃｙｔｏｋｉｎｅ―ｂｐｂ
KR20130103299A (ko) *	2010-04-20	2013-09-23	광주과학기술원	Ｒｔｋ에 특이적으로 결합하는 ｒｔｋ―ｂｐｂ
KR20130103300A (ko) *	2010-04-20	2013-09-23	광주과학기술원	Ｇｐｃｒ에 특이적으로 결합하는 ｇｐｃｒ-ｂｐｂ
EP2380909A1 (de)	2010-04-26	2011-10-26	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	An Brustkrebs beteiligtes Protein PTK-7
JP6022441B2 (ja)	2010-04-30	2016-11-09	アレクシオンファーマシューティカルズ，インコーポレイテッド	抗Ｃ５ａ抗体およびその抗体の使用のための方法
CN102958941A (zh)	2010-05-03	2013-03-06	霍夫曼-拉罗奇有限公司	用于肿瘤诊断和治疗的组合物和方法
CA2798273A1 (en)	2010-05-04	2011-11-10	Merrimack Pharmaceuticals, Inc.	Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011140151A1 (en)	2010-05-04	2011-11-10	Dyax Corp.	Antibodies against epidermal growth factor receptor (egfr)
EA201291181A1 (ru)	2010-05-06	2013-05-30	Новартис Аг	Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
CA2798432A1 (en)	2010-05-06	2011-11-10	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EP2568976B1 (de)	2010-05-10	2015-09-30	Academia Sinica	Zanamivir-phosphinat-kongenere mit antigrippewirkung und bestimmung der oseltamivir-empfänglichkeit von influenzaviren
AU2011252883B2 (en)	2010-05-14	2015-09-10	Abbvie Inc.	IL-1 binding proteins
EP2569335B1 (de)	2010-05-14	2018-08-22	Orega Biotech	Verfahren zur behandlung und/oder prävention von zellproliferationsstörungen mit il-17-antagonisten
CA2801917C (en)	2010-06-03	2017-04-25	Abbvie Biotechnology Ltd	Uses and compositions for treatment of hidradenitis suppurativa (hs)
WO2011154485A1 (en)	2010-06-10	2011-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mammalian sterile 20-like kinase 3
US9499813B2 (en)	2010-06-10	2016-11-22	President And Fellows Of Harvard College	Systems and methods for amplification and phage display
AU2011268310A1 (en)	2010-06-16	2013-01-10	Abbvie Inc.	Comparison of protein samples
CA2803391C (en)	2010-06-22	2021-11-09	Neogenix Oncology, Inc.	Npc1 antibodies that bind a muc5ac epitope
JP2013532627A (ja)	2010-07-01	2013-08-19	武田薬品工業株式会社	ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
WO2012006500A2 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
PH12013500064A1 (en)	2010-07-09	2013-03-11	Exelixis Inc	Combinations of kinase inhibitors for the treatment of cancer
WO2012006503A1 (en)	2010-07-09	2012-01-12	Genentech, Inc.	Anti-neuropilin antibodies and methods of use
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2591000B1 (de)	2010-07-09	2017-05-17	Janssen Vaccines & Prevention B.V.	Antikörper gegen humanes respiratorisches syncytialvirus (rsv) und ihre verwendung
EP2593475B1 (de)	2010-07-14	2016-03-02	Merck Sharp & Dohme Corp.	Monoklonaler antikörper gegen addl und anwendungen davon
WO2012007880A2 (en)	2010-07-16	2012-01-19	Ablynx Nv	Modified single domain antigen binding molecules and uses thereof
EP2598126A2 (de)	2010-07-30	2013-06-05	Saint Louis University	Verfahren zur behandlung von schmerz
CN103392182B (zh)	2010-08-02	2017-07-04	众有生物有限公司	用于发现遗传疾病中致病突变的系统和方法
MX339622B (es)	2010-08-02	2016-06-02	Macrogenics Inc	Diacuerpos covalentes y sus usos.
US8735546B2 (en)	2010-08-03	2014-05-27	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
US20120101108A1 (en)	2010-08-06	2012-04-26	Cell Signaling Technology, Inc.	Anaplastic Lymphoma Kinase In Kidney Cancer
JP2013535692A (ja)	2010-08-10	2013-09-12	アムジエン・インコーポレーテツド	標的抗体に対する中和抗体検出用インビトロ二重機能標的結合アッセイ
EP2420250A1 (de)	2010-08-13	2012-02-22	Universitätsklinikum Münster	Anti-Syndecan-4-Antikörper
CN105348387B (zh)	2010-08-14	2020-08-25	Abbvie 公司	β淀粉样蛋白结合蛋白
WO2012024650A2 (en)	2010-08-19	2012-02-23	Abbott Laboratories	Anti-ngf antibodies and their use
SG187908A1 (en)	2010-08-20	2013-03-28	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
GB201014033D0 (en)	2010-08-20	2010-10-06	Ucb Pharma Sa	Biological products
PH12013500337A1 (en)	2010-08-26	2017-08-23	Abbvie Inc	Dual variable domain immunoglobulins and uses thereof
US20130224191A1 (en)	2010-08-27	2013-08-29	Robert A. Stull	Notum protein modulators and methods of use
US20130224192A1 (en)	2010-09-02	2013-08-29	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Method for the prognosis of the progression of cancer
WO2012031273A2 (en)	2010-09-03	2012-03-08	Stem Centrx, Inc.	Novel modulators and methods of use
EP2614080A1 (de)	2010-09-10	2013-07-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Phosphoryliertes twist1 und metastasen
WO2012035518A1 (en)	2010-09-17	2012-03-22	Compugen Ltd.	Compositions and methods for treatment of drug resistant multiple myeloma
CA2810909A1 (en)	2010-09-20	2012-03-29	Abbvie Inc.	Purification of antibodies using simulated moving bed chromatography
EP2619226B1 (de)	2010-09-22	2018-09-12	Amgen Inc.	Träger-immunglobuline und verwendungen davon
WO2012040617A2 (en)	2010-09-23	2012-03-29	Neogenix Oncology, Inc.	Colon and pancreas cancer peptidomimetics
EP2621526B1 (de)	2010-09-29	2018-06-06	Agensys, Inc.	An 191p4d12-proteine bindende antikörper-wirkstoffkonjugate
US9005907B2 (en)	2010-10-01	2015-04-14	St. Jude Children's Research Hospital	Methods and compositions for typing molecular subgroups of medulloblastoma
JP2013543384A (ja)	2010-10-05	2013-12-05	ノバルティスアーゲー	抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
CA2814652C (en)	2010-10-13	2021-05-18	Janssen Biotech, Inc.	Human oncostatin m antibodies and methods of use
WO2012052391A1 (en)	2010-10-19	2012-04-26	Glaxo Group Limited	Polypeptide with jmjd3 catalytic activity
ES3004351T3 (en)	2010-10-22	2025-03-12	Seagen Inc	Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
KR20140075639A (ko)	2010-10-27	2014-06-19	더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕	암 치료법을 위한 e-카드헤린의 가용성 세포외 도메인의 표적화 조성물 및 관련 방법
EP2640366A2 (de)	2010-11-15	2013-09-25	Exelixis, Inc.	Benzoxazepine als pi3k/mtor-hemmer sowie verfahren zur ihrer verwendung und herstellung
WO2012065937A1 (en)	2010-11-15	2012-05-24	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research	Anti-fungal agents
WO2012068106A2 (en)	2010-11-15	2012-05-24	Exelixis, Inc.	Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012068463A2 (en)	2010-11-18	2012-05-24	Beth Israel Deaconess Medicall Center, Inc.	Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
HRP20181811T1 (hr)	2010-11-19	2018-12-28	Morphosys Ag	Zbirka sljedova protutijela i njezina upotreba
US20140378436A9 (en)	2010-11-24	2014-12-25	Exelixis, Inc.	Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture
US20130245233A1 (en)	2010-11-24	2013-09-19	Ming Lei	Multispecific Molecules
EP3786185A1 (de)	2010-12-06	2021-03-03	Seagen Inc.	Humanisierte antikörper gegen liv-1 und deren verwendung zur behandlung von krebs
TWI655210B (zh)	2010-12-08	2019-04-01	艾伯維史坦森特瑞斯有限責任公司	新穎調節劑及其使用方法
RU2622083C2 (ru)	2010-12-15	2017-06-09	ВАЙЕТ ЭлЭлСи	Антитела против notch1
TW201307388A (zh)	2010-12-21	2013-02-16	Abbott Lab	Ｉｌ－１結合蛋白
WO2012121775A2 (en)	2010-12-21	2012-09-13	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
CA2825370A1 (en)	2010-12-22	2012-06-28	President And Fellows Of Harvard College	Continuous directed evolution
CA2824279A1 (en)	2010-12-22	2012-06-28	Cephalon Australia Pty Ltd	Modified antibody with improved half-life
JP2014504503A (ja)	2010-12-28	2014-02-24	ゾーマテクノロジーリミテッド	Ｐｄｚドメインを用いた細胞表面提示
US9598499B2 (en)	2010-12-30	2017-03-21	Institut National De La Santé Et De La Recherche Médicale (Inserm)	Antigen binding formats for use in therapeutic treatments or diagnostic assays
EP2474612A1 (de)	2011-01-05	2012-07-11	University College Dublin, National University of Ireland Dublin	Affinitätstrennungsmittel und ihre Verwendungen zur Trennung, Reinigung und Konzentration von Zielmolekülen
GB201100282D0 (en)	2011-01-07	2011-02-23	Ucb Pharma Sa	Biological methods
US10208349B2 (en)	2011-01-07	2019-02-19	Ucb Biopharma Sprl	Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
ME02734B (de)	2011-01-14	2017-10-20	Ucb Biopharma Sprl	Antikörpermodule zur bindung an il-17a und il-17f
CA2858350A1 (en)	2011-01-14	2013-07-19	The Regents Of The University Of California	Therapeutic antibodies against ror-1 protein and methods for use of same
JP2014507136A (ja)	2011-01-18	2014-03-27	アムジエン・インコーポレーテツド	ＮａＶ１．７ノックアウトマウスとそれらの使用
RU2602039C2 (ru)	2011-01-24	2016-11-10	Эббви Байотекнолоджи Лтд.	Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
EP3763740A1 (de)	2011-01-26	2021-01-13	Celldex Therapeutics, Inc.	Anti-kit-antikörper und verwendungen davon
US9447187B2 (en)	2011-02-03	2016-09-20	Alexion Pharmaceuticals, Inc.	Use of an anti-CD200 antibody for prolonging the survival of allografts
WO2012109238A2 (en)	2011-02-07	2012-08-16	President And Fellows Of Harvard College	Methods for increasing immune responses using agents that directly bind to and activate ire-1
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
WO2012110824A1 (en)	2011-02-18	2012-08-23	Astrazeneca Ab	Binding agents with specificity for a nucleic acid modification
PH12013501802B1 (en)	2011-03-02	2018-06-27	Berg Llc	Interrogatory cell-based assays and uses thereof
US9383364B2 (en)	2011-03-07	2016-07-05	University Of Louisville Research Foundation, Inc.	Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker
CN108220297A (zh)	2011-03-09	2018-06-29	细胞信号科技公司	用于生成单克隆抗体的方法和试剂
US20120238730A1 (en)	2011-03-15	2012-09-20	Abbott Laboratories	Integrated approach to the isolation and purification of antibodies
WO2012129347A1 (en)	2011-03-21	2012-09-27	Biodesy, Llc	Classification of kinase inhibitors using nonlinear optical techniques
WO2012128810A1 (en)	2011-03-23	2012-09-27	Abbott Laboratories	Methods and systems for the analysis of protein samples
CN106039306A (zh)	2011-03-30	2016-10-26	埃博灵克斯股份有限公司	使用针对TNFα的单结构域抗体治疗免疫病症的方法
PE20140964A1 (es)	2011-03-30	2014-08-17	Boehringer Ingelheim Int	Antidotos anticoagulantes
WO2012134813A1 (en)	2011-03-31	2012-10-04	St. Jude Children's Research Hospital	Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
US20120328567A1 (en)	2011-04-08	2012-12-27	Steven Bushnell	Biomarkers predictive of therapeutic responsiveness to ifnb and uses thereof
WO2012139045A1 (en)	2011-04-08	2012-10-11	Gilead Biologics, Inc.	Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
US9150644B2 (en)	2011-04-12	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9409987B2 (en)	2011-04-15	2016-08-09	Compugen Ltd	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
SI2699264T1 (en)	2011-04-20	2018-08-31	Medimmune Llc	Antibodies and other molecules that bind b7-h1 and pd-1
US9587021B2 (en)	2011-05-21	2017-03-07	Macrogenics, Inc.	CD3-binding molecules capable of binding to human and non-human CD3
EA201391753A1 (ru)	2011-05-21	2014-08-29	Макродженикс, Инк.	Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
ES2765874T3 (es)	2011-05-25	2020-06-11	Innate Pharma Sa	Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
PH12013502378A1 (en)	2011-06-02	2014-01-06	Dyax Corp	Fc RECEPTOR BINDING PROTEINS
US8691231B2 (en)	2011-06-03	2014-04-08	Merrimack Pharmaceuticals, Inc.	Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
PH12013502489B1 (en)	2011-06-03	2019-04-24	Xoma Technology Ltd	Antibodies specific for tgf-beta
EP2717911A1 (de)	2011-06-06	2014-04-16	Novartis Forschungsstiftung, Zweigniederlassung	Proteintyrosinphosphatase, nicht-rezeptor typ 11 (ptpn11) und dreifach negativer brustkrebs
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
RS57024B1 (sr)	2011-06-10	2018-05-31	Medimmune Ltd	Anti-pseudomonas psl vezujući molekuli i njihova upotreba
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
AU2012271413B2 (en)	2011-06-17	2017-07-13	President And Fellows Of Harvard College	Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
CN103765212A (zh)	2011-06-27	2014-04-30	杰克逊实验室	治疗癌症和自体免疫性疾病的方法和组合物
CN103649121B (zh)	2011-06-28	2016-10-19	牛津生物疗法有限公司	针对adp-核糖基环化酶2的抗体
PL2726094T3 (pl)	2011-06-28	2017-06-30	Oxford Biotherapeutics Ltd	Cel terapeutyczny i diagnostyczny
WO2013001517A1 (en)	2011-06-30	2013-01-03	Compugen Ltd.	Polypeptides and uses thereof for treatment of autoimmune disorders and infection
DK2726099T3 (en)	2011-07-01	2018-11-05	Novartis Ag	Method of treating metabolic disorders
RU2640025C2 (ru)	2011-07-13	2017-12-25	Эббви Инк.	Способы и композиции для лечения астмы с использованием антител против il-13
GB201112056D0 (en)	2011-07-14	2011-08-31	Univ Leuven Kath	Antibodies
JP2014526886A (ja)	2011-07-15	2014-10-09	モルフォシス・アー・ゲー	マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
WO2013066438A2 (en)	2011-07-22	2013-05-10	President And Fellows Of Harvard College	Evaluation and improvement of nuclease cleavage specificity
EP2736928B1 (de)	2011-07-28	2019-01-09	i2 Pharmaceuticals, Inc.	Gegen erbb3-gerichtete sur-bindende proteine
WO2013025779A1 (en)	2011-08-15	2013-02-21	Amplimmune, Inc.	Anti-b7-h4 antibodies and their uses
ES2704126T3 (es)	2011-08-23	2019-03-14	Found Medicine Inc	Moléculas de fusión KIF5B-RET y usos de las mismas
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
US20140234903A1 (en)	2011-09-05	2014-08-21	Eth Zurich	Biosynthetic gene cluster for the production of peptide/protein analogues
JP6216317B2 (ja)	2011-09-09	2017-10-18	メディミューンリミテッド	抗Ｓｉｇｌｅｃ−１５抗体およびその使用
US10093705B2 (en)	2011-09-13	2018-10-09	Dana-Farber Cancer Institute, Inc.	Compositions and methods for brown fat induction and activity using FNDC5
WO2013040433A1 (en)	2011-09-15	2013-03-21	Genentech, Inc.	Methods of promoting differentiation
DK2766483T3 (da)	2011-10-10	2022-04-19	Hospital For Sick Children	Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
EP2766033B1 (de)	2011-10-14	2019-11-20	Novartis AG	Antikörper und verfahren für wnt-signalwegbedingte erkrankungen
WO2013056178A2 (en)	2011-10-14	2013-04-18	Foundation Medicine, Inc.	Novel estrogen receptor mutations and uses thereof
MX2014004426A (es)	2011-10-15	2014-07-09	Genentech Inc	Metodos de uso de antagonistas de scd1.
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
AR088512A1 (es)	2011-10-24	2014-06-18	Abbvie Inc	Anticuerpos dirigidos contra el tnf
EP2771360A1 (de)	2011-10-24	2014-09-03	AbbVie Inc.	Gegen sclerostin gerchtet immunbinder
AR088515A1 (es)	2011-10-25	2014-06-18	Pioneer Hi Bred Int	Metodos para alterar la composicion de la pared celular vegetal para obtener produccion de biocombustible y digestibilidad de silaje mejoradas
AU2012332593B2 (en)	2011-11-01	2016-11-17	Bionomics, Inc.	Anti-GPR49 antibodies
EP2773664A1 (de)	2011-11-01	2014-09-10	Bionomics, Inc.	Anti-gpr49-antikörper
EP2773373B1 (de)	2011-11-01	2018-08-22	Bionomics, Inc.	Verfahren zur blockierung eines krebsstammzellenwachstums
JP2014533247A (ja)	2011-11-01	2014-12-11	バイオノミクスインコーポレイテッド	抗体および癌を治療する方法
WO2013067268A1 (en)	2011-11-03	2013-05-10	Tripath Imaging, Inc.	Methods and compositions for preparing samples for immunostaining
US11180807B2 (en)	2011-11-04	2021-11-23	Population Bio, Inc.	Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
US10597439B2 (en)	2011-11-07	2020-03-24	Medimmune Limited	Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
HK1205522A1 (en)	2011-11-08	2015-12-18	辉瑞公司	Methods of treating inflammatory disorders using anti-m-csf antibodies
US20140294732A1 (en)	2011-11-08	2014-10-02	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute	Early diagnostic of neurodegenerative diseases
EP2776022A1 (de)	2011-11-08	2014-09-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Neue behandlung für neurodegenerative erkrankungen
US8871908B2 (en)	2011-11-11	2014-10-28	Rinat Neuroscience Corp.	Antibodies specific for Trop-2 and their uses
US9803004B2 (en)	2011-11-11	2017-10-31	Ucb Biopharma Sprl	Albumin binding antibodies and binding fragments thereof
SG11201402358RA (en)	2011-11-16	2014-06-27	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
ES2494190T3 (es)	2011-11-16	2014-09-15	Adrenomed Ag	Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
IL283215B2 (en)	2011-11-16	2024-05-01	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same
EP2780717B1 (de)	2011-11-16	2016-12-21	sphingotec GmbH	Adrenomedullintests und verfahren zur bestimmung von reifem adrenomedullin
SG11201402354YA (en)	2011-11-16	2014-06-27	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
PT3553084T (pt)	2011-11-16	2023-02-17	Adrenomed Ag	Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou esqueleto não-ig anti-adm para prevenção ou redução de disfunção de órgãos ou insuficiência de órgãos num paciente possuindo uma doença crónica ou aguda ou condição aguda
US20140017174A1 (en)	2011-11-30	2014-01-16	Raja Atreya	Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
JP2015500829A (ja)	2011-12-05	2015-01-08	ノバルティスアーゲー	上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉに対するｈｅｒ３の抗体
KR102083957B1 (ko)	2011-12-05	2020-03-04	노파르티스 아게	표피 성장 인자 수용체 3 (her3)에 대한 항체
CN104144947B (zh)	2011-12-14	2017-10-27	艾伯维德国有限责任两合公司	用于诊断和治疗铁相关病症的组合物和方法
EP2791175A2 (de)	2011-12-14	2014-10-22	Abbvie Deutschland GmbH & Co. KG	Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
JP6320300B2 (ja)	2011-12-19	2018-05-09	ゾーマ（ユーエス）リミテッドライアビリティカンパニー	座瘡を治療するための方法
ES2728278T3 (es)	2011-12-21	2019-10-23	Novartis Ag	Composiciones que comprenden anticuerpos dirigidos al factor P y C5
JP2015502975A (ja)	2011-12-22	2015-01-29	ライナットニューロサイエンスコーポレイション	ヒト成長ホルモン受容体アンタゴニスト抗体およびその使用方法
WO2013093693A1 (en)	2011-12-22	2013-06-27	Rinat Neuroscience Corp.	Staphylococcus aureus specific antibodies and uses thereof
EP2793940B1 (de)	2011-12-22	2018-11-14	i2 Pharmaceuticals, Inc.	Surrogatbindungsproteine
EP3539982B1 (de)	2011-12-23	2025-02-19	Pfizer Inc.	Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
US9120870B2 (en)	2011-12-30	2015-09-01	Abbvie Inc.	Dual specific binding proteins directed against IL-13 and IL-17
EP2800583A1 (de)	2012-01-02	2014-11-12	Novartis AG	Cdcp1 und brustkrebs
GB201200259D0 (en)	2012-01-09	2012-02-22	Ohlin Per M	Novel therapies
CA2862424A1 (en)	2012-01-18	2013-07-25	Genentech, Inc.	Methods of using fgf19 modulators
GB201201332D0 (en)	2012-01-26	2012-03-14	Imp Innovations Ltd	Method
EP3369746A1 (de)	2012-01-27	2018-09-05	AbbVie Deutschland GmbH & Co KG	Zusammensetzung und verfahren zur diagnose und behandlung von krankheiten im zusammenhang mit neuritenabbau
SG2014008304A (en)	2012-02-01	2014-06-27	Compugen Ltd	C10rf32 antibodies, and uses thereof for treatment of cancer
CA2863887C (en)	2012-02-09	2023-01-03	Population Diagnostics, Inc.	Methods of screening low frequency gdna variation biomarkers for pervasive developmental disorder (pdd) or pervasive developmental disorder - not otherwise specified (pdd_nos)
CN108324943B (zh)	2012-02-10	2024-03-08	思进股份有限公司	Cd30+癌症的检测和治疗
HK1211037A1 (en)	2012-02-11	2016-05-13	霍夫曼-拉罗奇有限公司	R-spondin translocations and methods using the same
US9550830B2 (en)	2012-02-15	2017-01-24	Novo Nordisk A/S	Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
ES2640268T3 (es)	2012-02-15	2017-11-02	Novo Nordisk A/S	Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
LT2814842T (lt)	2012-02-15	2018-11-12	Novo Nordisk A/S	Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1
GB201203071D0 (en)	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
US20150201588A1 (en)	2012-02-22	2015-07-23	Amgen Inc.	Autologous Mammalian Models Derived from Induced Pluripotent Stem Cells and Related Methods
GB201203051D0 (en)	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
RU2014138474A (ru)	2012-02-24	2016-04-10	СтемСентРкс, Инк.	Новые модуляторы и способы применения
BR122020002414B1 (pt)	2012-03-15	2022-03-03	Janssen Biotech, Inc	Uso de anticorpos anti-cd27 humanos
EP2825549B1 (de)	2012-03-16	2018-10-10	F. Hoffmann-La Roche SA	Gleichmässig stabilisierte manipulierte proteine
KR20140135198A (ko)	2012-03-16	2014-11-25	에프. 호프만-라 로슈 아게	Pak1 억제제로 흑색종을 치료하는 방법
US9139863B2 (en)	2012-03-16	2015-09-22	Genentech, Inc.	Engineered conformationally-stabilized proteins
WO2013140393A1 (en)	2012-03-21	2013-09-26	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Peptides derived from the d1 - domain of nkp46
WO2013142808A1 (en)	2012-03-23	2013-09-26	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pathogenic phlebovirus isolates and compositions and methods of use
EP2831112A1 (de)	2012-03-29	2015-02-04	Friedrich Miescher Institute for Biomedical Research	Hemmung von interleukin 8 und/oder dessen rezeptor cxcrl bei der behandlung von brustkrebs mit her2/her3-überexpression
AU2012376214B2 (en)	2012-04-02	2019-02-14	Berg Llc	Interrogatory cell-based assays and uses thereof
WO2013151649A1 (en)	2012-04-04	2013-10-10	Sialix Inc	Glycan-interacting compounds
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
ES2655842T3 (es)	2012-04-18	2018-02-21	Cell Signaling Technology, Inc.	EGFR y ROS1 en el cáncer
WO2013158279A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Protein purification methods to reduce acidic species
WO2013158275A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Cell culture methods to reduce acidic species
DK2838918T3 (da)	2012-04-20	2019-08-12	Merus Nv	Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
CN104583776B (zh)	2012-04-25	2016-09-07	比奥德赛公司	用于检测蛋白质的变构调节剂的方法
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
MX381731B (es)	2012-05-14	2025-03-13	Biogen Ma Inc	Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
WO2013172951A1 (en)	2012-05-15	2013-11-21	Morphotek, Inc.	Methods for treatment of gastric cancer
EP2850095B1 (de)	2012-05-17	2019-10-09	RA Pharmaceuticals, Inc.	Peptid- und peptidomimetische inhibitoren
US20130309223A1 (en)	2012-05-18	2013-11-21	Seattle Genetics, Inc.	CD33 Antibodies And Use Of Same To Treat Cancer
TW201348246A (zh)	2012-05-21	2013-12-01	Abbvie Inc	利用蛋白質ａ親和性層析之人類、人類化或嵌合抗體之新穎純化
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
JP6629069B2 (ja)	2012-06-06	2020-01-15	ゾエティス・エルエルシー	イヌ化抗ｎｇｆ抗体およびその方法
US9890215B2 (en)	2012-06-22	2018-02-13	King's College London	Vista modulators for diagnosis and treatment of cancer
CN104619722B (zh)	2012-06-22	2022-10-04	达特茅斯大学理事会	新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
BR112014032916A2 (pt)	2012-06-28	2017-08-01	Pfizer	anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
WO2014001557A1 (en)	2012-06-28	2014-01-03	Ucb Pharma S.A.	A method for identifying compounds of therapeutic interest
WO2014001482A1 (en)	2012-06-29	2014-01-03	Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research	Treating diseases by modulating a specific isoform of mkl1
UY34887A (es)	2012-07-02	2013-12-31	Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware	Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CA2877948C (en)	2012-07-02	2019-07-30	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Paramyxovirus and methods of use
WO2014006114A1 (en)	2012-07-05	2014-01-09	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	New treatment for neurodegenerative diseases
US20150224190A1 (en)	2012-07-06	2015-08-13	Mohamed Bentires-Alj	Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
TW201402608A (zh)	2012-07-12	2014-01-16	Abbvie Inc	Ｉｌ－１結合蛋白質
LT3338794T (lt)	2012-07-13	2020-05-25	The Trustees Of The University Of Pennsylvania	Car priešnavikinio aktyvumo toksiškumo reguliavimas
GB201213652D0 (en)	2012-08-01	2012-09-12	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
WO2014020140A1 (en)	2012-08-02	2014-02-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of transferrin receptor antagonist for the treatment of thalassemia
US10457733B2 (en)	2012-08-03	2019-10-29	Dana-Farber Cancer Institute, Inc.	Agents that modulate immune cell activation and methods of use thereof
US8603470B1 (en)	2012-08-07	2013-12-10	National Cheng Kung University	Use of IL-20 antagonists for treating liver diseases
WO2014031498A1 (en)	2012-08-18	2014-02-27	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
AU2013305827A1 (en)	2012-08-21	2015-03-05	Academia Sinica	Benzocyclooctyne compounds and uses thereof
SG10201912773TA (en)	2012-08-23	2020-02-27	Agensys Inc	Antibody drug conjugates (adc) that bind to 158p1d7 proteins
CA2881966C (en)	2012-08-24	2020-10-06	The Regents Of The University Of California	Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
US9737493B2 (en)	2012-09-07	2017-08-22	University Of Louisville Research Foundation, Inc.	Compositions and methods for modulating DNMT1 inhibitor activity
CA2884704C (en)	2012-09-07	2023-04-04	Randolph J. Noelle	Vista modulators for diagnosis and treatment of cancer
US9376489B2 (en)	2012-09-07	2016-06-28	Novartis Ag	IL-18 binding molecules
US9976180B2 (en)	2012-09-14	2018-05-22	Population Bio, Inc.	Methods for detecting a genetic variation in subjects with parkinsonism
WO2014052855A1 (en)	2012-09-27	2014-04-03	Population Diagnostics, Inc.	Methods and compositions for screening and treating developmental disorders
AR092745A1 (es)	2012-10-01	2015-04-29	Univ Pennsylvania	Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
UA118441C2 (uk)	2012-10-08	2019-01-25	Протена Біосаєнсиз Лімітед	Антитіло, що розпізнає альфа-синуклеїн
CN104870014A (zh)	2012-10-09	2015-08-26	比奥根Ma公司	联合治疗及用于治疗脱髓鞘病症的用途
JP6356134B2 (ja)	2012-10-12	2018-07-11	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	免疫応答の増強
ES2937015T3 (es)	2012-11-01	2023-03-23	Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft	Anticuerpo contra CD269 (BCMA)
AU2013337775B2 (en)	2012-11-01	2017-03-30	Abbvie Inc.	Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
WO2014071419A2 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
EP2917238A1 (de)	2012-11-08	2015-09-16	Eleven Biotherapeutics, Inc.	Il6-antagonisten und verwendungen davon
WO2014074942A1 (en)	2012-11-08	2014-05-15	Illumina, Inc.	Risk variants of alzheimer's disease
KR20150082503A (ko)	2012-11-09	2015-07-15	화이자 인코포레이티드	혈소판 유래 성장 인자 b 특이적 항체, 및 그의 조성물 및 용도
ES2831374T3 (es)	2012-11-21	2021-06-08	Janssen Biotech Inc	Anticuerpos de EGFR/c-Met biespecíficos
US20170275367A1 (en)	2012-11-21	2017-09-28	Janssen Biotech, Inc.	Bispecific EGFR/C-Met Antibodies
AU2012395148B2 (en)	2012-11-24	2016-10-27	Hangzhou Dac Biotech Co., Ltd.	Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
WO2014089111A1 (en)	2012-12-05	2014-06-12	Novartis Ag	Compositions and methods for antibodies targeting epo
PT2928923T (pt)	2012-12-10	2020-03-27	Biogen Ma Inc	Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos
CA2891686A1 (en)	2012-12-18	2014-06-26	Novartis Ag	Compositions and methods that utilize a peptide tag that binds to hyaluronan
BR112015014621A2 (pt)	2012-12-21	2017-10-03	Amplimmune Inc	Anticorpos anti-h7cr
WO2014100542A1 (en)	2012-12-21	2014-06-26	Abbvie, Inc.	High-throughput antibody humanization
GB201223276D0 (en)	2012-12-21	2013-02-06	Ucb Pharma Sa	Antibodies and methods of producing same
AU2013202668B2 (en)	2012-12-24	2014-12-18	Adelaide Research & Innovation Pty Ltd	Inhibition of cancer growth and metastasis
AU2013370171B2 (en)	2012-12-28	2018-09-13	Precision Biologics, Inc.	Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
US10717965B2 (en)	2013-01-10	2020-07-21	Gloriana Therapeutics, Inc.	Mammalian cell culture-produced neublastin antibodies
WO2014113729A2 (en)	2013-01-18	2014-07-24	Foundation Mecicine, Inc.	Methods of treating cholangiocarcinoma
MX371052B (es)	2013-02-08	2020-01-14	Novartis Ag	Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios.
GB201302447D0 (en)	2013-02-12	2013-03-27	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
WO2014129895A1 (en)	2013-02-19	2014-08-28	Stichting Vu-Vumc	Means and method for increasing the sensitivity of cancers for radiotherapy
MX2015010682A (es)	2013-02-22	2016-05-31	Stemcentrx Inc	Nuevos conjugados de anticuerpos y usos de los mismos.
KR20150118159A (ko)	2013-02-22	2015-10-21	에프. 호프만-라 로슈 아게	암의 치료 방법 및 약물 내성의 예방 방법
US9487587B2 (en)	2013-03-05	2016-11-08	Macrogenics, Inc.	Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
KR20150123250A (ko)	2013-03-06	2015-11-03	제넨테크, 인크.	암 약물 내성의 치료 및 예방 방법
MX375354B (es)	2013-03-13	2025-03-06	Prothena Biosciences Ltd	Anticuerpos que se unen a tau y usos de los mismos.
KR20150127216A (ko)	2013-03-14	2015-11-16	제넨테크, 인크.	암의 치료 및 암 약물 내성의 예방 방법
EP2970947A4 (de)	2013-03-14	2016-10-12	Abbott Lab	Rekombinante hcv-ns3-antigene und mutanten für den verbesserten nachweis von antikörpern
CA2899449A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014139130A1 (en)	2013-03-14	2014-09-18	Adagene Inc.	An integrated system for library construction, affinity binder screening and expression thereof
JP2016514130A (ja)	2013-03-14	2016-05-19	ノバルティスアーゲー	Ｎｏｔｃｈ３に対する抗体
CN105378099B (zh)	2013-03-14	2021-05-11	雅培制药有限公司	Hcv核心脂质结合结构域单克隆抗体
JP6505076B2 (ja)	2013-03-14	2019-04-24	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
CN111925437A (zh)	2013-03-14	2020-11-13	宏观基因有限公司	与表达激活受体的免疫效应细胞具有免疫反应性的双特异性分子
WO2014142882A1 (en)	2013-03-14	2014-09-18	Abbvie Inc.	Protein purification using displacement chromatography
RU2015142815A (ru)	2013-03-14	2017-04-12	Паркаш ГИЛЛ	Лечение рака с использованием антител, связывающихся с поверхностным grp78
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
KR20150129033A (ko)	2013-03-14	2015-11-18	애브비 인코포레이티드	저 산성 종 조성물 및 이의 제조 및 사용 방법
JP2016515120A (ja)	2013-03-15	2016-05-26	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
WO2014151006A2 (en)	2013-03-15	2014-09-25	Genentech, Inc.	Biomarkers and methods of treating pd-1 and pd-l1 related conditions
KR20220041957A (ko)	2013-03-15	2022-04-01	아비에 도이치란트 게엠베하 운트 콤파니 카게	항-egfr 항체 약물 접합체 제형
MX2015012562A (es)	2013-03-15	2016-06-21	Abbvie Inc	Purificacion de conjugados anticuerpo-farmaco (cafs).
WO2014152507A2 (en)	2013-03-15	2014-09-25	Pioneer Hi-Bred International, Inc.	Modulation of acc deaminase expression
US10160797B2 (en)	2013-03-15	2018-12-25	Sanofi Pasteur Biologics, Llc	Antibodies against Clostridium difficile toxins and methods of using the same
JP2016513682A (ja)	2013-03-15	2016-05-16	ダイアックスコーポレーション	抗血漿カリクレイン抗体
US9469686B2 (en)	2013-03-15	2016-10-18	Abbott Laboratories	Anti-GP73 monoclonal antibodies and methods of obtaining the same
EP2970459A2 (de)	2013-03-15	2016-01-20	AbbVie Inc.	Gegen il-1beta und il-17 gerichtete duale spezifische bindungsproteine
RU2015143437A (ru)	2013-03-15	2017-04-27	Дженентек, Инк.	Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
CN108362885B (zh)	2013-03-20	2021-05-14	斯弗因高泰克有限公司	用于指导血压下降疗法的肾上腺髓质素
WO2014168933A1 (en)	2013-04-08	2014-10-16	Cytodyn Inc.	Felinized antibodies and methods of treating retroviral infections in felines
EP2992331A4 (de)	2013-04-30	2017-03-29	Université de Montréal	Neuartige biomarker für akute myeloische leukämie
HUE052232T2 (hu)	2013-05-06	2021-04-28	Scholar Rock Inc	Készítmények és eljárások növekedési faktor modulálására
WO2014181229A2 (en)	2013-05-07	2014-11-13	Rinat Neuroscience Corp.	Anti-glucagon receptor antibodies and methods of use thereof
US10047156B2 (en)	2013-05-17	2018-08-14	Centre National De La Recherche Scientifique (Cnrs)	Anti-CXCL1, CXCL7 and CXCL8 antibodies and their applications
MX376808B (es)	2013-05-24	2025-03-07	Medimmune Llc	Anticuerpos anti-b7-h5 y sus usos.
SG10201708143QA (en)	2013-06-06	2017-11-29	Pf Medicament	Anti-c10orf54 antibodies and uses thereof
EP3293275B1 (de)	2013-06-06	2021-08-04	Dana-Farber Cancer Institute, Inc.	Zusammensetzung und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
WO2014197885A2 (en)	2013-06-07	2014-12-11	Duke University	Inhibitors of complement factor h
WO2014200349A1 (en)	2013-06-13	2014-12-18	Fast Forward Pharmaceutical B.V.	Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
US9678080B2 (en)	2013-06-14	2017-06-13	Pacific Biosciences Of California, Inc.	Bis-biotinylation tags
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US10086054B2 (en)	2013-06-26	2018-10-02	Academia Sinica	RM2 antigens and use thereof
WO2014210564A1 (en)	2013-06-27	2014-12-31	Academia Sinica	Glycan conjugates and use thereof
US9803017B2 (en)	2013-07-05	2017-10-31	University Of Washington Through Its Center For Commercialization	Soluble MIC neutralizing monoclonal antibody for treating cancer
WO2015004632A1 (en)	2013-07-12	2015-01-15	Neotope Biosciences Limited	Antibodies that recognize iapp
US9951131B2 (en)	2013-07-12	2018-04-24	Prothena Biosciences Limited	Antibodies that recognize IAPP
US10208125B2 (en)	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
US20160175401A1 (en)	2013-07-31	2016-06-23	Dana-Farber Cancer Institute Inc.	Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
JP2015030666A (ja)	2013-07-31	2015-02-16	学校法人順天堂	抗ヒトｃｄ２６モノクローナル抗体又はその抗原結合性断片
HK1225621A1 (zh)	2013-08-01	2017-09-15	Agensys, Inc.	结合cd37蛋白的抗体药物偶联物(adc)
KR101809072B1 (ko)	2013-08-02	2017-12-14	화이자 인코포레이티드	항-cxcr4 항체 및 항체-약물 접합체
ES2761587T3 (es)	2013-08-07	2020-05-20	Friedrich Miescher Institute For Biomedical Res	Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
US20150044192A1 (en)	2013-08-09	2015-02-12	President And Fellows Of Harvard College	Methods for identifying a target site of a cas9 nuclease
CA2918300A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Methods of treating sporadic inclusion body myositis
PL3036320T5 (pl)	2013-08-19	2024-06-10	Biogen Ma Inc.	Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
WO2015053871A2 (en)	2013-08-26	2015-04-16	MabVax Therapeutics, Inc.	NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
CA2922529A1 (en)	2013-08-28	2015-03-05	Stemcentrx, Inc.	Novel sez6 modulators and methods of use
PE20160674A1 (es)	2013-08-28	2016-07-21	Stemcentrx Inc	Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
US9340799B2 (en)	2013-09-06	2016-05-17	President And Fellows Of Harvard College	MRNA-sensing switchable gRNAs
JP6486368B2 (ja)	2013-09-06	2019-03-20	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
US9388430B2 (en)	2013-09-06	2016-07-12	President And Fellows Of Harvard College	Cas9-recombinase fusion proteins and uses thereof
WO2015035342A2 (en)	2013-09-08	2015-03-12	Oligasis Llc	Factor viii zwitterionic polymer conjugates
RU2666141C2 (ru)	2013-09-17	2018-09-06	Оби Фарма, Инк.	Композиции углеводной вакцины для индукции иммунного ответа и их применение при лечении рака
US9957506B2 (en)	2013-09-25	2018-05-01	Cornell University	Compounds for inducing anti-tumor immunity and methods thereof
EP3048899B1 (de)	2013-09-25	2021-09-08	Bioverativ Therapeutics Inc.	Verfahren zur virusinaktivierung auf einer säule
EP3757130A1 (de)	2013-09-26	2020-12-30	Costim Pharmaceuticals Inc.	Verfahren zur behandlung von blutkrebs
WO2015048635A1 (en)	2013-09-27	2015-04-02	Duke University	Mper-liposome conjugates and uses thereof
EP3470081A1 (de)	2013-10-01	2019-04-17	Mayo Foundation for Medical Education and Research	Verfahren zur behandlung von krebs bei patienten mit erhöhten bim-werten
WO2015057939A1 (en)	2013-10-18	2015-04-23	Biogen Idec Ma Inc.	Anti-s1p4 antibodies and uses thereof
CN111443069A (zh)	2013-10-28	2020-07-24	多茨技术公司	过敏原检测
JP6317440B2 (ja)	2013-10-29	2018-04-25	プレジデントアンドフェローズオブハーバードカレッジ	酸化ストレスを阻害するための方法および組成物
PL3065774T3 (pl)	2013-11-06	2021-12-13	Janssen Biotech, Inc	Przeciwciała anty-ccl17
EP2871189A1 (de)	2013-11-07	2015-05-13	Institut Pasteur	Hochaffiner, monoklonaler Anti-Strep-Tag-Antikörper
EP3066123A1 (de)	2013-11-07	2016-09-14	AbbVie Inc.	Isolierung und reinigung von antikörpern
EP2891722B1 (de)	2013-11-12	2018-10-10	Population Bio, Inc.	Verfahren und Zusammensetzungen zur Diagnose, Prognose und Behandlung von Endometriose
EP3068801A1 (de)	2013-11-13	2016-09-21	Pfizer Inc.	Tumornekrosefaktorähnliche ligand-1a-spezifische antikörper sowie zusammensetzungen damit und verwendungen davon
AU2014349828B2 (en)	2013-11-15	2021-01-28	Centre National De La Recherche Scientifique	A molecular marker of Plasmodium falciparum artemisinin resistance
WO2015087187A1 (en)	2013-12-10	2015-06-18	Rinat Neuroscience Corp.	Anti-sclerostin antibodies
US20150166984A1 (en)	2013-12-12	2015-06-18	President And Fellows Of Harvard College	Methods for correcting alpha-antitrypsin point mutations
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
CA2931684C (en)	2013-12-19	2024-02-20	Novartis Ag	Human mesothelin chimeric antigen receptors and uses thereof
WO2015095868A1 (en)	2013-12-20	2015-06-25	Wake Forest University Health Sciences	Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
JP2017500017A (ja)	2013-12-20	2017-01-05	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
EP2960252A1 (de)	2014-06-26	2015-12-30	Institut Pasteur	Phospholipase zur Behandlung von Immunosuppression
EP4043493A1 (de)	2013-12-24	2022-08-17	Janssen Pharmaceutica NV	Anti-vista-antikörper und -fragmente
US11014987B2 (en)	2013-12-24	2021-05-25	Janssen Pharmaceutics Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
AU2015206603B9 (en)	2014-01-14	2019-07-18	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
WO2016114819A1 (en)	2015-01-16	2016-07-21	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
TW201620939A (zh)	2014-01-16	2016-06-16	中央研究院	治療及檢測癌症之組合物及方法
WO2015109212A1 (en)	2014-01-17	2015-07-23	Pfizer Inc.	Anti-il-2 antibodies and compositions and uses thereof
EP3097196B1 (de)	2014-01-20	2019-09-11	President and Fellows of Harvard College	Negativauswahl und stringenzmodulation in systemen der kontinuierlichen evolution
KR20240049627A (ko)	2014-01-21	2024-04-16	다케다 파머수티컬 컴패니 리미티드	혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
CA2935423C (en)	2014-01-24	2023-11-07	Dana-Farber Cancer Institute, Inc.	Antibody molecules to pd-1 and uses thereof
WO2015116902A1 (en)	2014-01-31	2015-08-06	Genentech, Inc.	G-protein coupled receptors in hedgehog signaling
AU2015210750B2 (en)	2014-01-31	2020-08-20	Children's Medical Center Corporation	Antibody molecules to TIM-3 and uses thereof
CA2938590C (en)	2014-02-11	2023-10-17	Visterra, Inc.	Antibody molecules to dengue virus and uses thereof
WO2015127407A1 (en)	2014-02-21	2015-08-27	Stemcentrx, Inc.	Anti-dll3 antibodies and drug conjugates for use in melanoma
FI3122757T3 (fi)	2014-02-28	2023-10-10	Hangzhou Dac Biotech Co Ltd	Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
CA2938931A1 (en)	2014-03-12	2015-09-17	Prothena Biosciences Limited	Anti-laminin4 antibodies specific for lg1-3
KR20160127825A (ko)	2014-03-12	2016-11-04	프로테나 바이오사이언시즈 리미티드	항-mcam 항체 및 관련된 사용 방법
TW201623331A (zh)	2014-03-12	2016-07-01	普羅帝納生物科學公司	抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
JP2017514458A (ja)	2014-03-12	2017-06-08	プロセナバイオサイエンシーズリミテッド	Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
US9738702B2 (en)	2014-03-14	2017-08-22	Janssen Biotech, Inc.	Antibodies with improved half-life in ferrets
WO2015138920A1 (en)	2014-03-14	2015-09-17	Novartis Ag	Antibody molecules to lag-3 and uses thereof
MX378344B (es)	2014-03-21	2025-03-10	Teva Pharmaceuticals Int Gmbh	Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
WO2015148515A1 (en)	2014-03-24	2015-10-01	Biogen Ma Inc.	Methods for overcoming glutamine deprivation during mammalian cell culture
EP3129767B1 (de)	2014-03-27	2021-09-01	Academia Sinica	Reaktive markierungsverbindungen und ihre verwendungen
EP3122782A4 (de)	2014-03-27	2017-09-13	Dyax Corp.	Zusammensetzungen und verfahren zur behandlung von diabetischem makulaödem
MX378397B (es)	2014-03-31	2025-03-10	Univ Johns Hopkins	Uso de bacterias, productos bacterianos, y otras entidades inmunorreguladoras en combinacion con anticuerpos anti antigeno 4 de linfocitos t citotoxicos (ctla-4) y/o anti proteina 1 de muerte celular programada (pd-1) para tratar neoplasias de tumor solido.
AU2015240599B2 (en)	2014-04-04	2020-11-19	Bionomics, Inc.	Humanized antibodies that bind LGR5
US10562973B2 (en)	2014-04-08	2020-02-18	Prothena Bioscience Limited	Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TW201622746A (zh)	2014-04-24	2016-07-01	諾華公司	改善或加速髖部骨折術後身體復原之方法
CN106659146B (zh)	2014-05-05	2020-06-23	再生元制药公司	人源化c5和c3动物
CA2946606C (en)	2014-05-13	2023-06-06	Bavarian Nordic A/S	Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist of tim-3
EP3142700B1 (de)	2014-05-16	2021-03-03	Medimmune, LLC	Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
US10302653B2 (en)	2014-05-22	2019-05-28	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti B7-H1 antibodies
MX2016015163A (es)	2014-05-23	2017-03-03	Genentech Inc	Biomarcadores mit y metodos para su uso.
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267045B2 (en)	2014-05-27	2021-02-25	Academia Sinica	Anti-HER2 glycoantibodies and uses thereof
DK3149045T3 (da)	2014-05-27	2023-03-06	Academia Sinica	Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt
KR20170003720A (ko)	2014-05-27	2017-01-09	아카데미아 시니카	항-ｃｄ20 글리코항체 및 이의 용도
JP7063538B2 (ja)	2014-05-28	2022-05-09	アカデミアシニカ	抗ＴＮＦα糖操作抗体群およびその使用
DK3148579T3 (da)	2014-05-28	2021-03-08	Agenus Inc	Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
GB201409558D0 (en)	2014-05-29	2014-07-16	Ucb Biopharma Sprl	Method
SG10201913680PA (en)	2014-05-29	2020-03-30	Macrogenics Inc	Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
NZ726911A (en)	2014-06-03	2023-01-27	Xbiotech Inc	Compositions and methods for treating and preventing staphylococcus aureus infections
KR102226248B1 (ko)	2014-06-04	2021-03-12	바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드	강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
AU2015271709B2 (en)	2014-06-06	2020-11-26	Bristol-Myers Squibb Company	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
EP3154585B1 (de)	2014-06-11	2022-02-23	Kathy A. Green	Verwendung von vista-agonisten und antagonisten zur unterdrückung oder verbesserung der humoralen immunität
HUE045646T2 (hu)	2014-06-12	2020-01-28	Ra Pharmaceuticals Inc	Komplement aktivitás modulálása
EP3154589A1 (de)	2014-06-13	2017-04-19	Genentech, Inc.	Verfahren zur behandlung und prävention der antikrebsmittelresistenz
EP3154579A1 (de)	2014-06-13	2017-04-19	Friedrich Miescher Institute for Biomedical Research	Neue behandlung gegen das influenzavirus
JP6655074B2 (ja)	2014-06-20	2020-02-26	ジェネンテック，インコーポレイテッド	シャガシンに基づく足場組成物、方法及び使用
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
US10308935B2 (en)	2014-06-23	2019-06-04	Friedrich Miescher Institute For Biomedical Research	Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
GB201411320D0 (en)	2014-06-25	2014-08-06	Ucb Biopharma Sprl	Antibody construct
US20170327553A1 (en)	2014-06-25	2017-11-16	Novartis Ag	Compositions and methods for long acting proteins
EP3160990A2 (de)	2014-06-25	2017-05-03	Novartis AG	Zusammensetzungen und verfahren für proteine mit langer wirkung
US20170291939A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Antibodies specific for il-17a fused to hyaluronan binding peptide tags
WO2015200790A2 (en)	2014-06-26	2015-12-30	Yale University	Compositions and methods to regulate renalase in the treatment of diseases and disorders
TWI693232B (zh)	2014-06-26	2020-05-11	美商宏觀基因股份有限公司	與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
US20170165261A1 (en)	2014-07-01	2017-06-15	Brian Arthur Hemmings	Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
JP6913018B2 (ja)	2014-07-08	2021-08-04	ニューヨーク・ユニバーシティ	タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
KR102641268B1 (ko)	2014-07-17	2024-02-27	노보 노르디스크 에이/에스	점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
US9777061B2 (en)	2014-07-21	2017-10-03	Novartis Ag	Treatment of cancer using a CD33 chimeric antigen receptor
EP3171896A4 (de)	2014-07-23	2018-03-21	Mayo Foundation for Medical Education and Research	Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs
EP3511413B1 (de)	2014-07-25	2022-09-07	Theravectys	Lentivirale vektoren zur regulierten expression eines chimären antigenrezeptormoleküls
WO2016022363A2 (en)	2014-07-30	2016-02-11	President And Fellows Of Harvard College	Cas9 proteins including ligand-dependent inteins
SG10201805646WA (en)	2014-08-07	2018-08-30	Novartis Ag	Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en)	2014-08-07	2016-02-11	Novartis Ag	Angiopoetin-like 4 (angptl4) antibodies and methods of use
WO2016025880A1 (en)	2014-08-14	2016-02-18	Novartis Ag	Treatment of cancer using gfr alpha-4 chimeric antigen receptor
SG11201700770PA (en)	2014-08-19	2017-03-30	Novartis Ag	Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
WO2016036403A1 (en)	2014-09-05	2016-03-10	Population Diagnostics Inc.	Methods and compositions for inhibiting and treating neurological conditions
EP3191500A4 (de)	2014-09-08	2018-04-11	Academia Sinica	Aktivierung menschlicher inkt-zellen mithilfe von glykolipiden
PE20170676A1 (es)	2014-09-09	2017-05-22	Janssen Biotech Inc	Terapias de combinacion con anticuerpos anti-cd38
US20160075772A1 (en)	2014-09-12	2016-03-17	Regeneron Pharmaceuticals, Inc.	Treatment of Fibrodysplasia Ossificans Progressiva
WO2016040882A1 (en)	2014-09-13	2016-03-17	Novartis Ag	Combination therapies of egfr inhibitors
MX2017003247A (es)	2014-09-15	2017-11-30	Amgen Inc	Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
ES2748295T3 (es)	2014-09-16	2020-03-16	Symphogen As	Anticuerpos anti-MET y composiciones
EP3197557A1 (de)	2014-09-24	2017-08-02	Friedrich Miescher Institute for Biomedical Research	Lats und brustrkrebs
EP3201227A4 (de)	2014-09-29	2018-04-18	Duke University	Bispezifische moleküle mit einem hiv-1-hüll-targeting-arm
AU2015327064B2 (en)	2014-09-30	2021-03-18	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Binding molecules, especially antibodies, binding to L1CAM (CD171)
CA2963166C (en)	2014-10-01	2023-10-03	Medimmune Limited	Antibodies to ticagrelor and methods of use
KR20170066546A (ko)	2014-10-03	2017-06-14	노파르티스 아게	조합 요법
SG10201902924RA (en)	2014-10-03	2019-05-30	Massachusetts Inst Technology	Antibodies that bind ebola glycoprotein and uses thereof
WO2016061142A1 (en)	2014-10-14	2016-04-21	Novartis Ag	Antibody molecules to pd-l1 and uses thereof
EP3207146B1 (de)	2014-10-15	2021-09-29	Amgen Inc.	Promotor und regulatorische elemente zur verbesserten expression von heterologen genen in wirtszellen
MA41685A (fr)	2014-10-17	2017-08-22	Biogen Ma Inc	Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
KR20210013299A (ko)	2014-10-17	2021-02-03	코디악 사이언시스 인코포레이티드	부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
WO2016077052A2 (en)	2014-10-22	2016-05-19	President And Fellows Of Harvard College	Evolution of proteases
MA40864A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
US10738078B2 (en)	2014-11-03	2020-08-11	Bristol-Myers Squibb Company	Use of caprylic acid precipitation for protein purification
ES3013108T3 (en)	2014-11-05	2025-04-11	Annexon Inc	Humanized anti-complement factor c1q antibodies and uses thereof
WO2016073894A1 (en)	2014-11-07	2016-05-12	Eleven Biotherapeutics, Inc.	Therapeutic agents with increased ocular retention
US11142571B2 (en)	2014-11-07	2021-10-12	Sesen Bio, Inc.	IL-6 antibodies
US9879087B2 (en)	2014-11-12	2018-01-30	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
US20170306046A1 (en)	2014-11-12	2017-10-26	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
WO2016079219A1 (en)	2014-11-19	2016-05-26	Koninklijke Philips N.V.	Diagnostic method employing hnl
ES2832802T3 (es)	2014-11-21	2021-06-11	Univ Maryland	Sistemas de administración dirigida del particulado específico de una estructura
TWI711630B (zh)	2014-11-21	2020-12-01	美商必治妥美雅史谷比公司	抗ｃｄ７３抗體及其用途
JP2018505911A (ja)	2014-12-05	2018-03-01	イミュネクスト，インコーポレーテッド	推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
US11220545B2 (en)	2014-12-08	2022-01-11	Dana-Farber Cancer Institute, Inc.	Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
TWI595006B (zh)	2014-12-09	2017-08-11	禮納特神經系統科學公司	抗ｐｄ－１抗體類和使用彼等之方法
WO2016094837A2 (en)	2014-12-11	2016-06-16	Igenica Biotherapeutics, Inc.	Anti-c10orf54 antibodies and uses thereof
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
CN107278206B (zh)	2014-12-19	2021-04-02	雷根尼桑斯公司	结合人c6的抗体及其用途
EP3233918A1 (de)	2014-12-19	2017-10-25	Novartis AG	Kombinationstherapien
EP3789039A1 (de)	2014-12-22	2021-03-10	The Rockefeller University	Anti-mertk-antikörper und verwendungen davon
MY187045A (en)	2014-12-23	2021-08-27	Bristol Myers Squibb Co	Antibodies to tigit
EP3237906B8 (de)	2014-12-23	2020-10-28	Bluelight Therapeutics, Inc.	Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion
JP2018504400A (ja)	2015-01-08	2018-02-15	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10342858B2 (en)	2015-01-24	2019-07-09	Academia Sinica	Glycan conjugates and methods of use thereof
HK1247215A1 (zh)	2015-01-26	2018-09-21	Macrogenics, Inc.	包含dr5-结合结构域的多价分子
WO2016123371A1 (en)	2015-01-28	2016-08-04	Ra Pharmaceuticals, Inc.	Modulators of complement activity
TWI718122B (zh)	2015-01-28	2021-02-11	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
TWI781507B (zh)	2015-01-28	2022-10-21	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
TWI711631B (zh)	2015-01-28	2020-12-01	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
TWI717333B (zh)	2015-01-30	2021-02-01	中央研究院	增進抗體功效之通用糖型組合物及方法
AU2016215676B2 (en)	2015-02-02	2021-12-02	Children's Health Care D/B/A Children's Minnesota	Anti-surrogate light chain antibodies
WO2016128349A1 (en)	2015-02-09	2016-08-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
KR102740384B1 (ko)	2015-03-03	2024-12-06	키맵 리미티드	항체, 용도 및 방법
WO2016141111A1 (en)	2015-03-03	2016-09-09	Xoma (Us) Llc	Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
US9139653B1 (en)	2015-04-30	2015-09-22	Kymab Limited	Anti-human OX40L antibodies and methods of treatment
US20180042998A1 (en)	2015-03-10	2018-02-15	University Of Massachusetts	Targeting gdf6 and bmp signaling for anti-melanoma therapy
EP3268100A1 (de)	2015-03-13	2018-01-17	Bristol-Myers Squibb Company	Verwendung von alkalischen spülungen während der chromatografie während zum entfernen von verunreinigungen
US20180105555A1 (en)	2015-03-20	2018-04-19	Bristol-Myers Squibb Company	Use of dextran for protein purification
WO2016153978A1 (en)	2015-03-20	2016-09-29	Bristol-Myers Squibb Company	Use of dextran to enhance protein purification by affinity chromatography
WO2016154588A1 (en)	2015-03-25	2016-09-29	Children's Hospital Medical Center	Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation
CN107530427A (zh)	2015-03-27	2018-01-02	南加利福尼亚大学	针对用于实体肿瘤的治疗的lhr的car t细胞疗法
IL254292B2 (en)	2015-03-30	2026-01-01	Dyax Corp	Plasma kallikrein inhibitors and their uses for preventing the onset of hereditary angioedema
CN116327915A (zh)	2015-04-03	2023-06-27	佐马技术有限公司	使用TGF-β抑制剂和PD-1抑制剂治疗癌症
IL310723A (en)	2015-04-13	2024-04-01	Pfizer	Therapeutic antibodies and their uses
US11299729B2 (en)	2015-04-17	2022-04-12	President And Fellows Of Harvard College	Vector-based mutagenesis system
WO2016170022A1 (en)	2015-04-21	2016-10-27	Institut Gustave Roussy	Therapeutic methods, products and compositions inhibiting znf555
GB201506870D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
GB201506869D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
EP3286227A2 (de)	2015-04-24	2018-02-28	F. Hoffmann-La Roche AG	Multispezifische antigenbindende proteine
JP6704000B2 (ja)	2015-04-24	2020-06-03	ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア	Ｒｏｒ１−ｒｏｒ２結合のモジュレーター
AU2016256486B2 (en)	2015-04-29	2021-09-23	University Of South Australia	Compositions and methods for administering antibodies
EP3288976B1 (de)	2015-04-29	2020-04-08	Regeneron Pharmaceuticals, Inc.	Behandlung von fibrodysplasia ossificans progressiva
EP3292410A1 (de)	2015-05-06	2018-03-14	POC Medical Systems Inc.	Vorrichtungen und verfahren für den nachweis von biomarkern
WO2016179518A2 (en)	2015-05-06	2016-11-10	Janssen Biotech, Inc.	Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
AU2016256911B2 (en)	2015-05-07	2022-03-31	Agenus Inc.	Anti-OX40 antibodies and methods of use thereof
EP3294334B1 (de)	2015-05-11	2020-07-08	The Johns Hopkins University	Autoimmunantikörper zur verwendung bei der hemmung des wachstums von krebszellen
CA2985816A1 (en)	2015-05-15	2016-11-24	The General Hospital Corporation	Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
JP6857138B2 (ja)	2015-05-18	2021-04-14	アジェンシス，インコーポレイテッド	Ａｘｌタンパク質に結合する抗体
US10787517B2 (en)	2015-05-18	2020-09-29	Agensys, Inc.	Antibodies that bind to AXL proteins
CA2986594C (en)	2015-05-20	2025-06-10	Tufts Medical Center, Inc.	Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
JP6851322B2 (ja)	2015-05-27	2021-03-31	ユーシービーバイオファルマエスアールエル	神経疾患を治療する方法
CA2986765A1 (en)	2015-05-29	2016-12-08	Agenus Inc.	Anti-ctla-4 antibodies and methods of use thereof
EA035412B1 (ru)	2015-05-29	2020-06-10	Бристол-Майерс Сквибб Компани	Антитела к ox40 и их применение
RU2715597C2 (ru)	2015-05-29	2020-03-02	Эббви Инк.	Антитела к cd40 и способы их применения
EP3302559B1 (de)	2015-06-04	2022-01-12	University of Southern California	Auf lym-1 und lym-2 abgerichtete car-zellen-immuntherapie
EA201792561A1 (ru)	2015-06-05	2018-04-30	Новартис Аг	Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
TWI773646B (zh)	2015-06-08	2022-08-11	美商宏觀基因股份有限公司	結合lag-3的分子和其使用方法
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en)	2015-06-18	2015-08-05	Ucb Biopharma Sprl	Novel TNFa structure for use in therapy
CN107708734B (zh)	2015-06-22	2022-01-11	詹森生物科技公司	用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
EP3722314A1 (de)	2015-06-24	2020-10-14	Janssen Pharmaceutica NV	Anti-vista-antikörper und -fragmente
HRP20240338T1 (hr)	2015-06-24	2024-05-24	Janssen Biotech, Inc.	Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
US10479838B2 (en)	2015-06-29	2019-11-19	Bristol-Myers Squibb Company	Antibodies to CD40 with enhanced agonist activity
EP3319936B1 (de)	2015-07-12	2025-12-17	Hangzhou Dac Biotech Co., Ltd.	Brückenlinker zur konjugation von zellbindenden molekülen
US9839687B2 (en)	2015-07-15	2017-12-12	Suzhou M-Conj Biotech Co., Ltd.	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601073D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
GB201601075D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies molecules
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
US10877045B2 (en)	2015-07-21	2020-12-29	Saint Louis University	Compositions and methods for diagnosing and treating endometriosis-related infertility
JP7068160B2 (ja)	2015-07-21	2022-05-16	武田薬品工業株式会社	第ＸＩＩａ因子のモノクローナル抗体阻害剤
WO2017015545A1 (en)	2015-07-22	2017-01-26	President And Fellows Of Harvard College	Evolution of site-specific recombinases
WO2017015559A2 (en)	2015-07-23	2017-01-26	President And Fellows Of Harvard College	Evolution of bt toxins
US11066481B2 (en)	2015-07-23	2021-07-20	The Regents Of The University Of California	Antibodies to coagulation factor XIa and uses thereof
WO2017019897A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
ES2878188T3 (es)	2015-07-29	2021-11-18	Novartis Ag	Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP4378957A3 (de)	2015-07-29	2024-08-07	Novartis AG	Kombinationstherapien mit antikörpermolekülen gegen pd-1
AU2016298227B9 (en)	2015-07-30	2019-10-31	Macrogenics, Inc.	PD-1-binding molecules and methods of use thereof
WO2017019895A1 (en)	2015-07-30	2017-02-02	President And Fellows Of Harvard College	Evolution of talens
WO2017021893A1 (en)	2015-08-03	2017-02-09	Novartis Ag	Methods of treating fgf21-associated disorders
EA201890434A1 (ru)	2015-08-05	2018-10-31	Янссен Байотек, Инк.	Антитела к cd154 и способы их применения
WO2017024285A2 (en)	2015-08-06	2017-02-09	Xoma (Us) Llc	Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
CN108135986B (zh)	2015-08-13	2022-07-29	纽约大学	对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
WO2017040342A1 (en)	2015-08-28	2017-03-09	Genentech, Inc.	Anti-hypusine antibodies and uses thereof
EP3344656A1 (de)	2015-09-01	2018-07-11	Agenus Inc.	Anti-pd-1-antikörper und verfahren zur verwendung davon
AU2016315892B2 (en)	2015-09-02	2023-06-15	The Regents Of The University Of Colorado, A Body Corporate	Compositions and methods for modulating T-cell mediated immune response
JP2018532990A (ja)	2015-09-04	2018-11-08	オービーアイファーマ，インコーポレイテッド	グリカンアレイおよび使用の方法
US10000561B2 (en)	2015-09-09	2018-06-19	Novartis Ag	Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
KR20180042433A (ko)	2015-09-09	2018-04-25	노파르티스 아게	흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
WO2017044453A1 (en)	2015-09-10	2017-03-16	Becton, Dickinson And Company	Cyclophosphamide analogs for use as immunogens and assay conjugates for an immunoassay of cyclophosphamide and ifosfamide
CA2998174A1 (en)	2015-09-15	2017-03-23	Amgen Inc.	Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
PT3922645T (pt)	2015-09-15	2025-05-29	Scholar Rock Inc	¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
WO2017046774A2 (en)	2015-09-16	2017-03-23	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
EP3350226A2 (de)	2015-09-16	2018-07-25	Prothena Biosciences Limited	Verwendung von anti-mcam-antikörpern zur behandlung oder prophylaxe von riesenzellarteriitis, polymyalgia rheumatica oder takayasu-arteriitis
JP6959912B2 (ja)	2015-09-23	2021-11-05	ジェネンテック，インコーポレイテッド	抗ｖｅｇｆ抗体の最適化変異体
KR20180053744A (ko)	2015-09-23	2018-05-23	사이토이뮨 테라퓨틱스 엘엘씨	면역 요법을 위한 flt3 유도된 car 세포
RU2638457C2 (ru)	2015-09-28	2017-12-13	Общество С Ограниченной Ответственностью "Онкомакс"	Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
BR112018006360A2 (pt)	2015-09-30	2018-10-09	Janssen Biotech Inc	anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
CN108136010A (zh)	2015-10-08	2018-06-08	宏观基因有限公司	用于治疗癌症的联合疗法
AU2016337525B2 (en)	2015-10-16	2022-01-20	The Trustees Of Columbia University In The City Of New York	Compositions and methods for inhibition of lineage specific antigens
WO2017066561A2 (en)	2015-10-16	2017-04-20	President And Fellows Of Harvard College	Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
CA3002747A1 (en)	2015-10-19	2017-04-27	Dyax Corp.	Immunoassay to detect cleaved high molecular weight kininogen
WO2017070561A1 (en)	2015-10-23	2017-04-27	Pfizer Inc.	Anti-il-2 antibodies and compositions and uses thereof
SG10202104041PA (en)	2015-10-23	2021-06-29	Harvard College	Nucleobase editors and uses thereof
MY207225A (en)	2015-10-27	2025-02-06	UCB Biopharma SRL	Methods of treatment using anti-il-17a/f antibodies
US20180348224A1 (en)	2015-10-28	2018-12-06	Friedrich Miescher Institute For Biomedical Resear Ch	Tenascin-w and biliary tract cancers
EP3368157B1 (de)	2015-10-29	2022-06-29	Dana-Farber Cancer Institute, Inc.	Verfahren zur identifizierung, beurteilung, prävention und behandlung von stoffwechselerkrankungen mit verwendung von pm20d1 und n-lipidierten aminosäuren
US10875923B2 (en)	2015-10-30	2020-12-29	Mayo Foundation For Medical Education And Research	Antibodies to B7-H1
US10941204B2 (en)	2015-10-30	2021-03-09	Galaxy Biotech, Llc	Highly potent antibodies binding to death receptor 4
KR20250099459A (ko)	2015-11-03	2025-07-01	얀센 바이오테크 인코포레이티드	Pd-1과 특이적으로 결합하는 항체 및 그의 용도
HUE053366T2 (hu)	2015-11-03	2021-06-28	Janssen Biotech Inc	Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
AU2016354688B2 (en)	2015-11-09	2021-12-16	The University Of British Columbia	Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
EP3374379A4 (de)	2015-11-09	2019-05-15	The University Of British Columbia	N-terminale epitope in amyloid-beta und konformationsselektive antikörper dagegen
JP7452829B2 (ja)	2015-11-09	2024-03-19	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	アミロイドベータのエピトープおよびそれに対する抗体
US11168131B2 (en)	2015-11-10	2021-11-09	Visterra, Inc.	Antibody molecule-drug conjugates and uses thereof
CN108463248B (zh)	2015-11-12	2022-10-21	西雅图基因公司	聚糖相互作用化合物及使用方法
CN107406504B (zh)	2015-11-19	2021-04-30	蔡则玲	Ctla-4抗体及其用途
CA3005855A1 (en)	2015-11-19	2017-05-26	Bristol-Myers Squibb Company	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
DK3380522T5 (da)	2015-11-25	2024-09-30	Visterra Inc	Antistofmolekyler til april og anvendelser deraf
KR102630475B1 (ko)	2015-11-30	2024-01-26	브리스톨-마이어스 스큅 컴퍼니	항 인간 ip-10 항체 및 이의 용도
ES2975747T3 (es)	2015-11-30	2024-07-12	Univ California	Administración de carga útil específica de tumor y activación inmunitaria utilizando un anticuerpo humano que se dirige a un antígeno de superficie celular de tumor altamente específico
EP3383908A1 (de)	2015-12-02	2018-10-10	Stsciences, Inc.	Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator)
MX2018006613A (es)	2015-12-02	2019-01-30	Stcube & Co Inc	Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
GB201521391D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521389D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Method
GB201521383D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl And Ucb Celltech	Method
GB201521393D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
AU2016366548C1 (en)	2015-12-09	2024-07-25	Bioatla, Llc	Humanized anti-CD73 antibodies
US10829562B2 (en)	2015-12-10	2020-11-10	Katholieke Universiteit Leuven	Haemorrhagic disorder due to ventricular assist device
BR112018011622A2 (pt)	2015-12-11	2018-11-27	Dyax Corp	método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
JP6955507B2 (ja)	2015-12-14	2021-10-27	マクロジェニクス，インコーポレーテッド	Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
EP4218790B1 (de)	2015-12-16	2026-02-18	UCB Holdings, Inc.	Modulatoren der komplementaktivität
WO2017106684A2 (en)	2015-12-17	2017-06-22	Janssen Biotech, Inc.	Antibodies specifically binding hla-dr and their uses
RU2018125603A (ru)	2015-12-17	2020-01-21	Новартис Аг	Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения
EP3389712B1 (de)	2015-12-17	2024-04-10	Novartis AG	Antikörpermoleküle gegen pd-1 und verwendungen davon
CA3008102A1 (en)	2015-12-18	2017-06-22	Novartis Ag	Antibodies targeting cd32b and methods of use thereof
WO2017112954A1 (en)	2015-12-23	2017-06-29	Moonshot Pharma Llc	Methods for inducing an immune response by promoting premature termination codon read-through
KR20250057128A (ko)	2015-12-30	2025-04-28	코디악 사이언시스 인코포레이티드	항체 및 이의 접합체
JP7078536B2 (ja)	2016-01-08	2022-05-31	アルトゥルバイオ，インコーポレイテッド	四価抗ｐｓｇｌ－１抗体とその使用
CN115814077A (zh)	2016-01-08	2023-03-21	供石公司	抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
CN109219618B (zh)	2016-01-21	2022-08-09	辉瑞大药厂	针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
EP3405492B1 (de)	2016-01-21	2020-10-21	Novartis AG	Gegen cll-1 gerichtete multispezifische moleküle
GB201602413D0 (en)	2016-02-10	2016-03-23	Nascient Ltd	Method
TW202216201A (zh)	2016-02-12	2022-05-01	比利時商楊森製藥公司	抗vista抗體及片段、其用途及鑑定其之方法
TW201730212A (zh)	2016-02-17	2017-09-01	宏觀基因股份有限公司	Ｒｏｒ１－結合分子及其使用方法
EP3419599A4 (de)	2016-02-23	2019-09-11	Sesen Bio, Inc.	Il-6-antagonistformulierungen und verwendung davon
CN109476731A (zh)	2016-02-29	2019-03-15	基础医药有限公司	治疗癌症的方法
CN109196121B (zh)	2016-02-29	2022-01-04	基因泰克公司	用于癌症的治疗和诊断方法
WO2017149513A1 (en)	2016-03-03	2017-09-08	Prothena Biosciences Limited	Anti-mcam antibodies and associated methods of use
CA3016187A1 (en)	2016-03-04	2017-09-08	Bristol-Myers Squibb Company	Combination therapy with anti-cd73 antibodies
KR20180114223A (ko)	2016-03-04	2018-10-17	더 락커펠러 유니버시티	증진된 효능제 활성을 갖는 cd40에 대한 항체
CN116514976A (zh)	2016-03-04	2023-08-01	Jn生物科学有限责任公司	针对tigit的抗体
AU2017231749A1 (en)	2016-03-08	2018-09-20	Academia Sinica	Methods for modular synthesis of N-glycans and arrays thereof
US10287328B2 (en)	2016-03-08	2019-05-14	KeMyth Biotech Co., Ltd.	Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same
WO2017153955A1 (en)	2016-03-09	2017-09-14	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en)	2016-03-09	2017-09-14	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
JP6979976B2 (ja)	2016-03-10	2021-12-15	ヴィエラバイオ，インコーポレーテッド	Ｉｌｔ７結合分子及びその使用方法
PL3365368T3 (pl)	2016-03-11	2023-08-21	Scholar Rock, Inc.	Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie
WO2017160599A1 (en)	2016-03-14	2017-09-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Use of cd300b antagonists to treat sepsis and septic shock
US11186641B2 (en)	2016-03-17	2021-11-30	Oslo Universitetssykehus Hf	Fusion proteins targeting tumour associated macrophages for treating cancer
JP7082604B2 (ja)	2016-03-21	2022-06-08	マレンゴ・セラピューティクス，インコーポレーテッド	多重特異性および多機能性分子ならびにその使用
KR20180138205A (ko)	2016-03-22	2018-12-28	바이오노믹스 리미티드	항-lgr5 단클론성 항체의 투여
JP7155009B2 (ja)	2016-03-25	2022-10-18	ビステラ，インコーポレイテッド	デングウイルスに対する抗体分子の製剤
US11041017B2 (en)	2016-03-29	2021-06-22	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
EA201892190A1 (ru)	2016-03-29	2019-04-30	Янссен Байотек, Инк.	Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
WO2017175058A1 (en)	2016-04-07	2017-10-12	Janssen Pharmaceutica Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CN109414489B (zh)	2016-04-08	2022-08-16	埃缇健康公司D/B/A泽尔拜尔	网蛋白-1结合抗体及其用途
WO2017181098A2 (en)	2016-04-15	2017-10-19	Visterra, Inc.	Antibody molecules to zika virus and uses thereof
JP7184751B2 (ja)	2016-04-15	2022-12-06	イミュネクストインコーポレイテッド	抗ヒトｖｉｓｔａ抗体およびその使用
CA3020864A1 (en)	2016-04-15	2017-10-19	Macrogenics, Inc.	Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
JP7038064B2 (ja)	2016-04-18	2022-03-17	セルデックスセラピューティクスインコーポレイテッド	ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
MY200300A (en)	2016-04-21	2023-12-19	4TEEN4 Pharmaceuticals GmbH	Methods for determining dpp3 and therapeutic methods
KR20250048399A (ko)	2016-04-22	2025-04-08	오비아이 파머 인코퍼레이티드	글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
EA201892412A1 (ru)	2016-05-02	2019-05-31	Протена Биосайенсис Лимитед	Антитела, распознающие тау
CA3022515A1 (en)	2016-05-02	2017-11-09	Prothena Biosciences Limited	Antibodies recognizing tau
US10968279B2 (en)	2016-05-09	2021-04-06	Bristol-Myers Squibb Company	TL1A antibodies and uses thereof
UA127200C2 (uk)	2016-05-18	2023-06-07	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Молекула антитіла до pd1
WO2017201225A1 (en)	2016-05-19	2017-11-23	Poc Medical Systems, Inc.	Cancer screening via detection and quantification of multiple biomarkers
US11649291B2 (en)	2016-05-24	2023-05-16	Insmed Incorporated	Antibodies and methods of making same
MX389710B (es)	2016-05-27	2025-03-20	Agenus Inc	Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
WO2017208210A1 (en)	2016-06-03	2017-12-07	Prothena Biosciences Limited	Anti-mcam antibodies and associated methods of use
US11136405B2 (en)	2016-06-06	2021-10-05	Board Of Regents, The Unviersity Of Texas System	BAFF-R antibodies and uses thereof
CA3026640A1 (en)	2016-06-06	2017-12-14	City Of Hope	Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
US12048718B2 (en)	2016-06-07	2024-07-30	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft	Chimeric antigen receptor and CAR-T cells that bind BCMA
CA3027651A1 (en)	2016-06-15	2017-12-21	Novartis Ag	Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
JP7461741B2 (ja)	2016-06-20	2024-04-04	カイマブ・リミテッド	抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
MA45493A (fr)	2016-06-27	2019-05-01	Aicuris Anti Infective Cures Gmbh	Inhibiteurs d'entrée de hcmv.
EP3475706B1 (de)	2016-06-27	2021-08-11	Juno Therapeutics, Inc.	Mhc-e-beschränkte epitopen, bindungsmoleküle, und zugehörige verfahren und verwendungen
US20200182884A1 (en)	2016-06-27	2020-06-11	Juno Therapeutics, Inc.	Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
US20190233533A1 (en)	2016-06-28	2019-08-01	Umc Utrecht Holding B.V.	Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
EP3478714A2 (de)	2016-07-02	2019-05-08	Prothena Biosciences Limited	Anti-transthyretin-antikörper
JP7016470B2 (ja)	2016-07-02	2022-02-07	プロセナバイオサイエンシーズリミテッド	抗トランスサイレチン抗体
JP7017013B2 (ja)	2016-07-02	2022-02-08	プロセナバイオサイエンシーズリミテッド	抗トランスサイレチン抗体
CA3027350A1 (en)	2016-07-06	2018-01-11	Prothena Biosciences Limited	Assay for detecting total and s129 phosphorylated alpha-synuclein
CN109716136B (zh)	2016-07-08	2023-09-22	斯弗因高泰克有限公司	肾上腺髓质素用于评估急性心力衰竭患者的充血
EP3481864A1 (de)	2016-07-08	2019-05-15	Staten Biotechnology B.V.	Anti-apoc3-antikörper und verfahren zur verwendung davon
US20200031924A1 (en)	2016-07-13	2020-01-30	Biogen Ma Inc.	Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating Disorders
SG11201900026TA (en)	2016-07-14	2019-01-30	Bristol Myers Squibb Co	Antibodies against tim3 and uses thereof
CA3026757A1 (en)	2016-07-15	2018-01-18	Poseida Therapeutics, Inc.	Chimeric antigen receptors and methods for use
US20190328784A1 (en)	2016-07-15	2019-10-31	Poseida Therapeutics, Inc.	Chimeric antigen receptors (cars) specific for muc1 and methods for their use
SG11201900344YA (en)	2016-07-15	2019-02-27	Novartis Ag	Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
KR102550991B1 (ko)	2016-07-18	2023-07-04	더 유니버시티 오브 브리티쉬 콜롬비아	아밀로이드 베타에 대한 항체
EP3487506A1 (de)	2016-07-20	2019-05-29	Hybrigenics SA	Kombinationen von inecalcitol mit einem anti-cd38-mittel und deren verwendungen zur behandlung von krebs
US20200148750A1 (en)	2016-07-21	2020-05-14	Emory University	Ebola Virus Antibodies and Binding Agents Derived Therefrom
KR102435801B1 (ko)	2016-07-22	2022-08-25	암젠 인크	Fc-함유 단백질의 정제 방법
US20190330318A1 (en)	2016-07-25	2019-10-31	Biogen Ma Inc.	Anti-hspa5 (grp78) antibodies and uses thereof
WO2018022933A1 (en)	2016-07-27	2018-02-01	Obi Pharma, Inc.	Immunogenic/therapeutic glycan compositions and uses thereof
EP3491026A4 (de)	2016-07-29	2020-07-29	OBI Pharma, Inc.	Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren
EP3490568A4 (de)	2016-07-29	2020-04-15	New York University	Behandlung von soliden tumoren durch abzielung auf die dectin-1 signalisierung
EP3490600A1 (de)	2016-08-01	2019-06-05	Xoma (Us) Llc	Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
FI3494134T3 (fi)	2016-08-02	2026-02-19	Visterra Inc	Muunneltuja polypeptidejä ja niiden käyttötapoja
CA3032146A1 (en)	2016-08-03	2018-02-08	Bio-Techne Corporation	Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
KR20250103795A (ko)	2016-08-03	2025-07-07	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en)	2016-08-09	2023-05-30	President And Fellows Of Harvard College	Programmable CAS9-recombinase fusion proteins and uses thereof
MA45919A (fr)	2016-08-12	2019-06-19	Janssen Biotech Inc	Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
JP7009448B2 (ja)	2016-08-12	2022-02-10	ヤンセンバイオテツク，インコーポレーテツド	強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法
JP2019530646A (ja)	2016-08-12	2019-10-24	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	タンパク質精製法
AU2017316663B2 (en)	2016-08-22	2024-02-22	CHO Pharma Inc.	Antibodies, binding fragments, and methods of use
WO2018039438A1 (en)	2016-08-24	2018-03-01	President And Fellows Of Harvard College	Incorporation of unnatural amino acids into proteins using base editing
US10981976B2 (en)	2016-08-31	2021-04-20	University Of Rochester	Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
JP2019534858A (ja)	2016-09-09	2019-12-05	ジェネンテック，インコーポレイテッド	Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤
CN109906232B (zh)	2016-09-23	2023-11-07	马伦戈治疗公司	包含λ轻链和κ轻链的多特异性抗体分子
CN110087681A (zh)	2016-09-28	2019-08-02	佐马美国有限公司	结合白细胞介素-2的抗体和其用途
GB201616596D0 (en)	2016-09-29	2016-11-16	Nascient Limited	Epitope and antibodies
EP3519049B1 (de)	2016-09-30	2025-12-03	Janssen Biotech, Inc.	Sicheres und effizientes verfahren zur behandlung von psoriasis mit anti-il23-spezifischem antikörper
EP4521116A3 (de)	2016-10-03	2025-05-28	Abbott Laboratories	Verbesserte verfahren zur beurteilung des uch-l1-status in patientenproben
WO2018067992A1 (en)	2016-10-07	2018-04-12	Novartis Ag	Chimeric antigen receptors for the treatment of cancer
KR102576042B1 (ko)	2016-10-11	2023-09-07	아게누스 인코포레이티드	항-lag-3 항체 및 이의 사용 방법
CA3040189A1 (en)	2016-10-13	2018-04-19	Massachusetts Institute Of Technology	Antibodies that bind zika virus envelope protein and uses thereof
WO2018071576A1 (en)	2016-10-14	2018-04-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Treatment of tumors by inhibition of cd300f
SG11201903089RA (en)	2016-10-14	2019-05-30	Harvard College	Aav delivery of nucleobase editors
WO2018075408A1 (en)	2016-10-17	2018-04-26	Alexion Pharmaceuticals, Inc.	Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
KR102613430B1 (ko)	2016-10-19	2023-12-18	더 스크립스 리서치 인스티튜트	인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
RU2019114863A (ru)	2016-11-02	2020-12-03	Иммуноджен, Инк.	Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR102431830B1 (ko)	2016-11-07	2022-08-16	주식회사 뉴라클사이언스	서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
US20180125920A1 (en)	2016-11-09	2018-05-10	The University Of British Columbia	Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018089829A1 (en)	2016-11-10	2018-05-17	Fortis Therapeutics, Inc.	Cd46-specific effector cells and uses thereof
CA3043528A1 (en)	2016-11-14	2018-05-17	Amgen Inc.	Bispecific or biparatopic antigen binding proteins and uses thereof
AU2016429272A1 (en)	2016-11-14	2019-05-02	Hangzhou Dac Biotech Co., Ltd.	Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
EP3538546B1 (de)	2016-11-14	2025-01-08	Novartis AG	Zusammensetzungen, methoden und therapeutische verwendungen des fusogenen proteins minion
MX2019005661A (es)	2016-11-16	2019-10-07	Janssen Biotech Inc	Método para tratar la psoriasis con el anticuerpo específico anti-il23.
EP3541847A4 (de)	2016-11-17	2020-07-08	Seattle Genetics, Inc.	Glycaninteragierende verbindungen und verfahren zur verwendung
JP2019535731A (ja)	2016-11-21	2019-12-12	オービーアイファーマ，インコーポレイテッド	コンジュゲートさせた生物学的分子、医薬組成物及び方法
WO2018102594A1 (en)	2016-12-01	2018-06-07	Alexion Pharmaceuticals, Inc.	Methods of treating solid tumors with anti-cd200 antibodies
CN119161467A (zh)	2016-12-05	2024-12-20	图兰恩教育基金管理人	沙粒病毒单克隆抗体和用途
FI3551660T3 (fi)	2016-12-07	2023-12-11	Agenus Inc	Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
CN118634323A (zh)	2016-12-07	2024-09-13	艾吉纳斯公司	抗体和其使用方法
CA3045114A1 (en)	2016-12-07	2018-06-14	Ra Pharmaceuticals, Inc.	Modulators of complement activity
EP3339324A1 (de)	2016-12-22	2018-06-27	sphingotec GmbH	Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten
JP7727371B2 (ja)	2016-12-16	2025-08-21	アドレノメトアクチェンゲゼルシャフト	うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場
GB201621635D0 (en)	2016-12-19	2017-02-01	Ucb Biopharma Sprl	Crystal structure
EP3360898A1 (de)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
AU2017382234B2 (en)	2016-12-23	2025-01-30	Macrogenics, Inc.	ADAM9-binding molecules, and methods of use thereof
SI3558391T1 (sl)	2016-12-23	2022-06-30	Immunogen, Inc.	Imunokonjugati, ciljno usmerjeni na ADAM9, in načini njihove uporabe
RU2019123063A (ru)	2016-12-23	2021-01-26	Вистерра, Инк.	Связывающие полипептиды и способы их получения
WO2018119359A1 (en)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Editing of ccr5 receptor gene to protect against hiv infection
WO2018129329A1 (en)	2017-01-06	2018-07-12	Scholar Rock, Inc.	ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
PT3565592T (pt)	2017-01-06	2023-05-31	Scholar Rock Inc	Tratamento de doenças metabólicas através da inibição da ativação da miostatina
US11155611B2 (en)	2017-01-06	2021-10-26	Scholar Rock, Inc.	Compositions and methods for making and using anti-myostatin antibodies
TW201833140A (zh)	2017-01-09	2018-09-16	美商莫瑞麥克製藥公司	抗fgfr抗體及使用方法
WO2018130661A1 (en)	2017-01-13	2018-07-19	Academia Sinica	Reloadable hydrogel system for treating brain conditions
US11135164B2 (en)	2017-01-13	2021-10-05	Academia Sinica	Reloadable hydrogel system comprising an anti-PEG antibody for treating myocardial infarction
ES2994374T3 (en)	2017-01-18	2025-01-23	Visterra Inc	Antibody molecule-drug conjugates and uses thereof
JP2020506916A (ja)	2017-01-30	2020-03-05	ヤンセンバイオテツク，インコーポレーテツド	活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
US10240205B2 (en)	2017-02-03	2019-03-26	Population Bio, Inc.	Methods for assessing risk of developing a viral disease using a genetic test
EP3579871A4 (de)	2017-02-07	2021-07-21	Janssen Biotech, Inc.	Anti-tnf-antikörper, zusammensetzungen und verfahren zur behandlung von aktivem morbus bechterew
EP3580237B1 (de)	2017-02-08	2025-05-14	Novartis AG	Fgf21-mimetische antikörper und deren verwendungen
WO2018151820A1 (en)	2017-02-16	2018-08-23	Elstar Therapeutics, Inc.	Multifunctional molecules comprising a trimeric ligand and uses thereof
EA201991720A1 (ru)	2017-02-17	2020-01-20	Бристол-Маерс Сквибб Компани	Антитела к альфа-синуклеину и их применения
WO2018152496A1 (en)	2017-02-17	2018-08-23	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Compositions and methods for the diagnosis and treatment of zika virus infection
ES2975416T3 (es)	2017-02-27	2024-07-05	Regeneron Pharma	Modelo humanizado de trastornos renales y hepáticos
CN110382529B (zh)	2017-03-02	2024-03-08	诺华股份有限公司	工程化的异源二聚体蛋白质
KR20190124753A (ko)	2017-03-03	2019-11-05	리나트 뉴로사이언스 코프.	항-gitr 항체 및 이의 사용 방법
EP3589319A4 (de)	2017-03-03	2021-07-14	Seagen Inc.	Glycaninteragierende verbindungen und verfahren zur verwendung
EP3592381A1 (de)	2017-03-09	2020-01-15	President and Fellows of Harvard College	Krebsimpfstoff
US11898179B2 (en)	2017-03-09	2024-02-13	President And Fellows Of Harvard College	Suppression of pain by gene editing
WO2018165629A1 (en)	2017-03-10	2018-09-13	President And Fellows Of Harvard College	Cytosine to guanine base editor
IL269203B2 (en)	2017-03-13	2024-09-01	Poseida Therapeutics Inc	Compositions and methods for selective elimination and replacement of hematopoietic stem cells
WO2018176009A1 (en)	2017-03-23	2018-09-27	President And Fellows Of Harvard College	Nucleobase editors comprising nucleic acid programmable dna binding proteins
CA3261113A1 (en)	2017-03-23	2025-10-27	Abbott Laboratories	Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2018176019A1 (en)	2017-03-24	2018-09-27	The Regents Of The University Of California	Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
SI3600415T1 (sl)	2017-03-24	2026-01-30	Novartis Ag	Protitelo proti aktivinskemu receptorju tipa ii za uporabo pri zdravljenju srčnega popuščanja
KR20230148855A (ko)	2017-03-30	2023-10-25	더 존스 홉킨스 유니버시티	생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템
KR20200020662A (ko)	2017-04-03	2020-02-26	온콜로지, 인크.	면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
TWI788340B (zh)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	抗icos促效劑抗體及其用途
US20230192839A1 (en)	2017-04-12	2023-06-22	Pfizer Inc.	Antibodies having conditional affinity and methods of use thereof
JP7297672B2 (ja)	2017-04-13	2023-06-26	アジェナスインコーポレイテッド	抗ｃｄ１３７抗体およびその使用方法
AU2018250695A1 (en)	2017-04-14	2019-11-07	Kodiak Sciences Inc.	Complement factor D antagonist antibodies and conjugates thereof
CN110546513A (zh)	2017-04-15	2019-12-06	雅培实验室	使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
JP2020517256A (ja)	2017-04-19	2020-06-18	エルスターセラピューティクス，インコーポレイテッド	多重特異性分子およびその使用
JOP20190248A1 (ar)	2017-04-21	2019-10-20	Amgen Inc	بروتينات ربط مولد ضد trem2 واستخداماته
CA3059615A1 (en)	2017-04-21	2018-10-25	Genentech, Inc.	Use of klk5 antagonists for treatment of a disease
CA3059133A1 (en)	2017-04-21	2018-10-25	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
EP3615570A4 (de)	2017-04-25	2021-02-24	LBL Biotechnology Inc.	Verwendung von il-20-antagonisten zur behandlung von augenerkrankungen
EP4230649A3 (de)	2017-04-25	2023-10-25	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Antikörper und verfahren zur diagnose und behandlung von epstein barr-virusinfektion
ES3053676T3 (en)	2017-04-28	2026-01-23	Abbott Lab	Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
EP4328241A3 (de)	2017-04-28	2024-06-05	Marengo Therapeutics, Inc.	Multispezifische moleküle mit einer nichtimmunglobulin-heterodimerisierungsdomäne und verwendungen davon
RS64576B1 (sr)	2017-05-01	2023-10-31	Agenus Inc	Anti-tigit antitela i postupci njihove primene
KR102784294B1 (ko)	2017-05-02	2025-03-19	프로테나 바이오사이언시즈 리미티드	타우 인식 항체
US10865238B1 (en)	2017-05-05	2020-12-15	Duke University	Complement factor H antibodies
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
WO2018209320A1 (en)	2017-05-12	2018-11-15	President And Fellows Of Harvard College	Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
EP3630830A1 (de)	2017-05-23	2020-04-08	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Neuer cd73-antikörper, herstellung und verwendungen davon
AU2018272054B2 (en)	2017-05-25	2024-10-31	Abbott Laboratories	Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
KR102344616B1 (ko)	2017-05-30	2021-12-31	더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마	항-더블코르틴-유사 키나제 1 항체 및 사용 방법
JP7269182B2 (ja)	2017-05-30	2023-05-08	アボット・ラボラトリーズ	心臓トロポニンｉ及び早期バイオマーカーを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
KR20250036941A (ko)	2017-05-31	2025-03-14	주식회사 에스티큐브앤컴퍼니	Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
WO2018222685A1 (en)	2017-05-31	2018-12-06	Stcube & Co., Inc.	Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
WO2018222901A1 (en)	2017-05-31	2018-12-06	Elstar Therapeutics, Inc.	Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
PE20242042A1 (es)	2017-06-02	2024-10-10	Pfizer	Anticuerpos especificos para flt3 y sus usos
AU2018281045A1 (en)	2017-06-05	2019-12-12	Janssen Biotech, Inc.	Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
EP3635007A1 (de)	2017-06-06	2020-04-15	STCube & Co., Inc.	Verfahren zur behandlung von krebs unter verwendung von antikörpern und molekülen, die an btn1a1 oder btn1a1-liganden binden
AU2018281830B2 (en)	2017-06-09	2023-11-02	Agonox, Inc.	Utilization of CD39 and CD103 for identification of human tumor reactive cells for treatment of cancer
GB201709379D0 (en)	2017-06-13	2017-07-26	Univ Leuven Kath	Humanised ADAMTS13 binding antibodies
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018236904A1 (en)	2017-06-19	2018-12-27	Surface Oncology, Inc.	COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
WO2018237173A1 (en)	2017-06-22	2018-12-27	Novartis Ag	ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
EP3641752A4 (de)	2017-06-22	2021-03-17	Moonshot Pharma LLC	Verfahren zur behandlung von krebs mit zusammensetzungen mit amlexanox und immunmodulatoren
WO2019005817A2 (en)	2017-06-26	2019-01-03	Bio-Techne Corporation	HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME
JP7076059B2 (ja)	2017-06-27	2022-05-27	ニューラクルサイエンスカンパニーリミテッド	抗ｆａｍ１９ａ５抗体及びその用途
US20200223924A1 (en)	2017-06-27	2020-07-16	Novartis Ag	Dosage regimens for anti-tim-3 antibodies and uses thereof
EP3645564A1 (de)	2017-06-28	2020-05-06	Novartis AG	Verfahren zur prävention und behandlung von harninkontinenz
CA3068041C (en)	2017-07-03	2024-06-25	Abbott Laboratories	Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
WO2019010164A1 (en)	2017-07-06	2019-01-10	President And Fellows Of Harvard College	Evolution of trna synthetases
EP3652209A2 (de)	2017-07-11	2020-05-20	Compass Therapeutics LLC	Agonistische antikörper zur bindung von humanem cd137 und verwendungen davon
AU2018300189B2 (en)	2017-07-14	2025-05-15	Pfizer, Inc.	Antibodies to MAdCAM
US12286469B2 (en)	2017-07-18	2025-04-29	The University Of British Columbia	Humanized antibodies binding to amyloid-beta (A-beta)
CA3070085A1 (en)	2017-07-18	2019-01-24	The University Of British Columbia	Antibodies to amyloid beta
WO2019018629A1 (en)	2017-07-19	2019-01-24	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
EP3431496A1 (de)	2017-07-19	2019-01-23	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
KR20200031659A (ko)	2017-07-20	2020-03-24	노파르티스 아게	항-lag-3 항체의 투여 요법 및 그의 용도
WO2019016784A1 (en)	2017-07-21	2019-01-24	Universidade De Coimbra	ANTI-NUCLEOLIN ANTIBODIES
CN111801345A (zh)	2017-07-28	2020-10-20	哈佛大学的校长及成员们	使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US12358992B2 (en)	2017-07-28	2025-07-15	Scholar Rock, Inc.	LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11485781B2 (en)	2017-08-17	2022-11-01	Massachusetts Institute Of Technology	Multiple specificity binders of CXC chemokines
WO2019036631A1 (en)	2017-08-18	2019-02-21	The Johns Hopkins University	SUPRAMOLECULAR FILAMENT ASSEMBLIES FOR THE PURIFICATION OF PROTEINS
KR102804751B1 (ko)	2017-08-23	2025-05-13	막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트	Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포
TWI817952B (zh)	2017-08-25	2023-10-11	美商戊瑞治療有限公司	Ｂ７－ｈ４抗體及其使用方法
WO2019040935A1 (en)	2017-08-25	2019-02-28	President And Fellows Of Harvard College	EVOLUTION OF PEPTIDASES BONT
CA3074128A1 (en)	2017-08-28	2019-03-07	Shanghai Yile Biotechnology Co., Ltd.	Polypeptide and antibody bound to polypeptide
EP3676376B1 (de)	2017-08-30	2025-01-15	President and Fellows of Harvard College	Hocheffiziente baseneditoren mit gam
US12385061B2 (en)	2017-09-08	2025-08-12	Poseida Therapeutics, Inc.	Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
WO2019056002A1 (en)	2017-09-18	2019-03-21	President And Fellows Of Harvard College	CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
WO2019056199A1 (zh)	2017-09-20	2019-03-28	丰宥科技股份有限公司	卵巢癌生物标记及其应用
USD859683S1 (en)	2017-09-21	2019-09-10	Becton, Dickinson And Company	Collection device
AU2018337030B2 (en)	2017-09-21	2025-04-10	Becton, Dickinson And Company	Hazardous contaminant collection kit and rapid testing
US11002642B2 (en)	2017-09-21	2021-05-11	Becton, Dickinson And Company	Demarcation template for hazardous contaminant testing
CA3075775A1 (en)	2017-09-21	2019-03-28	Becton, Dickinson And Company	High dynamic range assays in hazardous contaminant testing
CA3076691A1 (en)	2017-09-25	2019-03-28	Adrenomed Ag	Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
TW201922780A (zh)	2017-09-25	2019-06-16	美商健生生物科技公司	以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11761963B2 (en)	2017-09-27	2023-09-19	Alexion Pharmaceuticals, Inc.	Biomarker signature for predicting tumor response to anti-CD200 therapy
MY205689A (en)	2017-10-02	2024-11-06	Visterra Inc	Antibody molecules to cd138 and uses thereof
ES2759622T3 (es)	2017-10-02	2020-05-11	Certest Biotec S L	Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
EP3692370A2 (de)	2017-10-04	2020-08-12	OPKO Pharmaceuticals, LLC	Artikel und verfahren zur personalisierten krebstherapie
PE20210042A1 (es)	2017-10-06	2021-01-08	Prothena Biosciences Ltd	Metodos para detectar transtiretina
WO2019070047A1 (ja)	2017-10-06	2019-04-11	小野薬品工業株式会社	二重特異性抗体
CN111630069B (zh)	2017-10-13	2024-05-31	勃林格殷格翰国际有限公司	针对Thomsen-nouvelle(Tn)抗原的人抗体
US11795443B2 (en)	2017-10-16	2023-10-24	The Broad Institute, Inc.	Uses of adenosine base editors
MX2020004072A (es)	2017-10-18	2020-07-28	Adrenomed Ag	Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm).
MX2020004074A (es)	2017-10-19	2020-10-16	Debiopharm Int Sa	Producto de combinacion para el tratamiento de cancer.
EP3697809A1 (de)	2017-10-20	2020-08-26	Institut Curie	Für rush angepasste dap10/12-basierte cars
EP3700937A2 (de)	2017-10-25	2020-09-02	4TEEN4 Pharmaceuticals GmbH	Dpp3-bindemittel gegen und zur bindung an spezifische dpp3-epitope und dessen verwendung in der prävention oder behandlung von krankheiten/akuten leiden, die im zusammenhang mit oxidativem stress stehen
WO2019081983A1 (en)	2017-10-25	2019-05-02	Novartis Ag	CD32B TARGETING ANTIBODIES AND METHODS OF USE
SG11202003652QA (en)	2017-10-27	2020-05-28	Univ New York	Anti-galectin-9 antibodies and uses thereof
US11718679B2 (en)	2017-10-31	2023-08-08	Compass Therapeutics Llc	CD137 antibodies and PD-1 antagonists and uses thereof
CA3080103A1 (en)	2017-10-31	2019-05-09	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
CN111565751A (zh)	2017-10-31	2020-08-21	詹森生物科技公司	治疗高危多发性骨髓瘤的方法
US20190160089A1 (en)	2017-10-31	2019-05-30	Immunogen, Inc.	Combination treatment with antibody-drug conjugates and cytarabine
JP7433224B2 (ja)	2017-11-02	2024-02-19	バイエル・アクチエンゲゼルシヤフト	Ａｌｋ－１およびｂｍｐｒ－２に結合する二重特異性抗体
US20190135910A1 (en)	2017-11-06	2019-05-09	Janssen Biotech, Inc.	Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
US11591385B2 (en)	2017-11-09	2023-02-28	Pinteon Therapeutics Inc.	Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
CN111655288A (zh)	2017-11-16	2020-09-11	诺华股份有限公司	组合疗法
EP3713961A2 (de)	2017-11-20	2020-09-30	Compass Therapeutics LLC	Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
CN111727075B (zh)	2017-11-27	2024-04-05	普渡制药公司	靶向人组织因子的人源化抗体
CN119857155A (zh)	2017-11-29	2025-04-22	海德堡医药研究有限责任公司	用于耗尽cd5+细胞的组合物和方法
EP3720881A1 (de)	2017-12-08	2020-10-14	Elstar Therapeutics, Inc.	Multispezifische moleküle und verwendungen davon
US11022617B2 (en)	2017-12-09	2021-06-01	Abbott Laboratories	Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
EP3721234A1 (de)	2017-12-09	2020-10-14	Abbott Laboratories	Verfahren zur unterstützung bei der diagnose und bewertung einer traumatischen hirnverletzung beim menschen mit einer kombination aus gfap und uch-l1
JP2021505637A (ja)	2017-12-12	2021-02-18	マクロジェニクス，インコーポレーテッド	二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
WO2019118949A1 (en)	2017-12-15	2019-06-20	The Broad Institute, Inc.	Systems and methods for predicting repair outcomes in genetic engineering
WO2019126133A1 (en)	2017-12-20	2019-06-27	Alexion Pharmaceuticals, Inc.	Liquid formulations of anti-cd200 antibodies
CA3086187A1 (en)	2017-12-20	2019-06-27	Poseida Therapeutics, Inc.	Vcar compositions and methods for use
WO2019126536A1 (en)	2017-12-20	2019-06-27	Alexion Pharmaceuticals Inc.	Humanized anti-cd200 antibodies and uses thereof
WO2019126472A1 (en)	2017-12-22	2019-06-27	Genentech, Inc.	Use of pilra binding agents for treatment of a disease
WO2019139987A1 (en)	2018-01-09	2019-07-18	Elstar Therapeutics, Inc.	Calreticulin binding constructs and engineered t cells for the treatment of diseases
JP7358361B2 (ja)	2018-01-12	2023-10-10	ブリストル－マイヤーズスクイブカンパニー	Ｔｉｍ３に対する抗体およびその使用
WO2019140216A1 (en)	2018-01-12	2019-07-18	Amgen Inc.	Pac1 antibodies and uses thereof
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
TWI878213B (zh)	2018-02-01	2025-04-01	美商輝瑞大藥廠	對cd70具特異性抗體及其用途
TW201936633A (zh)	2018-02-01	2019-09-16	美商輝瑞大藥廠	標靶至cd70的嵌合抗原受體
EP3746477A1 (de)	2018-02-02	2020-12-09	Bio-Techne Corporation	Verbindungen, die die wechselwirkung von vista und vsig3 modulieren, und verfahren zur herstellung und verwendung
WO2019150309A1 (en)	2018-02-02	2019-08-08	Hammack Scott	Modulators of gpr68 and uses thereof for treating and preventing diseases
JP2021513077A (ja)	2018-02-08	2021-05-20	シュピーンゴテックゲゼルシャフトミットベシュレンクテルハフツング	認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー
TWI890481B (zh)	2018-02-09	2025-07-11	日商小野藥品工業股份有限公司	雙特異性抗體
GB201802486D0 (en)	2018-02-15	2018-04-04	Ucb Biopharma Sprl	Methods
SG11202007572VA (en)	2018-02-15	2020-09-29	Macrogenics Inc	Variant cd3-binding domains and their use in combination therapies for the treatment of disease
BR112020016986A2 (pt)	2018-02-21	2021-03-02	Five Prime Therapeutics, Inc.	formulações de anticorpo contra b7-h4
CA3090305A1 (en)	2018-02-28	2019-09-06	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
US12071476B2 (en)	2018-03-02	2024-08-27	Kodiak Sciences Inc.	IL-6 antibodies and fusion constructs and conjugates thereof
CA3091801A1 (en)	2018-03-02	2019-09-06	Five Prime Therapeutics, Inc.	B7-h4 antibodies and methods of use thereof
ES3064335T3 (en)	2018-03-05	2026-04-24	Janssen Biotech Inc	Methods of treating crohn's disease with anti-il23 specific antibody
MX2020009526A (es)	2018-03-12	2020-10-28	Zoetis Services Llc	Anticuerpos anti-ngf y metodos de estos.
EP3765516A2 (de)	2018-03-14	2021-01-20	Elstar Therapeutics, Inc.	Multifunktionale moleküle und verwendungen davon
US10738128B2 (en)	2018-03-14	2020-08-11	Surface Oncology, Inc.	Antibodies that bind CD39 and uses thereof
CA3093838A1 (en)	2018-03-14	2019-09-19	Memorial Sloan Kettering Cancer Center	Anti-polysialic acid antibodies and uses thereof
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
EP3768317A4 (de)	2018-03-22	2021-12-22	Surface Oncology, Inc.	Anti-il-27-antikörper und verwendungen davon
CA3093407A1 (en)	2018-03-23	2019-09-26	Bristol-Myers Squibb Company	Antibodies against mica and/or micb and uses thereof
WO2019180272A1 (en)	2018-03-23	2019-09-26	Fundación Instituto De Investigación Sanitaria De Santiago De Compostela	Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
WO2019190877A1 (en)	2018-03-26	2019-10-03	Alexion Pharmaceuticals, Inc.	High throughput method for measuring the protease activity of complement c3 convertase
EP4253958A3 (de)	2018-03-26	2023-12-06	Glycanostics s.r.o.	Mittel und verfahren zur glykoprofilierung eines proteins
WO2019191416A1 (en)	2018-03-29	2019-10-03	Bristol-Myers Squibb Company	Methods of purifying monomeric monoclonal antibodies
AU2019248547B2 (en)	2018-04-02	2025-07-17	Bristol-Myers Squibb Company	Anti-TREM-1 antibodies and uses thereof
US12103972B2 (en)	2018-04-06	2024-10-01	Dana-Farber Cancer Institute, Inc.	KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
WO2019200357A1 (en)	2018-04-12	2019-10-17	Surface Oncology, Inc.	Biomarker for cd47 targeting therapeutics and uses therefor
US20210147547A1 (en)	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3781590A1 (de)	2018-04-20	2021-02-24	Medizinische Hochschule Hannover	Chimärer antigenrezeptor und car-t zellen, die ein herpesvirus-antigen binden
WO2019207159A1 (en)	2018-04-27	2019-10-31	Fondazione Ebri Rita Levi-Montalcini	Antibody directed against a tau-derived neurotoxic peptide and uses thereof
KR20240056644A (ko)	2018-05-10	2024-04-30	주식회사 뉴라클사이언스	서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
JP2021523138A (ja)	2018-05-11	2021-09-02	ヤンセンバイオテツク，インコーポレーテツド	Ｉｌ−２３抗体を使用してうつを治療する方法
TW202003048A (zh)	2018-05-15	2020-01-16	美商伊繆諾金公司	用抗體-藥物偶聯物及flt3抑制劑之組合治療
SG11202011306TA (en)	2018-05-16	2020-12-30	Janssen Biotech Inc	Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
EP3569614A1 (de)	2018-05-18	2019-11-20	Julius-Maximilians-Universität Würzburg	Verbindungen und verfahren zur immobilisierung von myostatin-inhibitoren auf der extrazellulären matrix durch transglutaminase
EP3569618A1 (de)	2018-05-19	2019-11-20	Boehringer Ingelheim International GmbH	Antagonisierender cd73-antikörper
WO2019226617A1 (en)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226658A1 (en)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Multispecific antigen-binding compositions and methods of use
BR112020022595A2 (pt)	2018-05-23	2021-02-09	Pfizer Inc.	anticorpos específicos para gucy2c e usos dos mesmos
US12157760B2 (en)	2018-05-23	2024-12-03	The Broad Institute, Inc.	Base editors and uses thereof
DK3797121T3 (da)	2018-05-23	2024-07-08	Pfizer	Antistoffer, der er specifikke for CD3, og anvendelser deraf
MA52777A (fr)	2018-05-24	2021-04-14	Janssen Biotech Inc	Agents de liaison psma et utilisations correspondantes
CN112912397B (zh)	2018-05-24	2025-03-14	詹森生物科技公司	抗cd3抗体及其用途
CR20200564A (es)	2018-05-24	2021-06-21	Janssen Biotech Inc	Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
UY38247A (es)	2018-05-30	2019-12-31	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019241649A1 (en)	2018-06-14	2019-12-19	President And Fellows Of Harvard College	Evolution of cytidine deaminases
SG11202012312UA (en)	2018-06-18	2021-01-28	UCB Biopharma SRL	Gremlin-1 antagonist for the prevention and treatment of cancer
KR20210035173A (ko)	2018-06-19	2021-03-31	아타르가, 엘엘씨	보체 성분 5에 대한 항체분자 및 이의 용도
TW202016144A (zh)	2018-06-21	2020-05-01	日商第一三共股份有限公司	包括cd3抗原結合片段之組成物及其用途
EP3586865A1 (de)	2018-06-21	2020-01-01	Charité - Universitätsmedizin Berlin	Ergänzende anaphylatoxinbindemittel und deren verwendung in der behandlung einer person mit okularer wunde und/oder fibrose
US12006357B2 (en)	2018-06-26	2024-06-11	Mor Research Applications Ltd.	Transthyretin antibodies and uses thereof
MX2020013466A (es)	2018-06-26	2021-04-19	Immunogen Inc	Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
US11203645B2 (en)	2018-06-27	2021-12-21	Obi Pharma, Inc.	Glycosynthase variants for glycoprotein engineering and methods of use
WO2020010250A2 (en)	2018-07-03	2020-01-09	Elstar Therapeutics, Inc.	Anti-tcr antibody molecules and uses thereof
WO2020008083A1 (es)	2018-07-05	2020-01-09	Consejo Superior De Investigaciones Científicas	Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
EP3820495A4 (de)	2018-07-09	2022-07-20	The Broad Institute Inc.	Rna-programmierbare epigenetische rna-modifikatoren und deren verwendungen
HRP20212034T1 (hr)	2018-07-11	2022-04-01	Scholar Rock, Inc.	Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe
US20210340238A1 (en)	2018-07-11	2021-11-04	Scholar Rock, Inc.	TGFß1 INHIBITORS AND USE THEREOF
US12252531B2 (en)	2018-07-11	2025-03-18	Scholar Rock, Inc.	Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors
JP7634474B2 (ja)	2018-07-18	2025-02-21	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
CA3106833A1 (en)	2018-07-20	2020-01-23	Aicuris Gmbh & Co. Kg	Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
IL280199B2 (en)	2018-07-20	2025-08-01	Pf Medicament	Receptor for vista
AU2019312200B2 (en)	2018-07-23	2024-11-14	Heidelberg Pharma Research Gmbh	Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
CN112739340B (zh)	2018-07-23	2025-05-13	海德堡医药研究有限责任公司	抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
JP2021531306A (ja)	2018-07-25	2021-11-18	アドバンスドアクセラレーターアプリケーションズエスエー	神経内分泌腫瘍の処置の方法
US20220193250A1 (en)	2018-08-02	2022-06-23	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
FI3625368T3 (fi)	2018-08-08	2023-01-13		Menetelmiä john cunningham -viruksen aiheuttaman progressiivin multifokaalin leukoenkefalopatian kehittymisen riskin arviointiin geneettisellä testauksella
WO2020033926A2 (en)	2018-08-09	2020-02-13	Compass Therapeutics Llc	Antibodies that bind cd277 and uses thereof
US20210388089A1 (en)	2018-08-09	2021-12-16	Compass Therapeutics Llc	Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en)	2018-08-09	2020-02-13	Compass Therapeutics Llc	Antibodies that bind cd277 and uses thereof
WO2020037215A1 (en)	2018-08-17	2020-02-20	Icahn School Of Medicine At Mount Sinai	Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
WO2020041360A1 (en)	2018-08-21	2020-02-27	Quidel Corporation	Dbpa antibodies and uses thereof
WO2020047164A1 (en)	2018-08-28	2020-03-05	Vor Biopharma, Inc	Genetically engineered hematopoietic stem cells and uses thereof
US20200109214A1 (en)	2018-08-30	2020-04-09	Dyax Corp.	Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CA3153959A1 (en)	2018-09-18	2020-03-26	Merrimack Pharmaceuticals, Inc.	Anti-tnfr2 antibodies and uses thereof
FI3852617T3 (fi)	2018-09-20	2025-10-21	Sfj Pharma X Inc	Vasta-ainefragmenttien käyttö tikagrelorin aktiivisuuden kääntämiseen
PL3883606T3 (pl)	2018-09-24	2023-11-27	Janssen Biotech, Inc.	Bezpieczny i skuteczny sposób leczenia wrzodziejącego zapalenia jelita grubego przeciwciałami anty-il12/il23
CN113164777B (zh)	2018-09-27	2024-12-13	马伦戈治疗公司	Csf1r/ccr2多特异性抗体
CA3114567A1 (en)	2018-09-28	2020-04-02	Lyvgen Biopharma Co., Ltd.	Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
EP3856773A1 (de)	2018-09-28	2021-08-04	Kyowa Kirin Co., Ltd.	Il-36-antikörper und verwendungen davon
AU2019352017A1 (en)	2018-10-03	2021-05-06	Staten Biotechnology B.V.	Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
EP3860641A1 (de)	2018-10-05	2021-08-11	Bavarian Nordic A/S	Kombinationstherapie zur behandlung von krebs mit einer intravenösen verabreichung eines rekombinanten mva und eines immunkontrollpunktantagonisten oder -agonisten
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
CN112805301B (zh)	2018-10-15	2023-07-21	安立玺荣生医(香港)有限公司	粒细胞-巨噬细胞集落刺激因子的抗体及其用途
BR112021007227A2 (pt)	2018-10-17	2021-08-10	Janssen Biotech, Inc.	método para fornecer administração subcutânea de anticorpos anti-cd38
JP7439076B2 (ja)	2018-10-23	2024-02-27	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	抗ｎｐｒ１抗体およびその使用
BR112021007765A2 (pt)	2018-10-23	2021-08-03	Scholar Rock, Inc.	inibidores seletivos de rgmc e uso dos mesmos
GB201817309D0 (en)	2018-10-24	2018-12-05	Ucb Biopharma Sprl	Antibodies
GB201817311D0 (en)	2018-10-24	2018-12-05	Ucb Biopharma Sprl	Antibodies
WO2020086408A1 (en)	2018-10-26	2020-04-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	A high-yield perfusion-based transient gene expression bioprocess
WO2020092453A1 (en)	2018-10-29	2020-05-07	The Broad Institute, Inc.	Nucleobase editors comprising geocas9 and uses thereof
CA3116412A1 (en)	2018-10-31	2020-05-07	Humanigen, Inc.	Materials and methods for treating cancer
WO2020092839A1 (en)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
EP3873540A4 (de)	2018-10-31	2022-07-27	Mayo Foundation for Medical Education and Research	Verfahren und materialien zur behandlung von krebs
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
BR112021009111A2 (pt)	2018-11-16	2021-08-24	Bristol-Myers Squibb Company	Anticorpos anti-nkg2a e usos dos mesmos
US12227548B2 (en)	2018-11-19	2025-02-18	Dana-Farber Cancer Institute, Inc.	Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
CN113056284A (zh)	2018-11-20	2021-06-29	巴法里安诺迪克有限公司	通过肿瘤内和/或静脉内施用编码4-1bbl(cd137l)和/或cd40l的重组mva治疗癌症的疗法
MX2021005905A (es)	2018-11-20	2021-06-23	Janssen Biotech Inc	Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
CA3120570A1 (en)	2018-11-28	2020-06-04	Forty Seven, Inc.	Genetically modified hspcs resistant to ablation regime
WO2020118011A1 (en)	2018-12-06	2020-06-11	Alexion Pharmaceuticals, Inc.	Anti-alk2 antibodies and uses thereof
SG11202105161YA (en)	2018-12-13	2021-06-29	Surface Oncology Inc	Anti-il-27 antibodies and uses thereof
JP2022514561A (ja)	2018-12-18	2022-02-14	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
JP2022514280A (ja)	2018-12-20	2022-02-10	ノバルティスアーゲー	Ｍｄｍ２阻害剤のための延長低用量レジメン
CN113498439A (zh)	2018-12-20	2021-10-12	波赛达治疗公司	纳米转座子组合物及使用方法
EP3898687A1 (de)	2018-12-20	2021-10-27	Kyowa Kirin Co., Ltd.	Fn14-antikörper und verwendungen davon
EP3898698B1 (de)	2018-12-21	2026-04-01	Multitude Therapeutics Co., Ltd.	Chimärer antigenrezeptor, spezifisch für muc18
US20220211798A1 (en)	2018-12-21	2022-07-07	4TEEN4 Pharmaceuticals GmbH	Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
CN113195533B (zh)	2019-01-02	2024-04-26	纽洛可科学有限公司	抗序列相似家族19成员a5的抗体及其使用方法
TWI852977B (zh)	2019-01-10	2024-08-21	美商健生生物科技公司	前列腺新抗原及其用途
WO2020150214A1 (en)	2019-01-14	2020-07-23	University Of Virginia Patent Foundation	Use of integrin inhibitors for treatment or prevention of a neurological immunity disorder and/or nervous system injury
JP7689074B2 (ja)	2019-01-15	2025-06-05	ヤンセンバイオテツク，インコーポレーテツド	若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
JP7539897B2 (ja)	2019-01-16	2024-08-26	コンパスセラピューティクスリミテッドライアビリティカンパニー	ヒトｃｄ１３７に結合する抗体の製剤およびその使用
GB201900732D0 (en)	2019-01-18	2019-03-06	Ucb Biopharma Sprl	Antibodies
EP3914622A1 (de)	2019-01-22	2021-12-01	Bristol-Myers Squibb Company	Antikörper gegen il-7r-alpha-untereinheit und deren verwendungen
CN114144190B (zh)	2019-01-23	2025-08-08	纽约大学	对T细胞受体的δ1链具有特异性的抗体
US12351837B2 (en)	2019-01-23	2025-07-08	The Broad Institute, Inc.	Supernegatively charged proteins and uses thereof
AU2020215639B2 (en)	2019-01-28	2025-08-21	Becton, Dickinson And Company	Hazardous contaminant collection device with integrated swab and test device
PH12021551860A1 (en)	2019-01-30	2022-05-16	Scholar Rock Inc	Ltbp complex-specific inhibitors of tgfã and uses thereof
US11738050B2 (en)	2019-02-01	2023-08-29	Regents Of The University Of Minnesota	Compounds binding to fibroblast activation protein alpha
EP3693063A1 (de)	2019-02-06	2020-08-12	Diaccurate	Verfahren und zusammensetzungen zur behandlung von krebs
EP3696191A1 (de)	2019-02-14	2020-08-19	Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC)	Car-t-zellen zur behandlung von cd1a-positivem krebs
US10871640B2 (en)	2019-02-15	2020-12-22	Perkinelmer Cellular Technologies Germany Gmbh	Methods and systems for automated imaging of three-dimensional objects
GB2597851B (en)	2019-02-21	2024-05-29	Marengo Therapeutics Inc	Antibody molecules that bind to NKP30 and uses thereof
JP7706373B2 (ja)	2019-02-21	2025-07-11	マレンゴ・セラピューティクス，インコーポレーテッド	カルレティキュリンに結合する多機能性分子およびその使用
EP3927745A1 (de)	2019-02-21	2021-12-29	Marengo Therapeutics, Inc.	Multifunktionsmoleküle, die an t-zellen binden, und deren verwendung zur behandlung von autoimmunerkrankungen
AU2020226893B2 (en)	2019-02-21	2025-02-27	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2020226904B2 (en)	2019-02-21	2025-05-01	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
ES2978570T3 (es)	2019-02-26	2024-09-16	Inspirna Inc	Anticuerpos anti-MERTK de alta afinidad y sus usos
CA3131953A1 (en)	2019-03-01	2020-09-10	Merrimack Pharmaceuticals, Inc.	Anti-tnfr2 antibodies and uses thereof
CN119371527A (zh)	2019-03-03	2025-01-28	普罗塞纳生物科学有限公司	识别tau的抗体
KR20210152472A (ko)	2019-03-11	2021-12-15	메모리얼 슬로안 케터링 캔서 센터	Cd22 항체 및 이를 사용하는 방법
WO2020183269A1 (en)	2019-03-14	2020-09-17	Janssen Biotech, Inc.	Manufacturing methods for producing anti-tnf antibody compositions
JP7635137B2 (ja)	2019-03-14	2025-02-25	ヤンセンバイオテツク，インコーポレーテツド	抗ｔｎｆ抗体組成物を産生するための方法
CN113840837A (zh)	2019-03-14	2021-12-24	詹森生物科技公司	用于产生抗tnf抗体组合物的方法
WO2020183418A1 (en)	2019-03-14	2020-09-17	Janssen Biotech, Inc.	Manufacturing methods for producing anti-il12/il23 antibody compositions
AU2020243588C1 (en)	2019-03-18	2026-04-02	Janssen Biotech, Inc.	Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody
EP3942043A2 (de)	2019-03-19	2022-01-26	The Broad Institute, Inc.	Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
AU2020247119A1 (en)	2019-03-25	2021-09-23	Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft	Enhancement of cytolytic T-cell activity by inhibiting EBAG9
EP3947454A1 (de)	2019-03-27	2022-02-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Rekombinante proteine mit cd40-aktivierenden eigenschaften
US20220169706A1 (en)	2019-03-28	2022-06-02	Danisco Us Inc	Engineered antibodies
JP7570344B2 (ja)	2019-03-29	2024-10-21	ブリストル－マイヤーズスクイブカンパニー	クロマトグラフィー樹脂の疎水性を測定する方法
JP2022527790A (ja)	2019-03-29	2022-06-06	アターガ，エルエルシー	抗ｆｇｆ２３抗体分子
TWI862565B (zh)	2019-04-04	2024-11-21	日商小野藥品工業股份有限公司	雙特異性抗體
AU2020258384B2 (en)	2019-04-15	2026-05-14	Qwixel Therapeutics Llc	Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
WO2020214842A1 (en)	2019-04-17	2020-10-22	The Broad Institute, Inc.	Adenine base editors with reduced off-target effects
WO2020215037A1 (en)	2019-04-18	2020-10-22	The Regents Of The University Of Michigan	Combination with checkpoint inhibitors to treat cancer
AR118720A1 (es)	2019-04-19	2021-10-27	Janssen Biotech Inc	Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
US20220289854A1 (en)	2019-04-30	2022-09-15	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
KR20220005568A (ko)	2019-05-09	2022-01-13	제넨테크, 인크.	항체의 제조 방법
US11780911B2 (en)	2019-05-23	2023-10-10	Janssen Biotech, Inc.	Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
SG11202112926YA (en)	2019-05-30	2021-12-30	Amgen Inc	Engineering the hinge region to drive antibody dimerization
KR20220030952A (ko)	2019-06-03	2022-03-11	얀센 바이오테크 인코포레이티드	활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
CA3142665A1 (en)	2019-06-03	2020-12-10	Janssen Biotech, Inc.	Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
JP2022536088A (ja)	2019-06-04	2022-08-12	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
US12594330B2 (en)	2019-06-04	2026-04-07	Regents Of The University Of Minnesota	Anti-opioid compounds and methods of making and using same
US12558398B2 (en)	2019-06-04	2026-02-24	Ucb Holdings, Inc.	Inflammatory disease treatment with complement inhibitors
CN113966345B (zh)	2019-06-12	2024-12-13	诺华股份有限公司	利钠肽受体1抗体及使用方法
CA3142021A1 (en)	2019-06-17	2020-12-24	Visterra, Inc.	Humanized antibody molecules to cd138 and uses thereof
GB201909135D0 (en)	2019-06-25	2019-08-07	Institute Of Cancer Res Royal Cancer Hospital	Means and methods for treating cancer
US20220363770A1 (en)	2019-06-28	2022-11-17	Amgen Inc.	Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
KR20220030956A (ko)	2019-07-05	2022-03-11	오노 야꾸힝 고교 가부시키가이샤	Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
EP4004044A1 (de)	2019-07-24	2022-06-01	H. Lundbeck A/S	Anti-mglur5-antikörper und verwendungen davon
PH12022550165A1 (en)	2019-07-26	2023-05-08	Visterra Inc	Interleukin-2 agents and uses thereof
WO2021020416A1 (ja)	2019-07-30	2021-02-04	小野薬品工業株式会社	二重特異性抗体
PT4007777T (pt)	2019-08-02	2024-01-12	Hospital CliNic De Barcelona	Células car t contra bcma para o tratamento de mieloma múltiplo
WO2021023860A1 (en)	2019-08-07	2021-02-11	Db Biotech, As	Improved horseradish peroxidase polypeptides
TW202120550A (zh)	2019-08-08	2021-06-01	日商小野藥品工業股份有限公司	雙特異性蛋白質
MX2022001882A (es)	2019-08-12	2022-05-30	Aptevo Res & Development Llc	Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
WO2021028752A1 (en)	2019-08-15	2021-02-18	Janssen Biotech, Inc.	Anti-tfn antibodies for treating type i diabetes
WO2021042066A1 (en)	2019-08-30	2021-03-04	Foundation Medicine, Inc.	Kmt2a-maml2 fusion molecules and uses thereof
JP2022546061A (ja)	2019-08-30	2022-11-02	４ティーン４ファーマシューティカルズゲゼルシャフトミットベシュレンクテルハフツング	ショック症治療のための治療法の誘導および／または治療法の監視
KR20220053007A (ko)	2019-08-30	2022-04-28	아게누스 인코포레이티드	항-cd96 항체 및 이의 사용 방법
EP4025606A1 (de)	2019-09-04	2022-07-13	Y-Biologics Inc.	Anti-vsig4-antikörper oder antigenbindendes fragment und verwendungen davon
EP4025303A1 (de)	2019-09-04	2022-07-13	Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)	Herv-inhibitoren zur verwendung bei der behandlung von tauopathien
WO2021046261A1 (en)	2019-09-05	2021-03-11	Poseida Therapeutics, Inc.	Allogeneic cell compositions and methods of use
TW202124444A (zh)	2019-09-16	2021-07-01	美商表面腫瘤學公司	抗ｃｄ３９抗體組合物及方法
JP2022548881A (ja)	2019-09-18	2022-11-22	ノバルティスアーゲー	Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
TWI875823B (zh)	2019-09-25	2025-03-11	美商表面腫瘤學有限責任公司	抗ｉｌ-２７抗體及用途
CN114729045B (zh)	2019-09-26	2025-09-09	斯特库比公司	对糖基化的ctla-4特异性的抗体及其使用方法
TWI878355B (zh)	2019-10-02	2025-04-01	德商百靈佳殷格翰國際股份有限公司	用於癌症治療之多重專一性結合蛋白
KR20220079590A (ko)	2019-10-04	2022-06-13	티에이이 라이프 사이언시스	Fc 돌연변이 및 부위-특이적인 접합 성질을 포함하는 항체 조성물
US20240050529A1 (en)	2019-10-07	2024-02-15	University Of Virginia Patent Foundation	Modulating lymphatic vessels in neurological disease
CN114829404B (zh)	2019-10-09	2025-09-09	斯特库比公司	对糖基化的lag3特异的抗体及其使用方法
AU2020364071A1 (en)	2019-10-10	2022-05-26	Kodiak Sciences Inc.	Methods of treating an eye disorder
US12435330B2 (en)	2019-10-10	2025-10-07	The Broad Institute, Inc.	Methods and compositions for prime editing RNA
WO2021072244A1 (en)	2019-10-11	2021-04-15	Beth Israel Deaconess Medical Center, Inc.	Anti-tn antibodies and uses thereof
TW202128191A (zh)	2019-10-21	2021-08-01	瑞士商諾華公司	Tim-3抑制劑及其用途
CA3158298A1 (en)	2019-10-21	2021-04-29	Novartis Ag	Combination therapies with venetoclax and tim-3 inhibitors
US11459389B2 (en)	2019-10-24	2022-10-04	Massachusetts Institute Of Technology	Monoclonal antibodies that bind human CD161
WO2021092355A1 (en)	2019-11-08	2021-05-14	Amgen Inc.	Engineering charge pair mutations for pairing of hetero-igg molecules
CN114980920A (zh)	2019-11-18	2022-08-30	詹森生物科技公司	基于突变体calr和jak2的疫苗及其用途
CA3160438A1 (en)	2019-11-19	2021-05-27	Amgen Inc.	Novel multispecific antibody format
CN114867491B (zh)	2019-11-20	2025-08-15	巴法里安诺迪克有限公司	用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒
JP2023502712A (ja)	2019-11-21	2023-01-25	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	抗ｐｄ－１／ｉｌ－１５免疫サイトカインによる新しいｐｄ－１標的免疫療法
GB201917480D0 (en)	2019-11-29	2020-01-15	Univ Oxford Innovation Ltd	Antibodies
AU2020408213A1 (en)	2019-12-19	2022-06-23	Ortho-Clinical Diagnostics, Inc.	Monoclonal antibody fusions
GB201919062D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
AU2020407235A1 (en)	2019-12-20	2022-07-07	Poseida Therapeutics, Inc.	Anti-MUC1 compositions and methods of use
GB201919061D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibody
KR20220116257A (ko)	2019-12-20	2022-08-22	노파르티스 아게	골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
GB201919058D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibodies
TWI877278B (zh)	2019-12-30	2025-03-21	美商思進公司	以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021138407A2 (en)	2020-01-03	2021-07-08	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to cd33 and uses thereof
AU2020416273A1 (en)	2020-01-03	2022-07-28	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
TWI906906B (zh)	2020-01-06	2025-12-01	美商法西尼克斯股份有限公司	抗ccr8抗體及其用途
IL294611B1 (en)	2020-01-08	2026-05-01	Regeneron Pharmaceuticals Inc	Treatment of fibrodysplasia ossificans progressive
CA3167427A1 (en)	2020-01-11	2021-07-15	Scholar Rock, Inc.	Tgfb inhibitors and use thereof
AU2021205440A1 (en)	2020-01-11	2022-09-01	Scholar Rock,Inc.	TGF-beta inhibitors and use thereof
TWI869528B (zh)	2020-01-13	2025-01-11	美商威特拉公司	C5ar1抗體分子及其用途
CA3167336A1 (en)	2020-01-13	2021-07-22	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
US20230058489A1 (en)	2020-01-17	2023-02-23	Novartis Ag	Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
EP4093513A4 (de)	2020-01-24	2024-05-08	Dana-Farber Cancer Institute, Inc.	Verwendung von biomarkern zur verbesserung der immuntherapie
EP4093426A1 (de)	2020-01-24	2022-11-30	University of Virginia Patent Foundation	Modulation von lymphgefässen bei neurologischen erkrankungen
CN115697388A (zh)	2020-01-30	2023-02-03	优莫佳生物制药股份有限公司	双特异性转导增强子
EP4100435A1 (de)	2020-02-05	2022-12-14	Larimar Therapeutics, Inc.	Tat-peptidbindende proteine und ihre verwendungen
AU2021221277A1 (en)	2020-02-11	2022-08-25	Crispr Therapeutics Ag	Anti-idiotype antibodies targeting anti-CD19 chimeric antigen receptor
EP4103608A1 (de)	2020-02-13	2022-12-21	UCB Biopharma SRL	Bispezifische antikörper gegen cd9 und cd137
EP4103612A1 (de)	2020-02-13	2022-12-21	UCB Biopharma SRL	Bispezifische antikörper gegen cd9
EP4103610A1 (de)	2020-02-13	2022-12-21	UCB Biopharma SRL	Anti-cd4-ctla4 bispezifische antikörper
EP4103609A1 (de)	2020-02-13	2022-12-21	UCB Biopharma SRL	Bispezifische antikörper gegen cd9 und cd7
EP4103611B1 (de)	2020-02-13	2024-03-27	UCB Biopharma SRL	Bispezifische, an hvem und cd9 bindende antikörper
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
JP2023513834A (ja)	2020-02-18	2023-04-03	アレクトルエルエルシー	Ｐｉｌｒａ抗体及びその使用方法
EP3871689A1 (de)	2020-02-26	2021-09-01	sphingotec GmbH	Anti-adm-antikörper, die an den freien n-terminus binden, für einen beschleunigten übergang von adm-gly zu bio-adm bei patienten mit einem adm-gly/bio-adm-verhältnis über einem schwellenwert und kombination mit vitamin c
BR112022015215A2 (pt)	2020-02-27	2022-10-11	4TEEN4 Pharmaceuticals GmbH	Dpp3 para orientação, monitoramento e estratificação de terapia de anticorpos nt-adm em pacientes com choque
US20230104578A1 (en)	2020-02-27	2023-04-06	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
US20230250166A1 (en)	2020-02-27	2023-08-10	Adrenomed Ag	Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
JP2023516724A (ja)	2020-03-06	2023-04-20	オーエヌエーセラピューティクスエセ．エレ．	抗ｃｄ３６抗体及び癌を治療するためのそれらの使用
US11896619B2 (en)	2020-03-10	2024-02-13	Massachusetts Institute Of Technology	Compositions and methods for immunotherapy of NPM1c-positive cancer
JP7545139B2 (ja)	2020-03-11	2024-09-04	フンダシオインスティテュートデレセルカコントララレウセミアジュゼップカレラス	Ｂ細胞急性リンパ芽球性白血病（ｂ－ａｌｌ）の処置のためのｃｄ２２標的化部分
WO2021183795A1 (en)	2020-03-11	2021-09-16	Poseida Therapeutics, Inc.	Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
JP2023518380A (ja)	2020-03-16	2023-05-01	アドレノメトアクチェンゲゼルシャフト	コロナウイルスに感染した患者におけるプロアドレノメデュリンまたはそのフラグメント、およびアドレノメデュリンに対する結合剤による治療
CN115769076A (zh)	2020-03-16	2023-03-07	4Teen4制药有限公司	感染冠状病毒的患者中的dpp3
EP3922993A1 (de)	2020-06-12	2021-12-15	4TEEN4 Pharmaceuticals GmbH	Dpp3 bei patienten, die mit coronavirus infiziert sind
MX2022011892A (es)	2020-03-26	2022-10-18	Univ Vanderbilt	Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
US20230203191A1 (en)	2020-03-30	2023-06-29	Danisco Us Inc	Engineered antibodies
EP4126064A1 (de)	2020-04-03	2023-02-08	Visterra, Inc.	Antikörpermolekül-wirkstoff-konjugate und verwendungen davon
WO2021202948A2 (en)	2020-04-04	2021-10-07	Dyax Corp.	Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
WO2021205325A1 (en)	2020-04-08	2021-10-14	Pfizer Inc.	Anti-gucy2c antibodies and uses thereof
WO2021211331A1 (en)	2020-04-13	2021-10-21	Abbott Point Of Care Inc.	METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
WO2021211628A1 (en)	2020-04-14	2021-10-21	Poseida Therapeutics, Inc.	Compositions and methods for use in the treatment of cancer
KR20230028242A (ko)	2020-04-24	2023-02-28	마렝고 테라퓨틱스, 인크.	T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
WO2021221783A1 (en)	2020-05-01	2021-11-04	Massachusetts Institute Of Technology	Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en)	2020-05-01	2021-11-04	Massachusetts Institute Of Technology	Chimeric antigen receptor-targeting ligands and uses thereof
US20230167193A1 (en)	2020-05-01	2023-06-01	Novartis Ag	Immunoglobulin variants
US20230242647A1 (en)	2020-05-01	2023-08-03	Novartis Ag	Engineered immunoglobulins
JP2023524125A (ja)	2020-05-05	2023-06-08	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ２３特異的抗体によるクローン病の治療方法
US20230181750A1 (en)	2020-05-06	2023-06-15	Crispr Therapeutics Ag	Mask peptides and masked anti-ptk7 antibodies comprising such
BR112022022603A2 (pt)	2020-05-08	2023-01-17	Broad Inst Inc	Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
KR20230012539A (ko)	2020-05-13	2023-01-26	디스크 메디슨, 인크.	골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US20230183366A1 (en)	2020-05-13	2023-06-15	Inserm (Institut National De La Santé Et De La Recherch Médicale)	Recombinant proteins with ox40 activating properties
WO2021231732A1 (en)	2020-05-15	2021-11-18	Bristol-Myers Squibb Company	Antibodies to garp
CA3182150A1 (en)	2020-05-17	2021-11-25	Astrazeneca Uk Limited	Sars-cov-2 antibodies and methods of selecting and using the same
CA3180665A1 (en)	2020-05-19	2021-11-25	Boehringer Ingelheim International Gmbh	Binding molecules for the treatment of cancer
MX2022014430A (es)	2020-05-21	2023-02-22	Janssen Biotech Inc	Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
WO2021239666A1 (en)	2020-05-26	2021-12-02	Diaccurate	Therapeutic methods
CA3184189A1 (en)	2020-05-27	2021-12-02	Janssen Biotech, Inc.	Proteins comprising cd3 antigen binding domains and uses thereof
US11820824B2 (en)	2020-06-02	2023-11-21	Arcus Biosciences, Inc.	Antibodies to TIGIT
US20230235080A1 (en)	2020-06-03	2023-07-27	Bionecure Therapeutics, Inc.	Trophoblast cell-surface antigen-2 (trop-2) antibodies
US20210380707A1 (en)	2020-06-04	2021-12-09	Crispr Therapeutics Ag	Anti-cd70 antibodies and uses thereof
AU2021297540A1 (en)	2020-06-24	2023-02-02	Prothena Biosciences Limited	Antibodies recognizing sortilin
CA3187823A1 (en)	2020-06-24	2021-12-30	Visterra, Inc.	Antibody molecules to april and uses thereof
WO2022009052A2 (en)	2020-07-06	2022-01-13	Janssen Biotech, Inc.	Prostate neoantigens and their uses
US20230256114A1 (en)	2020-07-07	2023-08-17	Bionecure Therapeutics, Inc.	Novel maytansinoids as adc payloads and their use for the treatment of cancer
CA3189402A1 (en)	2020-07-13	2022-01-20	Janssen Biotech, Inc.	Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
US11524998B2 (en)	2020-07-16	2022-12-13	Novartis Ag	Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
CA3189590A1 (en)	2020-07-17	2022-01-20	Pfizer Inc.	Therapeutic antibodies and their uses
BR112023000603A2 (pt)	2020-07-20	2023-01-31	Astrazeneca Uk Ltd	Proteínas sars-cov-2, anticorpos anti-sars-cov-2 e métodos de uso dos mesmos
WO2022026592A2 (en)	2020-07-28	2022-02-03	Celltas Bio, Inc.	Antibody molecules to coronavirus and uses thereof
WO2022024065A1 (en)	2020-07-30	2022-02-03	Janssen Biotech, Inc.	Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
US11795238B2 (en)	2020-08-04	2023-10-24	Crispr Therapeutics Ag	Anti-idiotype antibodies targeting anti-CD70 chimeric antigen receptor
EP4193149A1 (de)	2020-08-04	2023-06-14	Abbott Laboratories	Verbesserte verfahren und kits zum nachweis von sars-cov-2-protein in einer probe
AU2021320333A1 (en)	2020-08-07	2023-03-30	Fortis Therapeutics, Inc.	Immunoconjugates targeting CD46 and methods of use thereof
HUE070287T2 (hu)	2020-08-18	2025-05-28	Cephalon Llc	Anti-PAR-2 ellenanyagok és eljárások alkalmazásukra
JP2023538897A (ja)	2020-08-20	2023-09-12	アムジエン・インコーポレーテツド	Ｆａｂ領域中に非標準的なジスルフィドを有する抗原結合タンパク質
AU2021334950A1 (en)	2020-08-24	2023-03-02	Charité - Universitätsmedizin Berlin	Chimeric antigen receptor (CAR)-expressing cells recognizing CEA
JP2023540022A (ja)	2020-08-24	2023-09-21	シャリテ－ウニベルジテーツメディツィンベルリン	チェックポイント阻害分子及び免疫刺激性サイトカインをコードするキメラ抗原受容体構築物、並びにＣＤ４４ｖ６を認識するＣＡＲ発現細胞
WO2022043861A1 (en)	2020-08-25	2022-03-03	Crispr Therapeutics Ag	Anti-idiotype antibodies targeting anti-bcma chimeric antigen receptor
KR20230074144A (ko)	2020-08-26	2023-05-26	마렝고 테라퓨틱스, 인크.	NKp30에 결합하는 항체 분자 및 이의 용도
GB2616354A (en)	2020-08-26	2023-09-06	Marengo Therapeutics Inc	Methods of detecting TRBC1 or TRBC2
CN116249718A (zh)	2020-08-26	2023-06-09	马伦戈治疗公司	结合至钙网蛋白的多功能性分子及其用途
WO2022043557A1 (en)	2020-08-31	2022-03-03	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
EP4204020A1 (de)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Verfahren zur behandlung von psma-exprimierenden krebsarten
JP2023542497A (ja)	2020-09-11	2023-10-10	アレクシオンファーマシューティカルズ，インコーポレイテッド	抗セルロプラスミン抗体及びその使用
EP4210832A1 (de)	2020-09-14	2023-07-19	Vor Biopharma, Inc.	Chimäre antigenrezeptoren zur behandlung von krebs
US20230374162A1 (en)	2020-10-07	2023-11-23	Amgen Inc.	Rational selection of building blocks for the assembly of multispecific antibodies
WO2022081718A1 (en)	2020-10-14	2022-04-21	Five Prime Therapeutics, Inc.	Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
EP4229081A1 (de)	2020-10-15	2023-08-23	The United States of America, as represented by The Secretary, Department of Health and Human Services	Für sars-cov-2-rezeptor-bindungsdomäne spezifischer antikörper und therapeutische verfahren
US20230374148A1 (en)	2020-10-15	2023-11-23	UCB Biopharma SRL	Binding molecules that multimerise cd45
JP7633397B2 (ja)	2020-10-21	2025-02-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	眼の疾患の処置のための二重特異性抗ＶＥＧＦ及び抗ＴｒｋＢ結合分子
WO2022087274A1 (en)	2020-10-21	2022-04-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies that neutralize type-i interferon (ifn) activity
EP4231999B1 (de)	2020-10-21	2025-03-05	Poseida Therapeutics, Inc.	Zusammensetzungen und verfahren zur abgabe von nukleinsäuren
EP4232062A4 (de)	2020-10-23	2024-09-11	HAN, Hq	Bifunktionelle antagonisten von activin und tumornekrosefaktor-alpha und verwendungen davon
JP2023547499A (ja)	2020-11-06	2023-11-10	ノバルティスアーゲー	抗体Ｆｃ変異体
US20240002545A1 (en)	2020-11-10	2024-01-04	Amgen Inc.	Novel linkers of multispecific antigen binding domains
EP4251647A1 (de)	2020-11-24	2023-10-04	Bio-Techne Corporation	Anti-sever-antikörper des akuten atemwegssyndroms coronavirus
EP4255574A1 (de)	2020-12-01	2023-10-11	Aptevo Research and Development LLC	Heterodimere psma- und cd3-bindende bispezifische antikörper
CA3198161A1 (en)	2020-12-01	2022-06-09	Beth MCQUISTON	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en)	2021-11-30	2023-06-08	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4023218A1 (de)	2020-12-02	2022-07-06	S-Form Pharma	Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe
AU2021391924A1 (en)	2020-12-04	2023-06-22	The General Hospital Corporation	Methods of using interleukin-2 agents
US20240052042A1 (en)	2020-12-14	2024-02-15	Novartis Ag	Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
JP2024500747A (ja)	2020-12-18	2024-01-10	キニクサファーマシューティカルズ，リミテッド	タンパク質組成物ならびにそれを産生及び使用するための方法
JP2024503784A (ja)	2020-12-18	2024-01-29	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Ｎｐｒ１アゴニストに結合する免疫グロブリンタンパク質
EP4271998A1 (de)	2020-12-30	2023-11-08	Abbott Laboratories	Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
CA3202832A1 (en)	2020-12-31	2022-07-07	Romesh R. Subramanian	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2022153195A1 (en)	2021-01-13	2022-07-21	Memorial Sloan Kettering Cancer Center	Anti-dll3 antibody-drug conjugate
WO2022153194A1 (en)	2021-01-13	2022-07-21	Memorial Sloan Kettering Cancer Center	Antibody-pyrrolobenzodiazepine derivative conjugate
AU2022211021A1 (en)	2021-01-20	2023-08-03	Visterra, Inc.	Interleukin-2 mutants and uses thereof
WO2022157094A2 (en)	2021-01-22	2022-07-28	Bayer Aktiengesellschaft	Lrrc15 antibodies and conjugates thereof
KR20230137393A (ko)	2021-01-28	2023-10-04	얀센 바이오테크 인코포레이티드	Psma 결합 단백질 및 이의 용도
EP4284510A1 (de)	2021-01-29	2023-12-06	Novartis AG	Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon
US20220275090A1 (en)	2021-02-22	2022-09-01	Janssen Biotech, Inc.	Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
US20240230671A9 (en)	2021-02-24	2024-07-11	Alladapt Immunotherapeutics, Inc.	Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
KR20230156727A (ko)	2021-03-03	2023-11-14	피에르 파브르 메디카먼트	항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
JP2024512305A (ja)	2021-03-03	2024-03-19	ザユナイテッドステイツオブアメリカアズリプリゼンテッドバイザセクレタリー、デパートメントオブヘルスアンドヒューマンサービシーズ	破骨細胞生成の新規制御因子としてのＬａタンパク質
AU2022232007A1 (en)	2021-03-12	2023-10-26	Janssen Biotech, Inc.	Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
CA3212729A1 (en)	2021-03-12	2022-09-15	Janssen Biotech, Inc.	Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
CN117321418A (zh)	2021-03-18	2023-12-29	诺华股份有限公司	癌症生物标志物及其使用方法
WO2022204581A2 (en)	2021-03-26	2022-09-29	Scholar Rock, Inc.	Tgf-beta inhibitors and use thereof
EP4067381A1 (de)	2021-04-01	2022-10-05	Julius-Maximilians-Universität Würzburg	Neue tnfr2-bindende moleküle
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
JP2024515591A (ja)	2021-04-08	2024-04-10	マレンゴ・セラピューティクス，インコーポレーテッド	Ｔｃｒに結合する多機能性分子およびその使用
US20240238427A1 (en)	2021-04-14	2024-07-18	Kodiak Sciences Inc.	Methods of treating an eye disorder
CA3216559A1 (en)	2021-04-20	2022-10-27	Amgen Inc.	Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
US12472248B2 (en)	2021-04-29	2025-11-18	The Government Of The United States, As Represented By The Secretary Of The Army	Antibodies against fentanyl and fentanyl analogs
MX2023013149A (es)	2021-05-07	2023-11-28	Surface Oncology Llc	Anticuerpos anti-il-27 y usos de estos.
US20220381796A1 (en)	2021-05-18	2022-12-01	Abbott Laboratories	Methods of evaluating brain injury in a pediatric subject
EP4348263A1 (de)	2021-05-28	2024-04-10	Alexion Pharmaceuticals, Inc.	Verfahren zum nachweis von cm-tma-biomarkern
WO2022256723A2 (en)	2021-06-03	2022-12-08	Scholar Rock, Inc.	Tgf-beta inhibitors and therapeutic use thereof
AU2022288058A1 (en)	2021-06-07	2023-11-16	Agonox, Inc.	Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2022261183A2 (en)	2021-06-08	2022-12-15	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CA3218481A1 (en)	2021-06-14	2022-12-22	argenx BV	Anti-il-9 antibodies and methods of use thereof
EP4356129A1 (de)	2021-06-14	2024-04-24	Abbott Laboratories	Verfahren zur diagnose oder unterstützung der diagnose von hirnverletzungen durch akustische energie, elektromagnetische energie, überdruckwelle und/oder explosionswind
US12043671B2 (en)	2021-06-16	2024-07-23	Gundersen Lutheran Medical Foundation, Inc.	Antibodies targeting an amphiregulin-derived cell surface neo-epitope
TW202317625A (zh)	2021-06-17	2023-05-01	德商百靈佳殷格翰國際股份有限公司	新穎三特異性結合分子
US20250325634A1 (en)	2021-06-18	2025-10-23	Nammi Therapeutics, Inc.	Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods Thereof
JP2024524159A (ja)	2021-06-23	2024-07-05	スカラーロックインコーポレイテッド	代謝障害の治療における使用のためのｇｌｐ－１経路活性化剤と組み合わせたミオスタチン経路阻害剤
EP4362977A1 (de)	2021-06-29	2024-05-08	Seagen Inc.	Verfahren zur behandlung von krebs mit einer kombination aus einem nichtfucosylierten anti-cd70-antikörper und einem cd47-antagonisten
CN118139883A (zh)	2021-07-09	2024-06-04	詹森生物科技公司	用于生产抗tnf抗体组合物的制造方法
CN117957251A (zh)	2021-07-09	2024-04-30	詹森生物科技公司	用于制备抗tnf抗体组合物的制造方法
WO2023281466A1 (en)	2021-07-09	2023-01-12	Janssen Biotech, Inc.	Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2023285878A1 (en)	2021-07-13	2023-01-19	Aviation-Ophthalmology	Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
AU2022310862A1 (en)	2021-07-14	2024-02-01	Regeneron Pharmaceuticals, Inc.	Engineered t cell receptors fused to binding domains from antibodies
EP4372006A4 (de)	2021-07-16	2025-10-08	Brightpath Biotherapeutics Co Ltd	Anti-tim-3-antigen-antikörper oder antikörperderivat und verwendung davon
WO2023010118A1 (en)	2021-07-29	2023-02-02	Vor Biopharma Inc.	Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
CN118488964A (zh)	2021-07-30	2024-08-13	Ona疗法有限公司	抗cd36抗体及其治疗癌症的用途
CA3228822A1 (en)	2021-08-26	2023-03-02	Jan Tkac	Glycoprotein biomarkers for diagnosing cancer
CN118715440A (zh)	2021-08-31	2024-09-27	雅培实验室	诊断脑损伤的方法和系统
EP4396587A1 (de)	2021-08-31	2024-07-10	Abbott Laboratories	Verfahren und systeme zur diagnose von hirnverletzungen
EP4144898A1 (de)	2021-09-07	2023-03-08	New/era/mabs GmbH	Verfahren zur selektion oder screenen von antikörpern aus einer antikörperbibliothek
US20240385193A1 (en)	2021-09-14	2024-11-21	Glycanostics S.R.O.	Use of lectins to determine mammaglobin-a glycoforms in breast cancer
EP4405396A2 (de)	2021-09-20	2024-07-31	Voyager Therapeutics, Inc.	Zusammensetzungen und verfahren zur behandlung von her2-positivem krebs
EP4405478A1 (de)	2021-09-20	2024-07-31	Alnylam Pharmaceuticals, Inc.	Inhibinuntereinheits-beta-e (inhbe)-modulatorzusammensetzungen und verfahren zur verwendung davon
EP4409294A1 (de)	2021-09-30	2024-08-07	Abbott Laboratories	Verfahren und systeme zur diagnose von hirnverletzungen
US20240401085A1 (en)	2021-10-04	2024-12-05	Poseida Therapeutics, Inc.	Transposon compositions and methods of use thereof
AU2022374890A1 (en)	2021-10-29	2024-06-13	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
WO2023081705A1 (en)	2021-11-03	2023-05-11	Janssen Biotech, Inc.	Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
US20230134748A1 (en)	2021-11-03	2023-05-04	Janssen Biotech, Inc.	Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
CN117980327A (zh)	2021-11-03	2024-05-03	杭州多禧生物科技有限公司	抗体的特异性偶联
EP4177266A1 (de)	2021-11-05	2023-05-10	Katholieke Universiteit Leuven	Neutralisierende humane anti-sars-cov-2-antikörper
CA3238377A1 (en)	2021-11-15	2023-05-19	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
US20250034559A1 (en)	2021-11-17	2025-01-30	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
AU2022394462A1 (en)	2021-11-17	2024-05-02	AbbVie Deutschland GmbH & Co. KG	Methods for treating anemia of kidney disease
US20230159633A1 (en)	2021-11-23	2023-05-25	Janssen Biotech, Inc.	Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023097254A1 (en)	2021-11-24	2023-06-01	Visterra, Inc.	Engineered antibody molecules to cd138 and uses thereof
EP4440594A2 (de)	2021-11-29	2024-10-09	Dana-Farber Cancer Institute, Inc.	Verfahren und zusammensetzungen zur modulierung von riok2
CN120131911A (zh)	2021-12-01	2025-06-13	威特拉公司	使用白细胞介素-2药剂的方法
WO2023100153A1 (en)	2021-12-03	2023-06-08	Crispr Therapeutics Ag	Use of anti-cd70 antibodies for identifying subjects susceptible for treatment with nk cell-based anti-cd70 therapy
US11939391B2 (en)	2021-12-06	2024-03-26	MedAbome, Inc.	Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment
IL313265A (en)	2021-12-06	2024-08-01	Regeneron Pharma	Antagonistic antibodies against NPR1 and methods of using them
WO2023114978A1 (en)	2021-12-17	2023-06-22	Abbott Laboratories	Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
EP4452305A1 (de)	2021-12-23	2024-10-30	Bavarian Nordic A/S	Rekombinante mva-viren zur intraperitonealen verabreichung zur behandlung von krebs
AU2023210287A1 (en)	2022-01-21	2024-09-05	Poseida Therapeutics, Inc.	Compositions and methods for delivery of nucleic acids
IL314068A (en)	2022-01-24	2024-09-01	Novimmune Sa	Preparations and methods for selective activation of cytokine signaling pathways
EP4472740A1 (de)	2022-01-31	2024-12-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cd38 als biomarker und biotarget bei t-zell-lymphomen
EP4473311A1 (de)	2022-02-04	2024-12-11	Abbott Laboratories	Lateralflussverfahren, tests und vorrichtungen zum nachweis oder zur messung der anwesenheit oder der menge von ubiquitincarboxyterminaler hydrolase l1 und/oder glialem fibrillärem saurem protein in einer probe
TW202342548A (zh)	2022-02-07	2023-11-01	美商威特拉公司	抗獨特型(anti-idiotype)抗體分子及其用途
CA3251731A1 (en)	2022-02-10	2023-08-17	Amgen Inc.	ANTIBODY PROTEIN PROTEIN EXPRESSION CONSTRUCTIONS FOR HIGH-THROUGH SEQUENCING
TW202342510A (zh)	2022-02-18	2023-11-01	英商Ｒｑ生物科技有限公司	抗體
EP4490192A1 (de)	2022-03-07	2025-01-15	Novimmune S.A.	Cd28-bispezifische antikörper zur gezielten t-zell-aktivierung
EP4493592A1 (de)	2022-03-14	2025-01-22	LamKap Bio gamma AG	Bispezifische gpc3xcd28- und gpc3xcd3-antikörper und deren kombination zur gezielten tötung gpc3-positiver maligner zellen
CA3254142A1 (en)	2022-03-15	2023-09-21	Adrenomed Ag	STABLE AQUEOUS FORMULATION OF AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADM ANTIBODY FRAGMENT
GB202203588D0 (en)	2022-03-15	2022-04-27	Argonaut Therapeutics Ltd	Cancer diagnostic
CA3258517A1 (en)	2022-03-30	2023-10-05	Janssen Biotech, Inc.	TREATMENT METHOD FOR MILD TO MODERATE PSORIASIS WITH A SPECIFIC IL-23 ANTIBODY
WO2023192436A1 (en)	2022-03-31	2023-10-05	Alexion Pharmaceuticals, Inc.	Singleplex or multiplexed assay for complement markers in fresh biological samples
CN118974100A (zh)	2022-04-07	2024-11-15	朝途生物疗法株式会社	针对人tim-3和人cd39的双特异性抗体和其用途
GB202205203D0 (en)	2022-04-08	2022-05-25	UCB Biopharma SRL	Combination with inhibitor
GB202205200D0 (en)	2022-04-08	2022-05-25	Ucb Biopharma Sprl	Combination with chemotherapy
US20240092921A1 (en)	2022-04-25	2024-03-21	Visterra, Inc.	Antibody molecules to april and uses thereof
WO2023209568A1 (en)	2022-04-26	2023-11-02	Novartis Ag	Multispecific antibodies targeting il-13 and il-18
WO2023209177A1 (en)	2022-04-29	2023-11-02	Astrazeneca Uk Limited	Sars-cov-2 antibodies and methods of using the same
EP4522757A2 (de)	2022-05-13	2025-03-19	Voyager Therapeutics, Inc.	Zusammensetzungen und verfahren zur behandlung von her2-positivem krebs
KR20250011938A (ko)	2022-05-18	2025-01-22	얀센 바이오테크 인코포레이티드	Il23 항체에 의해 건선성 관절염을 평가 및 치료하기 위한 방법
WO2023240124A1 (en)	2022-06-07	2023-12-14	Regeneron Pharmaceuticals, Inc.	Pseudotyped viral particles for targeting tcr-expressing cells
EP4296279A1 (de)	2022-06-23	2023-12-27	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
CA3257731A1 (en)	2022-06-29	2024-01-04	Abbott Laboratories	OUTSIDE THE LABORATORY, MAGNETIC SYSTEMS AND ANALYSES FOR DETERMINING GLIOFIBRILLARY ACID PROTEIN IN BIOLOGICAL SAMPLES
JP2025525430A (ja)	2022-07-01	2025-08-05	ニューロジーン・インコーポレイテッド	Ｔ制御性細胞を優先的に刺激するためのｎｅｏ－２／１５バリアント及びそれらの使用
CN119546339A (zh)	2022-07-15	2025-02-28	丹尼斯科美国公司	用于产生单克隆抗体的方法
EP4554969A1 (de)	2022-07-15	2025-05-21	Janssen Biotech, Inc.	Material und verfahren zur verbesserten biotechnologischen paarung antigenbindender variabler regionen
EP4554677A1 (de)	2022-07-15	2025-05-21	Boehringer Ingelheim International GmbH	Bindungsmoleküle zur behandlung von krebs
IL318667A (en)	2022-07-29	2025-03-01	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
AU2023315168A1 (en)	2022-07-29	2025-02-13	4TEEN4 Pharmaceuticals GmbH	Prediction of an increase of dpp3 in a patient with septic shock
JP2025528068A (ja)	2022-08-03	2025-08-26	ボイジャーセラピューティクスインコーポレイテッド	血液脳関門を通過させるための組成物及び方法
EP4578876A1 (de)	2022-08-23	2025-07-02	ONO Pharmaceutical Co., Ltd.	Bispezifischer antikörper
CA3264339A1 (en)	2022-08-31	2024-03-07	Washington University	Alphavirus antigen-binding molecules and their uses
CN120129696A (zh)	2022-09-01	2025-06-10	乔治亚大学研究基金公司	用于指导载脂蛋白l1诱导哺乳动物细胞死亡的组合物和方法
CN120035450A (zh)	2022-09-06	2025-05-23	阿雷克森制药公司	造血干细胞移植物相关血栓性微血管病（hsct-tma）患者的诊断和预后生物标志物谱
JP2025532597A (ja)	2022-09-15	2025-10-01	アボット・ラボラトリーズ	軽度及び超軽度の外傷性脳損傷を区別するためのバイオマーカー及び方法
WO2024062072A2 (en)	2022-09-21	2024-03-28	Domain Therapeutics	Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062076A1 (en)	2022-09-21	2024-03-28	Domain Therapeutics	Anti-ccr8 monoclonal antibodies and their therapeutic use
EP4590705A1 (de)	2022-09-21	2025-07-30	Domain Therapeutics	Monoklonale anti-ccr8-antikörper und deren therapeutische verwendung
TW202421652A (zh)	2022-09-21	2024-06-01	瑞士商艾爾瑟拉股份有限公司	結合至l1cam之新穎結合分子
EP4345109A1 (de)	2022-09-30	2024-04-03	AdrenoMed AG	Anti-adrenomedullin (adm)-bindemittel zur verwendung bei der behandlung von pädiatrischen patienten mit angeborener herzerkrankung
US20240254234A1 (en)	2022-10-21	2024-08-01	Novimmune Sa	PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
IL320562A (en)	2022-11-02	2025-07-01	Janssen Biotech Inc	Cancer treatment methods
AU2023375570A1 (en)	2022-11-10	2025-06-12	Immuvia Inc	Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
JP2025539830A (ja)	2022-11-22	2025-12-09	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ２３特異的抗体で潰瘍性大腸炎を治療する方法
EP4633659A1 (de)	2022-12-15	2025-10-22	4TEEN4 Pharmaceuticals GmbH	Dpp3-hemmer zur verbesserung der lungenfunktion bei kritisch kranken patienten
AU2023413166A1 (en)	2022-12-22	2025-07-03	Scholar Rock, Inc.	Selective and potent inhibitory antibodies of myostatin activation
WO2024163477A1 (en)	2023-01-31	2024-08-08	University Of Rochester	Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024168061A2 (en)	2023-02-07	2024-08-15	Ayan Therapeutics Inc.	Antibody molecules binding to sars-cov-2
KR20250158054A (ko)	2023-03-02	2025-11-05	알로이 테라퓨틱스, 인크.	항-cd22 항체 및 이의 용도
WO2024194685A2 (en)	2023-03-17	2024-09-26	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
AU2024240129A1 (en)	2023-03-17	2025-10-09	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
EP4680243A1 (de)	2023-03-17	2026-01-21	The United States of America, as represented by the Secretary, Department of Health and Human Services	Verfahren zur behandlung von altersbedingter makuladegeneration
CN120731367A (zh)	2023-03-17	2025-09-30	Pam治疗诊断有限公司	肽基甘氨酸α-酰胺化单加氧酶（PAM）的测定方法及其诊断用途
JP2026513177A (ja)	2023-03-29	2026-04-23	４ティーン４ファーマシューティカルズゲゼルシャフトミットベシュレンクテルハフツング	血圧低下を有する重症患者における心筋保護及び心筋傷害の予防のためのｄｐｐ３阻害剤
WO2024211475A1 (en)	2023-04-04	2024-10-10	Abbott Laboratories	Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
EP4713682A1 (de)	2023-04-28	2026-03-25	Abbott Point of Care Inc.	Verbesserte tests, kartuschen und kits zum nachweis von biomarkern, einschliesslich biomarkern für hirnverletzungen
EP4705342A2 (de)	2023-05-04	2026-03-11	Novasenta, Inc.	Anti-cd161-antikörper und verfahren zur verwendung davon
CN121079327A (zh)	2023-05-12	2025-12-05	基因泰克公司	用于降低抗体粘度的方法和组合物
IL324556A (en)	2023-05-19	2026-01-01	Servier Lab	Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
WO2024243578A1 (en)	2023-05-25	2024-11-28	Dispatch Biotherapeutics, Inc.	Synthetic cancer antigens as targets for treating cancers
KR20260026054A (ko)	2023-06-13	2026-02-25	애드센트릭스 테라퓨틱스 잉크.	넥틴-4 단백질에 결합하는 항체 및 항체 약물 접합체 (adc)와 관련된 방법 및 조성물
CN119143869A (zh)	2023-06-16	2024-12-17	复旦大学	乙肝病毒表面抗体及其应用
EP4484445A1 (de)	2023-06-26	2025-01-01	Universität zu Köln	Hcmv neutralisierende antikörper
WO2025030010A1 (en)	2023-08-01	2025-02-06	Vor Biopharma Inc.	Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
CN117247454A (zh)	2023-08-22	2023-12-19	华中科技大学同济医学院附属协和医院	靶向gpc3的分子探针以及用途
US20250075000A1 (en)	2023-09-06	2025-03-06	Novimmune Sa	Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
CN121816192A (zh)	2023-09-14	2026-04-07	因斯布鲁克医科大学	通过抑制NR2f6增强CAR-T细胞疗效
WO2025061994A1 (en)	2023-09-21	2025-03-27	Domain Therapeutics	Anti-ccr8 monoclonal antibodies and their therapeutic use
EP4590714A1 (de)	2023-09-21	2025-07-30	Domain Therapeutics	Monoklonale anti-ccr8-antikörper und deren therapeutische verwendung
EP4527851A1 (de)	2023-09-22	2025-03-26	Bayer Aktiengesellschaft	Bispezifische antikörperzur bindung von ltbr und lrrc15
WO2025068313A1 (en)	2023-09-25	2025-04-03	Sphingotec Gmbh	A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
WO2025068389A2 (en)	2023-09-27	2025-04-03	Elthera Ag	L1cam binding molecules for treating hematological malignancy diseases
WO2025072888A2 (en)	2023-09-28	2025-04-03	Novavax, Inc.	Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025122634A1 (en)	2023-12-05	2025-06-12	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
EP4570262A1 (de)	2023-12-15	2025-06-18	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft	Chimärer antigenrezeptor gegen den chemokinrezeptor ccr7
WO2025133707A1 (en)	2023-12-19	2025-06-26	Vectory Therapeutics B.V.	Anti-tdp-43 antibodies and uses thereof
US20260022185A1 (en)	2024-01-03	2026-01-22	Kiniksa Pharmaceuticals, Gmbh	Method of reducing aggregation in the virus-inactivated preparation of anti-cd40 antibodies
WO2025160275A1 (en)	2024-01-24	2025-07-31	Arrowhead Pharmaceuticals, Inc.	Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof
TW202540204A (zh)	2024-01-26	2025-10-16	西班牙商阿爾米雷爾有限公司	雙特異性分子及使用其的治療方法
WO2025160432A1 (en)	2024-01-26	2025-07-31	Poseida Therapeutics, Inc.	Methods and compositions for enhancing in vivo persistence and potency of cell therapy
GB202401567D0 (en)	2024-02-06	2024-03-20	St Georges Hospital Medical School	Treatment of infectious disease
WO2025171388A1 (en)	2024-02-09	2025-08-14	Dispatch Biotherapeutics, Inc.	Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en)	2024-02-09	2025-08-14	Dispatch Biotherapeutics, Inc.	Engineered cancer antigens and related methods and uses
WO2025176860A1 (en)	2024-02-23	2025-08-28	Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts	Dual chimeric antigen receptor construct targeting cea and epcam
US20250361297A1 (en)	2024-03-12	2025-11-27	Adaptam Therapeutics, S.L.	Anti- siglec-15 binding molecules and methods of use
CA3249015A1 (en)	2024-03-20	2025-10-31	Janssen Biotech, Inc.	Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025226603A1 (en)	2024-04-22	2025-10-30	Surface Oncology, LLC	Methods for treating cancer using anti-ccr8 antibodies
US20260041768A1 (en)	2024-05-03	2026-02-12	Janssen Biotech, Inc.	Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025229075A1 (en)	2024-05-03	2025-11-06	Sphingotec Gmbh	A method for the specific determination of proenkephalin fragment 119-159
WO2025231372A2 (en)	2024-05-03	2025-11-06	Janssen Biotech, Inc.	Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025235420A1 (en)	2024-05-06	2025-11-13	Generate Biomedicines, Inc.	Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
EP4650368A1 (de)	2024-05-13	2025-11-19	Epok Therapeutics Inc.	Tetravalente erythropoietinrezeptoragonisten
WO2025248139A1 (en)	2024-05-31	2025-12-04	4TEEN4 Pharmaceuticals GmbH	Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
WO2025264533A1 (en)	2024-06-17	2025-12-26	Adcentrx Therapeutics Inc.	Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
WO2025262604A1 (en)	2024-06-17	2025-12-26	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
WO2026006492A2 (en)	2024-06-25	2026-01-02	Ypsilon Therapeutics, Inc.	Anti-prame/hla-a2 antibodies and uses thereof
US20260022180A1 (en)	2024-06-25	2026-01-22	Kiniksa Pharmaceuticals, Gmbh	Compositions of il-1r1 antibodies and methods of producing and using the same
WO2026006494A1 (en)	2024-06-25	2026-01-02	Alloy Therapeutics, Inc.	Anti-cd3 antibodies and uses thereof
WO2026006495A1 (en)	2024-06-25	2026-01-02	Alloy Therapeutics, Inc.	Anti-wt1/hla-a2 antibody and uses thereof
CA3258952A1 (en)	2024-06-27	2026-03-01	Janssen Biotech, Inc.	Methods of treating ulcerative colitis with anti-il23 specific antibody
EP4674430A1 (de)	2024-07-01	2026-01-07	Universität zu Köln	Editierte zytotoxische zellen mit chimären antigenrezeptoren zum targeting von cd30 zur behandlung von infektionen
WO2026011013A1 (en)	2024-07-02	2026-01-08	Epibiologics, Inc.	Binding agents and uses thereof
EP4675277A1 (de)	2024-07-05	2026-01-07	Predemtec AG	Verfahren zur diagnose von morbus alzheimer oder zur bestimmung des risikos des leidens an morbus alzheimer
TW202606759A (zh)	2024-08-02	2026-02-16	比利時商Ｕｃｂ生物製藥公司	抗Gremlin-1抗體的調配物
WO2026036047A1 (en)	2024-08-08	2026-02-12	Altus Enterprises, Inc.	Antibody molecules to fixa and fx and uses thereof
WO2026037841A1 (en)	2024-08-12	2026-02-19	ONA Therapeutics S.L.	Anti-fgfr4 molecules and uses thereof
WO2026046968A1 (en)	2024-08-26	2026-03-05	4TEEN4 Pharmaceuticals GmbH	Dpp3 binders for the treatment of endothelial dysfunction
WO2026046947A1 (en)	2024-08-26	2026-03-05	4TEEN4 Pharmaceuticals GmbH	Anti-dpp3 antibody directed to and binding to dpp3 for the treatment of shock in extreme-critically ill patients
WO2026046982A1 (en)	2024-08-26	2026-03-05	Pam Theragnostics Gmbh	A method for the prediction of a risk or severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cell therapy (iect)
WO2026046978A1 (en)	2024-08-26	2026-03-05	Pam Theragnostics Gmbh	Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects
WO2026050572A2 (en)	2024-08-29	2026-03-05	Marengo Therapeutics, Inc.	Multifunctional molecules binding to tcr and uses thereof
WO2026055167A1 (en)	2024-09-05	2026-03-12	Surface Oncology, LLC	Anti-il-27 antibodies and use of biomarkers in uses thereof
WO2026055461A1 (en)	2024-09-05	2026-03-12	Aperture Therapeutics, Inc.	Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof
WO2026055168A1 (en)	2024-09-06	2026-03-12	Surface Oncology, LLC	Anti-il-27 antibodies and uses and doses thereof
WO2026058155A1 (en)	2024-09-11	2026-03-19	Novartis Ag	Antibodies targeting il-31
WO2026078067A1 (en)	2024-10-08	2026-04-16	Novimmune Sa	Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof
WO2026088159A1 (en)	2024-10-24	2026-04-30	Imuno Therapeutics	Hla-a2 p53 antibodies and methods of use thereof
WO2026096383A1 (en)	2024-10-28	2026-05-07	The Broad Institute, Inc.	Compositions and methods for inducing phagocytosis
WO2026096502A1 (en)	2024-10-28	2026-05-07	Tae Life Sciences Llc	Methods of performing boron neutron capture therapy (bnct) in combination with immune checkpoint inhibitors
WO2026095974A1 (en)	2024-10-30	2026-05-07	Horizon Therapeutics Ireland Dac	Methods of treating thyroid eye disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4593002A (en) *	1982-01-11	1986-06-03	Salk Institute Biotechnology/Industrial Associates, Inc.	Viruses with recombinant surface proteins
JPS58212781A (ja) *	1982-06-02	1983-12-10	Noda Sangyo Kagaku Kenkyusho	新種バクテリオフア−ジ及びその育種法
DE3546807C2 (de) *	1985-03-30	1991-03-28	Marc Genf/Geneve Ch Ballivet
ES2065333T3 (es) *	1987-01-12	1995-02-16	Stratagene Inc	Vector de clonacion de adn con plasmidos escindibles in vivo.
DE3703825A1 (de) *	1987-02-07	1988-08-18	Didier Eng	Verfahren und vorrichtung zum herstellen von kohlenstoff-fasern
DE3852304T3 (de) *	1987-03-02	1999-07-01	Enzon Labs Inc., Piscataway, N.J.	Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
WO1989006694A1 (en) *	1988-01-15	1989-07-27	Trustees Of The University Of Pennsylvania	Process for selection of proteinaceous substances which mimic growth-inducing molecules
EP0768377A1 (de) *	1988-09-02	1997-04-16	Protein Engineering Corporation	Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
ES2052027T5 (es) *	1988-11-11	2005-04-16	Medical Research Council	Clonacion de secuencias de dominio variable de inmunoglobulina.
CA2016841C (en) *	1989-05-16	1999-09-21	William D. Huse	A method for producing polymers having a preselected activity
CA2016842A1 (en) *	1989-05-16	1990-11-16	Richard A. Lerner	Method for tapping the immunological repertoire
EP0478627A4 (en) *	1989-05-16	1992-08-19	William D. Huse	Co-expression of heteromeric receptors
AU7247191A (en) *	1990-01-11	1991-08-05	Molecular Affinities Corporation	Production of antibodies using gene libraries
US5427908A (en) *	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
DK0600866T3 (da) *	1990-06-01	1998-03-09	Chiron Corp	Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
GB9015198D0 (en) *	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
JPH0568599A (ja) *	1990-07-31	1993-03-23	Wistar Inst	遺伝子工学的に作られた抗体
IL99552A0 (en) *	1990-09-28	1992-08-18	Ixsys Inc	Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9022190D0 (en) *	1990-10-12	1990-11-28	Perham Richard N	Immunogenic material
EP0575410B1 (de) *	1991-03-07	1999-05-19	BRADBURY, Andrew Raymon Morton	Auswahl spezifischer proteine durch ein biologisches verfahren
AU662148B2 (en) *	1991-04-10	1995-08-24	Scripps Research Institute, The	Heterodimeric receptor libraries using phagemids

1990
- 1990-05-01 US US07/517,659 patent/US5427908A/en not_active Expired - Lifetime
1991
- 1991-05-01 AU AU77939/91A patent/AU7793991A/en not_active Abandoned
- 1991-05-01 DE DE69133437T patent/DE69133437T2/de not_active Revoked
- 1991-05-01 DK DK91908963T patent/DK0527839T3/da active
- 1991-05-01 ES ES91908963T patent/ES2124224T3/es not_active Expired - Lifetime
- 1991-05-01 EP EP05075052A patent/EP1555328A3/de not_active Withdrawn
- 1991-05-01 AT AT91908963T patent/ATE174067T1/de not_active IP Right Cessation
- 1991-05-01 WO PCT/US1991/002989 patent/WO1991017271A1/en not_active Ceased
- 1991-05-01 ES ES98200770T patent/ES2235284T3/es not_active Expired - Lifetime
- 1991-05-01 DE DE98200770T patent/DE98200770T1/de active Pending
- 1991-05-01 EP EP91908963A patent/EP0527839B1/de not_active Revoked
- 1991-05-01 EP EP98200770A patent/EP0866136B1/de not_active Revoked
- 1991-05-01 JP JP50889691A patent/JP3344584B2/ja not_active Expired - Fee Related
- 1991-05-01 DE DE69130563T patent/DE69130563T2/de not_active Revoked
- 1991-05-01 AT AT98200770T patent/ATE286985T1/de not_active IP Right Cessation
- 1991-05-01 DK DK98200770T patent/DK0866136T3/da active
1995
- 1995-01-20 US US08/376,326 patent/US5580717A/en not_active Expired - Lifetime
1999
- 1999-02-17 GR GR990400504T patent/GR3029421T3/el unknown

Also Published As

Publication number	Publication date
DE69133437T2 (de)	2006-01-05
EP0866136B1 (de)	2005-01-12
EP1555328A3 (de)	2009-05-06
EP0527839A4 (en)	1993-06-09
EP0527839A1 (de)	1993-02-24
ATE286985T1 (de)	2005-01-15
ES2235284T3 (es)	2005-07-01
DE69130563D1 (de)	1999-01-14
DK0866136T3 (da)	2005-05-17
EP1555328A2 (de)	2005-07-20
EP0866136A1 (de)	1998-09-23
AU7793991A (en)	1991-11-27
GR3029421T3 (en)	1999-05-28
DE69133437D1 (de)	2005-02-17
ES2124224T3 (es)	1999-02-01
WO1991017271A1 (en)	1991-11-14
US5427908A (en)	1995-06-27
JP3344584B2 (ja)	2002-11-11
DE98200770T1 (de)	2004-09-30
DK0527839T3 (da)	1999-08-16
JPH05506782A (ja)	1993-10-07
EP0527839B1 (de)	1998-12-02
DE69130563T2 (de)	1999-06-24
US5580717A (en)	1996-12-03

Legal Events

Date	Code	Title
2000-10-15	UEP	Publication of translation of european patent specification
2003-11-15	EEFA	Change of the company name
2007-02-15	REN	Ceased due to non-payment of the annual fee
2010-01-15	RZN	Patent revoked

Publication	Publication Date	Title
DE69133437D1 (de)	2005-02-17	Siebtestverfahren für Genbanken (recombinant libraries)
DK1007654T3 (da)	2005-09-19	In vitro peptid- eller proteinekspressionsbibliotek
IL186154A0 (en)	2008-01-20	Methods and compositions for inhibiting neoplastic cell growth
CA2153507A1 (en)	1995-05-18	A fas ligand, a fragment thereof and dna encoding the same
KR960705041A (ko)	1996-10-09	Tgf 수용체 족 및/ 또는 bmp 수용체 족에 속하는 액티빈 수용체 유사 키나제(alk) (activin receptors-like kinase (alk), belonging to the tgf receptor family and/or to the bmp receptor family)
JPH05508321A (ja)	1993-11-25	ペプチドライブラリィ及びスクリーニングシステム
DE69323765D1 (de)	1999-04-08	Säugetier-rezeptoren für interleukin 10 (il-10)
DE69837268D1 (de)	2007-04-19	Neue moleküle aus der familie der tango-77-ähnlichen proteine und ihre verewendungen.
DE59410401D1 (de)	2005-02-03	VERFAHREN ZUR HERSTELLUNG REKOMBINANTER PilC-PROTEINE
GR3023593T3 (en)	1997-08-29	Protein structure of the plant toxin gelonin
FI104495B (fi)	2000-02-15	Soluvastetta tyypin I interferonille mukauttavan proteiinin kloonaus ja ilmeneminen
WO2000032778A3 (en)	2000-10-19	Methods and compositions for inhibiting neoplastic cell growth
US20050054000A1 (en)	2005-03-10	Fv constructs with an influenceable affinity for a substance that is to be linked
Dower et al.	1996	Recombinant library screening methods
CN106905435A (zh)	2017-06-30	一种制备基于蛋白a突变体的结合蛋白的方法
DE69637484D1 (de)	2008-05-15	Vektoren/DNA-Sequenzen aus humanen kombinatorischen Antikörper-Bibliotheken
Nygren	2011	Affinity ligands from biological combinatorial libraries
CN118684776A (zh)	2024-09-24	一种靶向mica的全人源抗体或抗体片段及其嵌合抗原受体和应用
Fairbairn	1989	INVESTIGATIONS ON ERYTHROCYTE MEMBRANE PROTEINS USING MOLECULAR CLONING TECHNIQUES.
UA35624C2 (uk)	2001-04-16	МОЛЕКУЛА ДНК, ЩО КОДУЄ ПРОТЕЇН TGF-<font face="Symbol">b</font>-РОДИНИ, ВЕКТОР, L-КЛІТИНА, ПРОТЕЇН TGF-<font face="Symbol">b</font>-РОДИНИ, СПОСІБ ЙОГО ОТРИМАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, МОНОКЛОНАЛЬНЕ АНТИТІЛО
EP2075335A3 (de)	2009-09-30	Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
CA2335335A1 (en)	2001-09-02	Human erythrocyte differentiation related factor
DK1191101T3 (da)	2004-10-11	PRO241 polypeptider og nucleinsyre kodende herfor
DE69827532D1 (de)	2004-12-16	Polypeptide und dafür kodierende Nukleinsäure
CA2306450A1 (en)	1999-05-06	Polypeptides and nucleic acids encoding same